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bemoedigend	woord.	Bedankt	aan	allen	voor	de	fijne	samenwerking!	
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Chapter	1: General	introduction	
1.1 The	neuropeptide	PACAP	
1.1.1 Structure	and	function	of	PACAP	
The	 pituitary	 adenylate	 cyclase-activating	 polypeptide	 (PACAP)	 is	 a	 highly	
conserved	 neuropeptide,	 which	 was	 first	 isolated	 in	 1989	 from	 ovine	
hypothalamic	 tissue	 and	 was	 identified	 to	 stimulate	 cAMP	 formation	 in	 rat	
anterior	 pituitary	 cells.[1]	 The	 ADCYAP1	 gene	 is	 located	 on	 chromosome	
18p11.32	and	encodes	a	176-amino	acid	prepro-protein	of	PACAP	 (18.8	kDa),	
from	which	 two	active	PACAP	peptides	are	processed:	PACAP(1-38)	 (4.5	 kDa)	
and	 its	 shorter	 variant	 PACAP(1-27)	 (3	 kDa).[2]	 The	 secondary	 structure	 of	
PACAP	consists	of	a	helical	conformation.[3]	In	human	plasma,	PACAP	is	bound	
to	 ceruloplasmin	 (132	 kDa),	 which	 prevents	 its	 rapid	 degradation.[4]	 PACAP	
shares	 sequence	 homology	 with	 vasoactive	 intestinal	 peptide	 (VIP),	 secretin,	
growth	hormone	releasing	hormone	and	glucagon.	PACAP	is	widely	expressed	
in	the	nervous	system	and	in	several	peripheral	tissues,	notably	the	urogenital,	
respiratory	and	gastro-intestinal	tracts	and	the	endocrine	organs	as	the	thyroid	
gland,	 the	gonads	and	 the	pancreas.[3]	 PACAP(1-38)	 is	 the	predominant	 form,	
both	 in	 the	 nervous	 system	 and	 other	 organs.[5]	 The	 sequence	 of	 PACAP	 has	
been	 well	 conserved	 during	 evolution	 from	 protochordates	 to	 mammals,	
suggesting	 a	 role	 in	 important	 biological	 processes.[3]	 It	 plays	 a	 role	 as	 a	
neurotransmitter,	 a	 hormone	 and	 a	 trophic	 factor	 and	 takes	 part	 in	multiple	
biological	 processes,	 including	 neurotransmitter	 release,	 prevention	 of	
apoptosis	and	stimulation	of	cell	multiplication	and	differentiation.[3]		
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1.1.2 PACAP	receptors	and	signalization	
Three	 PACAP	 binding	 receptors	 have	 been	 identified:	 PAC1,	 VPAC1	 and	
VPAC2.[6-8]	PAC1	recognizes	PACAP	with	high	affinity,	while	its	affinity	for	VIP	is	
much	 lower.	VPAC1	and	VPAC2	are	G	protein-coupled	 receptors,	 exhibiting	 a	
high	 affinity	 for	 both	 PACAP	 and	 VIP.	 The	 PAC1	 receptor	 is	 particularly	
abundant	 in	 the	 brain	 and	 peripheral	 nervous	 system,	 while	 the	 VPAC1	 and	
VPAC2	receptors	are	particularly	expressed	in	peripheral	organs,	for	example	in	
lung,	gonads	and	spleen.	The	PAC1	receptor	is	coupled	to	several	transduction	
systems.	Activation	of	PAC1	stimulates	cAMP	production	via	adenylyl	 cyclase,	
activates	 phospholipase	 C,	 and	 leads	 to	 increased	 calcium	 levels.	 VPAC1	 and	
VPAC2	 are	 mainly	 coupled	 to	 adenylyl	 cyclase,	 increasing	 cAMP	 levels	 upon	
activation.[3]	
	
1.1.3 Inhibitory	role	of	PACAP	on	megakaryopoiesis	and	platelet	activation	
Kis	 et	 al	 reported	 for	 the	 first	 time	 an	 inhibitory	 effect	 of	 PACAP	 on	 the	
cyclooxygenase	pathway	in	rat	platelets	via	a	PACAP	receptor-activated,	cAMP-
dependent	pathway.[9]	 In	2004,	PACAP	was	identified,	 in	our	 laboratory,	as	an	
important	 inhibitor	 of	 platelet	 function	 via	 its	 receptor	 VPAC1.[10]	 A	 study	 in	
patients	 with	 elevated	 PACAP	 plasma	 levels	 due	 to	 a	 partial	 trisomy	 18p	
(having	 three	 PACAP	 gene	 copies),	 revealed	 an	 increased	 bleeding	 tendency	
and	decreased	platelet	aggregation	responses	to	collagen	and	ADP,	which	can	
be	 antagonized	 by	 the	 addition	 of	 a	 PACAP	 antagonist	 PACAP(6-38).	
Megakaryocytes	 and	 platelets	 express	 the	 Gs-coupled	 VPAC1	 receptor	 that	
stimulates	adenylyl	cyclase.	Platelets	of	PACAP-overexpressing	patients	contain	
elevated	 levels	 of	 basal	 cAMP,	 explaining	 the	 reduced	 platelet	 activation.	
Accordingly,	 transgenic	 mice	 with	 megakaryocyte-specific	 PACAP	
overexpression	 via	 cloning	of	 the	ADCYAP1	 gene	 after	 the	 glycoprotein	GPIIB	
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promoter,	have	increased	PACAP	release	from	platelets,	a	 longer	tail	bleeding	
time	and	decreased	platelet	aggregation	responses	to	collagen.	Moreover,	the	
opposite	 phenotype	with	 stimulation	of	 platelet	 function	 is	 seen	 in	wild-type	
mice	 injected	with	a	PACAP	antagonist	PACAP(6-38)	or	an	 inhibitory	antibody	
against	 PACAP	 or	 its	 receptor	 VPAC1,	 as	 well	 as	 in	 PACAP	 knockout	 mice.	
Accordingly,	human	platelets	 treated	with	a	PACAP	antagonist	or	neutralizing	
anti-PACAP	antibody,	show	increased	aggregation	responses	to	collagen.[10]		
Since	patients	with	elevated	PACAP	plasma	levels	due	to	a	partial	trisomy	18p	
also	 have	mild	 thrombocytopenia,	 the	 effect	 of	 PACAP	 on	megakaryopoiesis	
and	platelet	production	was	further	studied.	Patients	with	partial	trisomy	18p	
and	transgenic	mice	with	megakaryocyte-specific	PACAP	overexpression,	have	
reduced	numbers	of	mature	megakaryocytes	 in	their	bone	marrow	and	the	 in	
vitro	 differentiation	 of	 hematopoietic	 stem	 cells	 to	 megakaryocytes	 is	
decreased	 compared	 to	 controls.	 Furthermore,	 the	 addition	 of	 recombinant	
PACAP	to	healthy	cord	blood	derived	CD34+	hematopoietic	stem	cells	 inhibits	
megakaryocyte	differentiation.	On	the	contrary,	addition	of	a	neutralizing	anti-
PACAP	 or	 anti-VPAC1	 antibody	 leads	 to	 increased	 megakaryocyte	
differentiation	 and	 reduced	 formation	 of	 cAMP.	 Moreover,	 wild-type	 mice	
injected	with	 a	monoclonal	 inhibitory	 antibody	 against	 PACAP	or	 its	 receptor	
VPAC1	 show	 an	 increased	 platelet	 count.[11]	 These	 antibodies	 also	 induce	
elevated	 platelet	 numbers	 in	 murine	 models	 of	 thrombocytopenia.[11,12]	
Recently,	a	proteomic	study	suggested	that	PACAP	signaling	via	VPAC1	leads	to	
interference	of	the	normal	regulation	of	apoptosis	in	megakaryocytes,	probably	
via	 the	 nuclear	 factor	 kappa-light-chain-enhancer	 of	 activated	 B	 cells	 (NF-κB)	
pathway.[13]		
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1.1.4 Renoprotective	role	of	PACAP	
Although	 an	 important	 regulatory	 role	 of	 PACAP	 has	 been	 demonstrated	 in	
many	peripheral	tissues,	little	is	known	about	its	expression	and	function	in	the	
kidney.	While	PACAP	expression	has	been	shown	by	radioimmunoassay	(RIA)	in	
the	 rat	 kidney[14],	 it	 was	 never	 studied	 in	 human	 renal	 tissue.	 The	 VPAC1	
receptor	 is	 expressed	 in	 the	 human	 kidney,	 particularly	 in	 the	 glomeruli.[7,15]	
The	VPAC2	receptor	is	also	expressed	at	the	RNA	level	in	the	human	kidney,	but	
the	exact	localization	has	not	been	determined.[16]	In	mice,	VPAC2	expression	is	
restricted	 to	 the	 renal	 vasculature	 only.[17]	 One	 study	 reported	 expression	 of	
PAC1	 in	 the	 rat	 kidney	 using	 RIA[18],	 but	 its	 expression	 has	 never	 been	
demonstrated	 in	 human	 kidney.	 Furthermore,	 RNA	 expression	 of	 VPAC1	 and	
PAC1	 receptors	 was	 demonstrated	 in	 only	 one	 study	 using	 the	 SV40	
immortalized	 human	 proximal	 tubular	 epithelial	 cell	 line,	 while	 no	 VPAC2	
expression	was	observed.[19]		
Recently,	several	studies	have	revealed	a	nephroprotective	effect	of	PACAP	in	
different	 in	vitro	and	 in	vivo	renal	disease	models.[20]	PACAP	protects	proximal	
tubular	 cells	 in	 vitro	 against	 cisplatin[21,22],	 cyclosporine	 A[23],	 hypoxia[24]	 and	
myeloma	 light	 chain[19,25].	 Changes	 induced	 by	 PACAP	 include	 inhibition	 of	
apoptotic	 pathways,	 increased	 cell	 survival	 and	 decreased	 production	 of	
proinflammatory	 and	 profibrotic	 substances.[20]	 In	 Table	 1.1	 an	 overview	 is	
provided	of	all	studies	that	showed	in	vitro	nephroprotective	effects	of	PACAP.	
In	vivo	studies	confirm	a	nephroprotective	effect	of	PACAP	in	mouse	models	of	
renal	 damage	 due	 to	 cisplatin[21,22]	 and	 cyclosporine	 A[23],	 in	 ischemia	 caused	
renal	 damage	 in	 mice	 and	 rats[24,26-28],	 in	 multiple	 myeloma	 in	 rats[19,29]	 and	
humans[30],	 in	 diabetic	 nephropathy	 in	 rats[29],	 and	 in	 contrast-induced	
nephropathy	in	mice[31].	PACAP	administration	in	those	in	vivo	models	led	to	an	
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amelioration	of	renal	function	and	a	decrease	of	tubulointerstitial	damage	and	
expression	of	proinflammatory	and	profibrotic	markers.[20]	
	
Table	1.1:	Overview	of	studies	that	reported	in	vitro	nephroprotective	effects	of	PACAP	
	
Damaging	insult	
	
Cell	type	
	
Observed	changes	
	
	
References	
	Cisplatin	 	primary	mouse	renal	proximal	tubular	cells		
	Apoptosisê	 	[21]	
Cisplatin	 human	proximal	tubular	HK-2	cells	 Apoptosisê, caspase	7ê, PARP1ê, p53	activationê, TNF-αê, APE-1	é, Bcl-2é, Bcl-xLé, Baxê 	
[22]	
Cyclosporine	A	 human	proximal	tubular	HK-2	cells		 TGF-β1ê, morphological	integrityé, LDHê, ROSê	 [23]	Hypoxia	 primary	mouse	renal	proximal	tubular	cells	 MCP-1ê, IL-6ê, MIP-2ê, MyD88ê, TLR4ê, TRAF6ê, TRIFê, IRF3ê, apoptosisê 	
[24]	
Myeloma	light	chain	 SV40	immortalized	human	tubular	cells		 IL-6ê, TNF-αê	 [19,29]	Oxidative	stress	(H2O2)	 primary	kidney	cell	culture		 Cell	survivalé	 [32]	Oxidative	stress	(H2O2)	 primary	kidney	cell	culture		 Cell	survivalé	 [33]	Lipopolysaccharide	(diabetic	nephropathy)	 mouse	podocytes,	transformed	by	ectopic	expression	of	cyclin-dependent	kinase	4		
MCP-1ê, IL-6ê [34]	
PARP1	 =	 poly	 [ADP-ribose]	 polymerase	 1;	 TNF-α	 =	 tumor	 necrosis	 factor	 α;	 APE-1	 =	
apurinic/apyrimidinic	endonuclease-1;	Bcl-2	=	B-cell	lymphoma	2;	Bcl-xL	=	B-cell	lymphoma-
extra	large;	Bax	=	Bcl-2-like	protein	4;	TGF-β1	=	transforming	growth	factor	β1;	LDH	=	lactate	
dehydrogenase;	ROS	=	 reactive	oxygen	species;	MCP-1	=	monocyte	chemotactic	protein	1;	
IL-6	 =	 interleukin-6;	 MIP-2	 =	 macrophage	 inflammatory	 protein-2;	 MyD88	 =	 Myeloid	
differentiation	primary	response	gene	88;	TLR4	=	toll-like	receptor	4;	TRAF6	=	TNF	receptor	
associated	 factor	 6;	 TRIF	 =	 TIR	 domain-containing	 adaptor	 inducing	 interferon	 β;	 IRF3	 =	
interferon	regulatory	factor	3.	Adapted	from	Reglodi	et	al.[20]	
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1.2 Nephrotic	syndrome:	general	introduction	
In	this	section	a	general	 introduction	to	the	nephrotic	syndrome	(NS)	is	given,	
with	a	focus	on	childhood	idiopathic	NS	and	Finnish-type	congenital	NS.	
	
1.2.1 Epidemiology	and	classification	
NS	 is	 a	 renal	 disease	 defined	 by	 severe	 proteinuria	 (urinary	 protein	 levels	
exceeding	 50	 mg/kg/day	 or	 40	 mg/h/m2),	 hypoalbuminemia,	 edema	 and	
hyperlipidemia,	 due	 to	 increased	 glomerular	 permeability.[35]	 NS	 is	 the	 most	
common	 glomerular	 disease	 during	 childhood,	 with	 an	 incidence	 of	 2-7	 per	
100.000	cases	per	year	and	a	prevalence	of	around	16	children	per	100.000.[35]		
Different	 classifications	 of	NS	 are	 proposed,	 based	 on	 age	 of	 onset,	 etiology,	
histology,	response	to	treatment	or	relapse	frequency.	These	classifications	are	
of	clinical	 importance,	as	disease	course,	treatment	and	prognosis	can	vary	 in	
different	subtypes.	 In	children,	NS	can	be	subdivided	 into	3	 types,	dependent	
on	age	at	 first	presentation.	When	the	first	symptoms	occur	under	3	months,	
between	 3	 and	 12	months	 or	 after	 12	months	 of	 age,	 the	NS	 is	 classified	 as	
congenital,	infantile	or	childhood	NS,	respectively.	Based	on	etiology,	different	
forms	of	NS	can	be	 identified.	First,	 there	are	genetic	 forms	of	NS,	which	can	
have	different	clinical	presentations	(congenital	or	 infantile	NS,	syndromic	NS,	
steroid-resistant	NS	and	chronic	proteinuria).	Finnish-type	congenital	NS	 is	an	
example	of	a	genetic	form	of	NS,	based	on	a	mutation	in	the	nephrin	gene.	A	
second	 form	 is	 the	 idiopathic	 NS,	 which	 can	 start	 at	 any	 age.	 Genetic	 and	
idiopathic	NS	are	primary	forms	of	NS.	A	third	subtype	is	secondary	NS,	which	
can	 be	 due	 to	 autoimmune	 diseases	 (for	 example	 lupus	 nephropathy,	 ANCA	
(anti	 neutrophil	 cytoplasmic	 antibody)	 vasculitis	 and	 Goodpasture	 disease),	
primary	 complement	 diseases	 (for	 example	 atypical	 hemolytic	 uremic	
syndrome,	 membranoproliferative	 glomerulonephritis	 and	 dense	 deposit	
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disease),	infectious	diseases	(for	example	acute	glomerulonephritis,	hepatitis	B	
or	C	and	toxoplasmosis),	abnormal	IgA	regulation	(as	in	Henoch-Schönlein	and	
Berger	disease)	or	miscellaneous	causes	(for	example	renal	vein	thrombosis	in	
the	 neonate	 and	 toxic	 exposure	 to	mercury,	 penicillamine	 and	 non-steroidal	
anti-inflammatory	 drugs).[35]	 NS	 can	 further	 be	 classified	 based	 on	 histologic	
findings	 on	 renal	 biopsy.	 The	 most	 common	 forms	 of	 idiopathic	 NS	 during	
childhood	 are	 minimal	 change	 NS	 (MCNS)	 and	 focal	 segmental	
glomerulosclerosis	 (FSGS),	 occurring	 in	 respectively	 77%	 and	 8%	 of	 cases.[36]	
Membranous	 nephropathy	 is	 a	 third	 form	 of	 idiopathic	 NS,	 but	 is	 rare	 in	
children.	 As	 the	 responsiveness	 to	 steroid	 treatment	 is	 of	 greater	 prognostic	
importance	than	histologic	findings,	idiopathic	NS	is	also	classified	based	on	the	
response	 to	 treatment.	 If	 the	 patient	 achieves	 remission	 under	 steroid	
treatment,	 he/she	 has	 a	 steroid-sensitive	 NS	 (SSNS).	 In	 steroid-resistant	 NS	
(SRNS),	 nephrotic	 proteinuria	 remains	 despite	 steroid	 treatment.	 Steroid-
dependent	 NS	 (SDNS)	 is	 defined	 by	 the	 occurrence	 of	 relapses	 when	
corticosteroids	 are	 tapered	 or	within	 2	weeks	 of	 discontinuation.	When	 2	 or	
more	relapses	occur	in	the	first	6	months,	or	4	or	more	in	any	12-month	period,	
it	is	called	a	frequent	relapsing	NS.[36]	
	
1.2.2 Pathophysiology	
The	glomerular	filtration	barrier	is	a	size	and	charge	selective	barrier,	consisting	
of	 three	 structural	 components:	 the	 fenestrated	 endothelial	 cells,	 the	
glomerular	basement	membrane	and	 the	podocyte	 foot	processes	 connected	
with	 a	 slit	 diaphragm	 (Figure	 1.1).	 Under	 normal	 circumstances,	 only	 small	
quantities	of	 intermediate	molecular	weight	proteins	as	albumin	(70	kDa)	and	
almost	 no	 high	 molecular	 weight	 proteins	 (>100	 kDa)	 pass	 the	 glomerular	
filtration	 barrier.	 In	 NS,	 perm-selectivity	 is	 lost	 and	 large	 amounts	 of	 plasma	
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proteins,	 including	proteins	with	a	molecular	weight	over	70	kDa,	are	 filtered	
and	are	excreted	in	the	urine.[37,38]	Damage	of	the	glomerular	filtration	barrier	
can	 be	 caused	 by	 genetic,	 immunologic,	 infectious	 or	 toxic	 factors.	 Table	 1.2	
provides	an	overview	of	genetic	causes	of	NS.		
	
	
	
	
Figure	1.1:	Structure	of	the	glomerular	filtration	barrier		
Electron	 microscopy	 shows	 the	 glomerular	 filtration	 barrier,	 containing	 three	 structural	
layers:	 the	 fenestrated	 endothelial	 cells	 (Endo),	 the	 basement	 membrane	 (BM)	 and	 the	
podocyte	 (Podo)	 foot	 processes	 (FP).	 The	 adjacent	 foot	 processes	 are	 connected	 by	 a	 slit	
diaphragm	(arrowhead).	Magnification	40.000x.	Adapted	from	Schlöndorff	et	al.[39] 
	
	
	
	 	
	 21	
Table	1.2:	Overview	of	genetic	causes	of	nonsyndromic	nephrotic	syndrome	
	 Gene	 Locus	 Inheritance	 Protein	 Phenotype	(histology)	
Slit	diaphragm	
	 NPHS1	 19q13.1	 AR	 Nephrin	 CNS	(characteristic	findings)	
	 NPHS2	 1q25.2	 AR	 Podocin	 CNS	or	early	onset	SRNS	(FSGS)	
	 PLCE1	 10q23.33	 AR	 Phospholipase	C	epsilon	1	 Early-onset	SRNS	or	SDNS	(DMS,	FSGS)	
	 CD2AP	 6p12		 AD		 CD2	associated	protein	 Adult	onset	SRNS	if	heterozygous,	early	onset	SRNS	if	homozygous	(FSGS)	
	 TRPC6	 11q22.1		 AD	 TRPC6	 Adult-onset	SRNS	(FSGS)	
Actin	cytoskeleton	
	 ACTN4		 	 19q13		 	 AD	or	AR	 Alpha-actinin	4	 Adult-onset	SRNS	(FSGS)	
	 INF2		 	 14q32.33		 AD	 Inverted	formin	2	 Adult-onset	SRNS	(FSGS)	
	 MYO1E			 15q22.2		 AR	 Myosin	1E		 Childhood-onset	SRNS	(FSGS)	
	 ARHGAP24		 4q22.1		 	 AD	 Arhgap24	 Adolescent-onset	SRNS	(FSGS)	
	 ARHGDIA	 17q25.3		 AR	 Arhgdia	 Childhood-onset	SRNS		(FSGS)	
Nuclear	
	 WT1		 	 11p13		 	 AD	 Wilms’	tumor	1	 Early	onset	SRNS,	isolated	or	as	part	of	Frasier	or	Denys	Drash	syndrome	(DMS	in	Denys-Drash	syndrome;	FSGS	in	Frasier	syndrome)	
Glomerular	basement	membrane	
	 LAMB2		 	 3p21		 	 AR	 Laminin	β2	 Early	onset	SRNS,	isolated	or	as	part	of	Pierson	syndrome	(FSGS	if	isolated;	DMS	if	syndromic)	
Others	
	 APOL1		 	 22q13.1	 Complex	 Apolipoprotein	1	 Adult	onset	SRNS	(FSGS)	
	 CUBN		 	 10p13		 	 AR	 Cubilin	 Childhood-onset	SRNS	(histology	unknown)	
AR	=	autosomal	recessive;	AD	=	autosomal	dominant;	CNS	=	congenital	nephrotic	syndrome;	
SRNS	 =	 steroid-resistant	 nephrotic	 syndrome;	 SDNS	 =	 steroid-dependent	 nephrotic	
syndrome;	 FSGS	 =	 focal	 segmental	 glomerulosclerosis;	 DMS	 =	 diffuse	mesangial	 sclerosis.	
Adapted	from	Sinha	et	al[40]	and	Brown	et	al[41].	
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Congenital	 and	 infantile	NS	 are	 primary	 forms	 in	 the	majority	 of	 cases,	most	
often	 based	 on	 a	 genetic	mutation.	 A	 recessive	mutation	 in	 the	NPHS1	 gene	
causes	congenital	NS	of	the	Finnish	type.	NPHS1	encodes	for	nephrin,	which	is	
an	important	structural	component	of	the	podocyte	slit	diaphragm	and	acts	as	
a	 signaling	molecule.[42]	The	disease	 is	 called	 ‘Finnish-type’	NS	because	of	 the	
higher	 incidence	 in	 Finland.[43]	 Mutations	 in	 other	 genes	 important	 for	
podocyte	 structure	or	 function	as	NPHS2,	WT1,	 LAMB2	or	 PLCE1	 cause	other	
forms	of	congenital	or	 infantile	NS.[44,45]	Congenital	or	 infantile	NS	can	also	be	
secondary,	most	often	due	to	infections	(as	toxoplasmosis,	syphilis	or	hepatitis	
B	or	C).	Secondary	NS	can	also	be	caused	by	drugs	(for	example	penicillamine	
or	pamidronate)	or	by	a	malignant	disease	(as	lymphoma	or	leukemia).[35]	
The	 pathogenesis	 of	 idiopathic	 NS	 is	 still	 poorly	 understood.	 A	 widespread	
hypothesis	 is	 that	 a	 soluble	 factor	 in	 the	 blood	 would	 induce	 changes	 in	
podocyte	shape	and	function,	leading	to	increased	glomerular	permeability	and	
proteinuria.	 Although	 several	 candidates	 have	 been	 proposed,	 this	
‘permeability	factor’	 is	still	unidentified.[35,46]	The	immune	system	is	suspected	
to	 play	 an	 important	 role	 in	 the	 pathophysiology,	 seen	 the	 response	 to	
immunosuppressive	 drugs	 and	 the	 association	 with	 allergies	 and	 Hodgkin’s	
disease.	T-lymphocytes	have	been	suspected	since	a	long	time	to	be	involved	in	
the	pathophysiology	and	 the	production	of	 the	soluble	 factor.	More	 recently,	
the	successful	 treatment	of	steroid-dependent	NS	with	rituximab	suggested	a	
potential	role	for	B-lymphocytes.[46]	
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1.2.3 Clinical	symptoms	
The	 key	 symptoms	 of	 NS	 are	 proteinuria,	 hypoalbuminemia,	 edema	 and	
hyperlipidemia.	 Hypoalbuminemia	 and	 decreased	 levels	 of	 other	 important	
plasma	proteins	 (such	as	 gamma	globulins)	 are	evidently	 the	 consequence	of	
proteinuria.	 The	 pathogenesis	 of	 edema	 is	 still	 controversial.	 Traditionally,	
edema	 in	 NS	 was	 believed	 to	 be	 the	 consequence	 of	 translocation	 of	 fluids	
from	 the	 vessels	 to	 the	 interstitial	 space,	 because	 of	 reduced	 intravascular	
oncotic	 pressure	 due	 to	 hypoproteinemia.	 Currently,	 salt	 retention	 due	 to	 a	
primary	 defect	 of	 salt	 excretion	 is	 believed	 to	 be	 more	 important	 in	 the	
pathogenesis.[47]	 Hyperlipidemia,	 including	 hypertriglyceridemia	 and	
hypercholesterolemia,	 are	 caused	 by	 altered	 lipoprotein	 metabolism	 due	 to	
diminished	 plasma	 catabolism	 and	 hepatic	 hyperfunction	 responding	 to	
hypoproteinemia.[48]	 Hypertension	 can	 also	 be	 present,	 resulting	 from	 the	
disease	 process	 itself	 or	 due	 to	 the	 use	 of	 corticosteroids.[35]	 The	 first	
symptoms	in	Finnish-type	congenital	NS	patients	present	shortly	after	birth	and	
these	 patients	 have	 a	 very	 severe	 disease	 course	 with	 extremely	 severe	
proteinuria	and	profound	hypoalbuminemia.[44]		
	
1.2.4 Diagnosis	
The	diagnosis	of	NS	can	be	made	 if	 the	 two	main	characteristics	are	present:	
nephrotic	 range	 proteinuria	 (total	 urinary	 protein	 loss	 >	 50	 mg/kg/day	 or	
protein/creatinine	 ratio	 of	 >	 2	 g/g)	 and	 hypoalbuminemia	 (serum	 albumin	
levels	 <	 30	 g/L).[49]	 Edema	 is	 usually	 the	 presenting	 symptom,	 but	 it	 is	 not	
strictly	necessary	to	confirm	the	diagnosis	of	NS.[36]	
Children	 with	 new-onset	 NS	 between	 1	 and	 12	 years	 old,	 without	 a	 known	
underlying	cause	and	with	a	negative	family	history,	are	likely	to	have	MCNS.[35]	
Since	steroid	responsiveness	is	of	higher	prognostic	importance	than	histology,	
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children	without	atypical	 features	are	usually	treated	with	a	course	of	steroid	
therapy	without	confirmation	on	renal	biopsy.	 If	 the	patient	 responds	well	 to	
this	steroid	course,	no	further	diagnostic	evaluation	will	be	performed.	A	renal	
biopsy	should	be	performed	when	atypical	symptoms	are	present	and	another	
type	 than	MCNS	 is	 presumed.	Atypical	 features	 are	 age	under	1	or	 above	12	
years,	 positive	 family	 history,	 extrarenal	 symptoms,	 renal	 failure,	 severe	
hypertension	and	hematuria.	Steroid-resistance	is	also	an	indication	for	a	renal	
biopsy.[35]	Renal	biopsies	of	MCNS	patients	do	not	show	any	light	microscopical	
changes,	 while	 diffuse	 foot	 process	 effacement	 is	 visible	 on	 electron	
microscopy	 (Figure	1.2).	 FSGS	 is	 characterized	by	 segmental	 sclerosis	 in	 some	
glomeruli	 on	 light	 microscopy,	 while	 electron	 microscopy	 also	 reveals	
effacement	 of	 podocyte	 foot	 processes.[50]	 It	 is	 not	 clear	 if	 MCNS	 and	 FSGS	
represent	 distinct	 disease	 entities	 or	 if	 they	 represent	 two	 ends	 of	 a	 disease	
spectrum	with	FSGS	as	a	more	severe	presentation	of	the	same	disease.		
If	NS	develops	during	the	first	year	of	life,	a	genetic	or	infectious	cause	is	much	
more	 common	 than	 an	 idiopathic	 form	of	NS.[35]	 So	 in	 congenital	 or	 infantile	
NS,	 further	 biochemical,	 genetic	 and	 histologic	 investigations	 are	 always	
recommended	 to	 identify	 the	 underlying	 cause.	 If	 a	 recessive	 mutation	 in	
NPHS1	is	found,	the	diagnosis	of	Finnish-type	congenital	NS	is	made.	Histologic	
findings	 in	 Finnish-type	 congenital	 NS	 are	 progressive	 glomerulosclerosis	 and	
microcystic	 dilatation	 of	 proximal	 tubules.[51]	 On	 electron	 microscopy,	
effacement	of	foot	processes	and	absence	of	the	slit	diaphragm	are	frequently	
seen.[52]	
	 25	
 
Figure	1.2:	Podocyte	foot	process	effacement		
Scanning	 electron	 microscopy	 visualizing	 glomerular	 podocytes.	 Left:	 Healthy	 podocytes	
form	a	network	of	 interdigitating	foot	processes.	Right:	Nephrotic	podocytes	undergo	foot	
process	effacement.	Adapted	from	Lennon	et	al.[53]	
	
1.2.5 Treatment	
Idiopathic	 and	 congenital	 NS	 require	 a	 different	 therapeutic	 approach.	
Corticosteroids	are	the	cornerstone	in	the	treatment	of	idiopathic	NS.	The	aim	
of	treatment	in	idiopathic	NS	is	achieving	remission,	defined	as	the	absence	of	
proteinuria	 for	 3	 consecutive	 days.	 The	 current	 treatment	 protocol	 used	 by	
most	 centers	 for	 the	 first	 NS	 episodes	 is	 a	 12-week	 prednisone	 course	 (60	
mg/m2	 daily	 for	 6	 weeks	 followed	 by	 40	 mg/m2	 on	 alternate	 days	 for	 6	
weeks).[54]	The	majority	of	MCNS	patients	respond	to	corticosteroid	therapy	as	
75%	 achieves	 complete	 remission	 within	 two	 weeks	 and	 95%	 achieves	
remission	 after	 8	 weeks.[55]	 Despite	 the	 high	 initial	 response	 rate	 to	
corticosteroids,	 about	 60%	 of	 steroid-responsive	 patients	 will	 relapse	 more	
than	5	times.[35]	The	treatment	of	choice	for	a	relapse	is	prednisone	60	mg/m2	
daily	until	disappearance	of	proteinuria	for	3	consecutive	days,	followed	by	40	
mg/m2	 on	 alternate	 days	 for	 4	weeks.	 Only	 around	 20-25%	 of	 FSGS	 patients	
respond	to	an	 initial	 treatment	with	corticosteroids.[35]	Several	 important	side	
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effects	as	obesity,	impaired	growth,	cataract	and	hypertension	limit	the	chronic	
use	 of	 steroids.	 When	 remission	 cannot	 be	 achieved	 or	 maintained	 using	
steroids	 in	 case	 of	 steroid-dependent,	 steroid-resistant	 or	 frequent	 relapsing	
NS,	 alternative	 steroid-sparing	 agents	 can	 be	 used.	 Alkylating	 agents	
(cyclophosphamide),	 mycophenolate	 mofetil,	 calcineurin	 inhibitors	
(cyclosporine	or	tacrolimus),	levamisole	and	rituximab	have	been	shown	to	be	
effective	 in	 reducing	 relapses.[56]	 However,	 these	 agents	 can	 also	 have	
important	 side	effects	 as	bone	marrow	 suppression,	 immunosuppression	and	
nephrotoxicity.	
Symptomatic	treatment	is	also	important	in	the	management	of	idiopathic	NS.	
This	can	include	salt	and	fluid	restriction,	diuretics,	albumin	infusions,	calcium	
and	vitamin	D	suppletion.	Prophylactic	treatment	with	antibiotics	can	be	given	
to	 prevent	 bacterial	 infections.	 Pneumococcal	 and	 varicella	 vaccines	 are	
recommended.	 Most	 centers	 do	 not	 prescribe	 prophylactic	 medication	 to	
prevent	 thromboembolism.	 In	 some	 centers,	 anticoagulation	 therapy	 or	 low-
dose	aspirin	is	given	in	high-risk	patients	such	as	patients	above	12	years	of	age	
or	if	plasma	albumin	levels	are	<	20	g/dL.	Angiotensin	converting	enzyme	(ACE)	
inhibitors	 or	 angiotensin	 II	 receptor	 blockers	 are	 the	 best	 choice	 of	
antihypertensiva	 in	 case	 of	 hypertension,	 because	 of	 their	 additional	
antiproteinuric	effect.[36]		
Congenital	 NS	 does	 not	 respond	 to	 immunosuppressive	 drugs.	 Standard	
conservative	 treatment	 includes	 regular	 albumin	 infusions,	 gamma	 globulin	
replacement,	 a	 high-protein	 low-salt	 diet,	 vitamin	 and	 thyroxine	 substitution	
and	prevention	of	infection	and	thrombotic	complications.[57]	The	combination	
of	indomethacin	and	an	ACE	inhibitor	was	demonstrated	to	lead	to	decreased	
proteinuria	and	better	growth	in	3	infants	with	Finnish-type	congenital	NS.[58,59]	
Hence,	 indomethacin	 and	 ACE	 inhibitors	 are	 now	 part	 of	 the	 standard	
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treatment	 in	many	centers.	End-stage	renal	 failure	typically	occurs	between	3	
and	 8	 years	 of	 age.	However,	 bilateral	 nephrectomy	may	 be	 required	 before	
end-stage	renal	failure	has	developed	because	of	poor	growth	and	a	high	rate	
of	 intercurrent	 complications	 due	 to	 severe	 nephrosis,	 followed	 by	 renal	
replacement	therapy	in	the	form	of	dialysis	or	renal	transplantation.[57]	
	
1.2.6 Complications	
Potentially	serious	complications	can	occur	in	NS.	The	risk	for	viral	and	bacterial	
infections	 is	 increased	 in	patients	with	NS,	because	of	altered	T-cell	 function,	
decreased	 plasma	 levels	 of	 gamma	 globulins	 and	 the	 use	 of	
immunosuppressive	 medication.[35]	 Peritonitis,	 cellulitis	 and	 sepsis	 can	 occur	
and	 can	 be	 life-threatening.	 Streptococcus	 pneumoniae	 and	 gram-negative	
bacteria	 are	 the	most	 frequent	 etiologic	 agents.[35]	 Furthermore,	 NS	 patients	
have	 an	 increased	 risk	 of	 thromboembolic	 complications,	 both	 arterial	 and	
venous,	 increasing	morbidity	 and	mortality.[60]	 In	 a	 next	 section,	 the	 relation	
between	 NS	 and	 arterial	 versus	 venous	 thrombosis	 is	 discussed	 in	 detail.	
Anasarca	 (generalized	 and	 massive	 edema)	 or	 severe	 hypovolemia	 can	 also	
occur	 in	 the	 acute	 phase	 of	 NS.	 Acute	 renal	 failure	 is	 a	 severe	 but	 rare	
complication,	 especially	 in	 children	 with	 MCNS.	 In	 patients	 with	 refractory	
steroid-resistant	 NS,	 progression	 to	 chronic	 renal	 failure	 can	 occur.	 Due	 to	
massive	 and	 chronic	 nephrosis,	 children	 with	 Finnish-type	 congenital	 NS	 are	
highly	susceptible	for	complications.[61]	
	
1.2.7 Prognosis		
For	 idiopathic	 NS,	 steroid	 responsiveness	 is	 the	 most	 important	 prognostic	
predictor.	 More	 than	 60%	 of	 steroid-responsive	 nephrotic	 children	 will	
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experience	 relapses	and	about	60%	of	 relapsing	patients	will	 have	5	or	more	
relapses.	However,	 steroid-responsive	patients	hardly	ever	develop	end-stage	
renal	 failure.[35]	 Moreover,	 in	 most	 cases	 the	 disease	 disappears	 during	
adulthood,	with	only	16%	of	childhood	idiopathic	NS	patients	still	experiencing	
relapses	during	adulthood.[62]	The	small	group	of	steroid-resistant	patients	who	
cannot	 achieve	 long-term	 remission	 despite	 alternative	 agents,	 will	 develop	
end-stage	renal	disease	and	will	require	renal	replacement	therapy.[35]	
Finnish-type	congenital	NS	is	associated	with	a	poor	outcome.	End-stage	renal	
failure	 or	 the	need	of	 bilateral	 nephrectomy	will	 almost	 always	 require	 renal	
replacement	therapy	in	the	first	years	of	life.[57]	
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1.3 Platelet	 abnormalities	 and	 increased	 risk	 for	 thrombosis	 in	
patients	with	nephrotic	syndrome	
Section	based	on	review	article:	
Eneman	 B,	 Levtchenko	 E,	 van	 den	 Heuvel	 L,	 Van	 Geet	 C,	 Freson	 K.	 Platelet	
abnormalities	 in	 nephrotic	 syndrome.	 Pediatric	 Nephrology,	 2015	 Aug;	 epub	
ahead	of	print.	
	
Patients	with	NS	have	an	 increased	risk	of	 thromboembolic	disease,	 including	
both	 deep	 venous	 and	 arterial	 thrombosis,	 which	 significantly	 increases	
morbidity	and	mortality	 rates.	 It	occurs	 in	20%-37%	of	adults,	and	1%-27%	of	
children,	depending	on	etiology	and	severity	of	the	NS	and	on	whether	imaging	
to	diagnose	 thromboembolism	 is	performed	 in	all	patients	or	only	 in	patients	
with	clinical	symptoms.[60,63,64]	Underlying	mechanisms	of	thromboembolism	in	
NS	are	considered	to	be	multifactorial.	Several	studies	report	 increased	 levels	
of	 prothrombotic	 factors	 as	 factor	 V,	 factor	 VIII,	 von	 Willebrand	 factor	 and	
fibrinogen,	 probably	 due	 to	 liver	 hyperfunction	 in	 response	 to	
hypoalbuminemia.	 Moreover,	 decreased	 plasma	 levels	 of	 antithrombotic	
factors	 such	 as	 antithrombin	 and	 protein	 C	 and	 protein	 S	 and	 of	 the	
thrombolytic	 factor	 plasminogen	were	 found	 in	NS	 patients,	 probably	 due	 to	
urinary	losses.	Besides	this,	nephrosis	leads	to	certain	features	that	predispose	
for	 thromboembolic	disease,	 in	particular	 intravascular	 volume	depletion	and	
therapeutic	 use	 of	 diuretics	 and	 steroids.	 Thrombotic	 risk	 factors	 such	 as	
increased	 platelet	 counts	 and	 platelet	 hyperaggregability	 are	 also	 associated	
with	NS.	However,	the	underlying	molecular	mechanisms	for	these	changes	in	
platelet	count	and	function	in	NS	are	still	poorly	understood.[60]	
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1.3.1 General	introduction	on	platelets	
1.3.1.1 Platelet	morphology	and	function	
Platelets	 are	 anucleated	 discoid	 circulating	 blood	 cells.	 They	 are	 2-3	 μm	 in	
diameter	and	have	a	volume	of	about	9-10	fL.	Platelets	are	derived	from	giant	
precursor	 cells,	 called	 megakaryocytes.	 Megakaryocytes	 arise	 from	
differentiation	 of	 hematopoietic	 stem	 cells	 in	 the	 bone	marrow	 and	undergo	
fragmentation	 of	 their	 cytoplasm,	 leading	 to	 platelet	 production.	 Platelet	
production	is	controlled	by	thrombopoietin	and	other	cytokines.[65]	The	normal	
range	for	platelet	counts	in	human	blood	is	150	-	350	x	109/L.[66]	Platelets	have	
a	 lifespan	of	about	8-10	days,	meaning	that	about	1011	platelets	are	produced	
daily.[67]	 The	 glycocalyx	 forms	 the	 outer	 layer	 of	 the	 platelet,	 consisting	 of	
glycoprotein	 receptors	 that	 play	 an	 important	 role	 in	 platelet	 adhesion,	
activation	 and	 aggregation.	 The	 plasma	 membrane	 is	 located	 under	 the	
glycocalyx	and	contains	phospholipids.	Phospholipids	help	convert	prothrombin	
to	 thrombin,	 promoting	 the	 coagulation	 cascade.	 The	 platelet	 cytoskeleton	
consists	of	contractile	proteins,	which	are	essential	for	maintaining	the	discoid	
shape	 and	 are	 responsible	 for	 the	 shape	 change	 after	 activation.	 Platelets	
contain	 3	 major	 types	 of	 granules:	 α-granules,	 dense	 granules	 and	
lysosomes.[68]	 Furthermore,	 platelets	 contain	 a	 surface-connected	 open	
canalicular	system	(OCS)	with	indentations	and	channels	throughout	the	inner	
part	of	the	platelet.	The	OCS	probably	plays	a	role	in	the	transport	of	external	
substances	 into	 the	 platelet	 and	 in	 the	 release	 of	 α-granule	 contents.	
Moreover,	 this	extensive	membrane	reservoir	may	take	part	 in	 the	 formation	
of	 filopodia	 during	 platelet	 adhesion.	 Lastly,	 it	 serves	 as	 a	 storage	 site	 for	
plasma	membrane	 glycoproteins,	 regulating	which	platelet	 receptors	 become	
available	for	interaction	with	plasma.[69]	
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Platelets	 play	 a	 crucial	 role	 in	 thrombus	 formation	 in	 response	 to	 vascular	
endothelial	 injury.	 They	 form	 plugs	 (primary	 hemostasis),	 which	 are	 then	
covered	with	 fibrin	strands,	as	a	 result	of	 the	coagulation	cascade	 (secondary	
hemostasis).[70]	 An	 increasing	 number	 of	 studies	 indicate	 that	 platelets	might	
also	 play	 a	 role	 in	 intercellular	 communication	 and	 as	 mediators	 of	
inflammation	and	immunomodulation.[71-73]		
In	 order	 to	 exert	 their	 biological	 functions,	 platelets	 need	 to	 be	 activated.	
Exposure	of	platelets	 to	specific	 receptor	agonists	or	physical	 factors	 leads	 to	
platelet	activation	with	dramatic	 changes	 in	platelet	 shape,	 adhesion,	 release	
of	active	substances	from	their	granules	and	aggregation	(Figure	1.3).	At	a	site	
of	 vascular	 endothelial	 injury,	 circulating	 platelets	 are	 exposed	 to	 von	
Willebrand	 factor	 (vWF)	 and	 collagen	 in	 the	 subendothelial	 connective	 tissue	
matrix.	Binding	of	vWF	to	the	platelet	GP	Ib/IX/V	receptor	plays	a	crucial	role	in	
platelet	 adhesion.[74]	 Subendothelial	 collagen	 contributes	 to	platelet	 adhesion	
via	 the	 platelet	 GP	 Ia/IIa	 and	 GP	 VI	 collagen	 receptors.	 Due	 to	 cytoskeletal	
changes,	 activated	 platelets	 change	 their	 discoid	 shape	 into	 an	 irregular	
morphology,	with	pseudopodia	formation	facilitating	adhesion.[66]		
Besides	 serving	 as	 a	 surface	 for	 platelet	 adhesion,	 collagen	 is	 also	 a	 potent	
stimulator	 of	 platelet	 activation.	 Collagen	 binding	 leads	 to	 an	 increased	
cytosolic	 calcium	 concentration	 in	 platelets.	 Increased	 cytosolic	 calcium	
concentration	 plays	 an	 important	 role	 in	 platelet	 activation	 by	 stimulating	
activity	 of	 enzymes	 involved	 in	 platelet	 activation	 and	 improving	 protein-
protein	 interactions.	 Other	 platelet	 stimulatory	 agonists	 besides	 collagen	 are	
thrombin,	 adenosine	 diphosphate	 (ADP),	 epinephrine	 and	 thromboxane	 A2	
(TXA2).	Thrombin	activates	the	protease-activated	receptor	1	(PAR1)	and	PAR4	
receptors,	ADP	 interacts	with	the	P2Y1	and	P2Y12	receptors	and	TXA2	with	the	
TP	 receptor	 on	 platelets.	 All	 of	 these	 receptors	 are	 G-protein	 coupled	 ones.	
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Activation	 of	 these	 receptors	 leads	 to	 intracellular	 protein	 phosphorylation,	
increased	 TXA2	 formation	 and	 elevated	 cytosolic	 calcium	 concentrations.	
Epinephrine	 is	 another	 platelet	 agonist,	 which	 stimulates	 the	 Gi-coupled	 α2-
adrenergic	 receptor	 on	 platelets,	 resulting	 in	 inhibition	 of	 cAMP	 formation.	
Intracellular	 cAMP	 antagonizes	 platelet	 activation	 by	 inhibition	 of	 calcium	
release.	 TXA2	 is	 metabolized	 from	 arachidonic	 acid	 (AA)	 by	 cyclooxygenase	
(COX)	 in	 activated	 platelets.	 It	 stimulates	 activation	 of	 other	 platelets	 and	
induces	 platelet	 aggregation,	 by	 activation	 of	 the	 platelet	 fibrinogen-binding	
αIIbβ3	 receptors.	 Binding	 of	 fibrinogen	 to	 the	 activated	 αIIbβ3	 receptors	 of	
different	platelets	 leads	 to	platelet-platelet	 interactions	and	 to	 the	 formation	
of	platelet	aggregates.		
Activation	of	platelets	further	leads	to	degranulation	and	the	release	of	active	
substances	 from	 α-	 and	 dense	 granules.	 α-Granules	 are	 rapidly	 exocytosed	
upon	 platelet	 activation	 and	 secrete	 many	 different	 proteins	 involved	 in	
platelet	 adhesion,	 aggregation	 and	 secretion,	 but	 also	 proteins	 that	 are	
involved	 in	 chemotaxis,	 proliferation	 and	 inflammatory	 processes.	 Dense	
granules	 contain	 ADP,	 adenosine	 triphosphate	 (ATP),	 calcium,	 serotonin	 and	
other	substances	inducing	platelet	aggregation	and	production	of	inflammatory	
mediators.	Lysosomes	contain	degradative	enzymes	that	can	contribute	to	the	
clearance	of	platelet	thrombi	and	extracellular	matrix.[75]	Degranulation	occurs	
by	 fusion	 of	 granule	 membranes	 with	 the	 cell	 membranes.	 This	 leads	 to	
expression	of	specific	receptor	proteins	on	the	platelet	plasma	membrane	that	
are	 normally	 only	 located	 in	 the	 secretory	 granules	 in	 resting	 platelets.	 An	
example	 of	 a	 platelet	 surface	 activation-dependent	 marker	 that	 is	 normally	
located	in	the	α-granule	membrane	is	P-selectin	(CD62P).		
As	 indicated	 above,	 platelet	 membrane	 phospholipids	 play	 a	 role	 in	 the	
formation	 of	 thrombin,	 a	 central	 component	 of	 the	 coagulation	 system.	 In	
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resting	platelets,	the	plasma	membrane	aminophospholipid	phosphatidylserine	
(PS)	 is	 almost	 exclusively	 located	 in	 the	 inner	 (cytosolic)	 leaflet	 of	 the	 cell	
membrane.	Upon	platelet	activation,	PS	 is	 translocated	to	the	outer	 leaflet	of	
the	platelet	membrane,	making	it	accessible	to	circulating	coagulation	factors.	
Moreover,	 platelet	 activation	 leads	 to	 the	 shedding	 of	 microparticles,	 also	
exposing	PS	in	their	outer	membrane	leaflet.	PS	binds	and	activates	factors	Xa	
and	 Va,	 which	 form	 the	 prothrombinase	 complex,	 catalyzing	 the	 conversion	
from	 prothrombin	 to	 thrombin.[76]	 While	 the	 relative	 amount	 of	 PS	 in	 the	
plasma	 membrane	 increases	 in	 response	 to	 platelet	 activation,	 the	
phospholipid	phosphatidylinositol	is	reduced,	as	it	is	processed	to	diacylglycerol	
(DAG)	 and	 inositol	 triphosphate	 (IP3).[77]	 PS	 exposure	 is	 not	 the	 only	 link	
between	 platelet	 activation	 and	 promotion	 of	 the	 coagulation	 system.	 After	
stimulation	with	collagen	and	thrombin,	a	subpopulation	of	so-called	 'coated-
platelets’	 are	 formed,	 serving	 as	 a	 surface	 promoting	 thrombin	 generation.	
These	coated-platelets	not	only	express	PS	in	the	outer	membrane	leaflet,	but	
also	retain	high	levels	of	procoagulant	proteins	on	their	surface,	such	as	vWF,	
fibronectin,	thrombospondin	and	fibrinogen.[78]		
Recently,	 it	 was	 discovered	 that	 the	 degree	 and	 the	mechanisms	 of	 platelet	
activation	 are	 not	 uniform	 throughout	 the	 hemostatic	 plug.	 The	 primary	
thrombus	 is	a	hierarchically	organized	structure,	with	a	core	of	 fully	activated	
platelets	at	the	site	of	injury,	with	an	overlaying	shell	of	less	activated	platelets.	
Fibrin	formation	and	thrombin	activity	were	found	to	be	much	more	present	in	
the	 core	 than	 in	 the	 shell	 of	 the	 primary	 thrombus.	 The	 core	 also	 shows	 a	
greater	density	of	platelets	than	the	shell	does,	facilitating	contact-dependent	
signaling.	ADP	was	 found	 to	 regulate	platelets	 in	 the	 shell,	while	 it	 did	much	
less	so	in	the	core.[79]	
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Figure	1.3:	Mechanisms	of	platelet	activation	
Complex	 mechanisms	 underlie	 platelet	 activation.	 Vascular	 endothelial	 injury	 induces	
exposure	of	von	Willebrand	factor	 (vWF)	 in	the	subendothelial	matrix,	which	 leads	to	vWF	
binding	to	the	platelet	GP	Ib/XI/V	receptor.	Collagen	contributes	to	platelet	adhesion	via	the	
GP	Ia/IIa	and	GP	VI	receptors.	Increased	cytosolic	calcium	concentration	and	the	release	of	
activation	mediators	such	as	 thrombin,	adenosine	diphosphate	 (ADP)	and	thromboxane	A2	
(TXA2)	 further	 stimulate	 platelet	 activation.	 Thrombin	 activates	 the	 protease-activated	
receptor	1	(PAR1)	and	PAR4,	ADP	interacts	with	P2Y1	and	P2Y12	receptors	and	TXA2	with	the	
TP	receptor,	all	G-protein	coupled	receptors.	P2Y12	and	PAR1	have	a	Gi	α-subunit,	inhibiting	
adenylate	cyclase	(AC)	and	as	a	consequence,	preventing	the	formation	of	cAMP.	PAR4,	P2Y1	
and	TP	have	a	Gq	α-subunit,	which	activates	phospholipase	C	β	(PLCβ).	Binding	of	collagen	to	
the	GP	VI	receptor	also	induces	activation	of	PLCβ.	PLCβ	catalyzes	the	production	of	inositol	
triphosphate	 (IP3)	 and	 diacylglycerol	 (DAG)	 from	 phosphatidylinositol	 bisphosphate	 (PIP2).	
IP3	 binds	 endoplasmatic	 reticulum	 calcium	 channels,	 leading	 to	 an	 increased	 cytosolic	
calcium	concentration.	DAG	activates	protein	kinase	C	(PKC),	which	promotes	degranulation	
of	dense	and	α-granules.	The	release	of	active	substances	from	dense	and	α-granules	further	
stimulates	 activation	 of	 other	 platelets.	 TXA2,	 ADP	 and	 increased	 cytosolic	 calcium	
concentration	activate	the	platelet	fibrinogen	binding	αIIbβ3	receptor.	Binding	of	fibrinogen	
to	the	activated	αIIbβ3	receptors	of	different	platelets	leads	to	platelet-platelet	interactions	
and	the	formation	of	platelet	aggregates.	
	
1.3.1.2 Laboratory	investigations	of	platelet	morphology	and	function	
The	 platelet	 count	 (PLT	 count)	 can	 be	 measured	 manually	 or	 automatically.	
Mean	 platelet	 volume	 (MPV)	 gives	 information	 about	 the	 mean	 volume	 of	
individual	 platelets	 and	 platelet	 distribution	 width	 (PDW)	 indicates	 the	
variation	in	size	of	platelets.[80]	Platelet	count	and	morphology	are	investigated	
using	a	May-Grünwald	stained	blood	smear.	However,	detailed	ultrastructural	
platelet	 abnormalities	 such	 as	 granule	 defects	 can	 only	 be	 evaluated	 using	
electron	microscopy.	
Platelet	 function	 tests	 are	 generally	 used	 for	 the	 diagnosis	 of	 bleeding	
disorders.	 When	 the	 role	 of	 platelets	 in	 arterial	 thrombosis	 became	 clear,	
platelet	 function	 tests	 were	 also	 implemented	 for	 the	 identification	 of	
increased	 risk	 of	 thrombosis.	 The	 clinical	 use	 of	 platelet	 function	 tests	 has	
recently	 been	 reviewed.[75]	 Platelet	 function	 can	 be	 tested	 using	 several	
methods.	 Light	 transmission	 aggregometry	 (LTA)	 is	 still	 the	most	widely	 used	
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test	 to	 study	 platelet	 aggregability.[75]	 In	 this	 test,	 platelet	 aggregation	 is	
induced	 ex	 vivo	 by	 the	 addition	 of	 an	 agonist	 such	 as	 ADP,	 collagen,	
epinephrine,	AA	and	thrombin.[81]	Other	 less	 frequently	used	agonists	such	as	
thrombin-activating	peptide	 (TRAP)	and	U46619	may	be	employed	as	well.[82]	
Spontaneous	aggregation	without	addition	of	an	agonist	can	also	be	measured.	
Ristocetin-induced	 platelet	 agglutination	 can	 also	 be	 assessed	 by	 LTA.	
Ristocetin	 leads	 to	 a	 conformational	 change	 in	 vWF,	 inducing	 platelet	
agglutination	 (clumping	 together	 of	 platelets	 without	 platelet	 activation	 or	
fibrinogen	 binding).[83]	Much	 information	 can	 be	 obtained	 by	 LTA,	 as	 platelet	
function	is	studied	directly.	However,	a	limitation	of	this	technique	is	that	it	is	
an	 ex	 vivo	 assay,	 which	may	 not	 always	 reliably	 reflect	 in	 vivo	 conditions.[68]	
Moreover,	LTA	 is	quite	 labor-intensive,	requiring	a	certain	degree	of	technical	
expertise	 for	 performance	 and	 interpretation.	 Hence,	 its	 use	 is	 limited	 to	
specialized	laboratories.	
Platelet	function	can	also	be	assessed	using	indirect	markers	of	in	vivo	platelet	
activity.	Flow	cytometry	can	be	used	to	measure	platelet	surface	expression	of	
activation-dependent	 markers	 as	 P-selectin	 (CD62P),	 the	 active	 form	 of	 the	
fibrinogen	αIIbβ3	 receptor	 and	negatively	 charged	phospholipids,	 such	 as	 PS.	
Platelet	microparticles	can	also	be	quantified	with	flow	cytometry,	but	this	test	
is	not	routinely	performed	in	clinical	practice.	Flow	cytometry	is	a	sensitive,	but	
expensive	technique.	Whole-blood	samples	should	be	taken	 in	a	standardized	
way	 with	 a	 wide	 needle	 to	 prevent	 stasis	 and	 in	 vitro	 platelet	 activation.	
Furthermore,	several	soluble	markers	released	from	platelets	upon	activation,	
as	 for	 example	 β-thromboglobulin,	 platelet-derived	 growth	 factor	 (PDGF),	
platelet	 factor	 4,	 soluble	 P-selectin	 and	 thromboxanes	 can	 be	 measured	 in	
plasma,	 using	 enzyme-linked	 immuno	 sorbent	 assay	 (ELISA).	 Those	 markers,	
however,	are	surrogate	markers,	as	they	only	 indirectly	reflect	 in	vivo	platelet	
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activity.	Other	 factors	 besides	 platelet	 activation,	 such	 as	 platelet	 lysis,	 could	
lead	to	increased	levels.	Table	1.3	summarizes	laboratory	investigations	used	to	
study	platelet	morphology	and	function.	
	
Table	1.3:	Laboratory	investigations	of	platelet	morphology	and	function	
	
Morphology		 -Platelet	count		 -Platelet	indices:	MPV,	PDW		 -Blood	smear	for	light	microscopic	evaluation	-Electron-microscopic	evaluation		
Function		 Direct	measures	of	platelet	function:		 -Light-transmission	aggregometry		 Spontaneous	aggregation		 Aggregation	in	response	to	ADP,	collagen,	epinephrine,	AA,	thrombin	Agglutination	in	response	to	ristocetin			 Indirect	measures	of	platelet	function:		 -Flow	cytometry		 	 	 Expression	of	activation-dependent	markers	on	platelet	surface		 	 	 Quantification	of	platelet	microparticles		 	 -ELISA	for	soluble	markers	of	platelet	activation	in	plasma	or	urine		 	 	
MPV	 =	 mean	 platelet	 volume;	 PDW	 =	 platelet	 distribution	 width;	 ELISA	 =	 enzyme-linked	
immuno	sorbent	assay;	ADP	=	adenosine	diphosphate;	AA	=	arachidonic	acid	
	
1.3.2 Platelet	morphology	and	function	abnormalities	in	nephrotic	syndrome	
Patients	with	NS	have	an	 increased	risk	of	 thromboembolic	disease,	 including	
both	 deep	 venous	 and	 arterial	 thrombosis,	 which	 significantly	 increases	
morbidity	and	mortality	rates.	Underlying	mechanisms	of	thromboembolism	in	
NS	are	considered	to	be	multifactorial.	Disturbances	of	the	coagulation	system	
seem	 to	 play	 an	 important	 role	 in	 venous	 thrombotic	 events.[60]	 However,	
because	 the	 risk	 for	 arterial	 thrombosis	 is	 also	 elevated,	 a	 role	 has	 been	
postulated	for	platelets	 in	the	prothrombotic	state	 in	NS.	We	here	provide	an	
overview	 of	 the	 literature	 that	 supports	 a	 role	 for	 platelets	 as	 risk	 for	
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thrombosis	 in	 NS.	 Table	 1.4	 shows	 a	 summary	 of	 platelet	 abnormalities	 that	
have	already	been	reported	in	NS.	
	
Table	1.4:	Overview	of	platelet	changes	in	nephrotic	syndrome	
	
Platelet	morphology	 		 Platelet	count	(PLT	count)	 ì	[84-89],	~	[90-93]		 Mean	platelet	volume	(MPV)	 ì	[94],	î	[84]		 Platelet	distribution	width	(PDW)	 ì	[84]		 Plateletcrit	(PCT)	 ~	[84]	
Platelet	aggregation	 		 Aggregation	after	stimulation	with			 	 ADP	 ì	[86,89,90,93,95-97]		 	 Collagen	 ì	[89,90,93,95,96,98,99],	~	[86]		 	 Arachidonic	acid	 ì	[92,96,97],	~	[89,90,92]		 	 Epinephrine	 ì	[100]			 	 Spontaneous	 ì	[85,86,88,89,96,100]		 Agglutination	after	stimulation	with	 		 	 Ristocetin	 ì	[101],	~	[90]	Plasma	platelet	aggregate	ratio	 î	[102,103] 	 Platelet-platelet	aggregates	 ì	[87]		 Shear	stress	induced	platelet	aggregation		 ì	[104]	
Release	of	active	substances	from	platelets	 		 β-thromboglobulin	 ì	[88,89,95,105,106]		 Platelet	derived	growth	factor	 ì	[84]		 Interleukin-7	 ì	[107]		 Platelet	factor	4	 ~	[88,89]		 Soluble	P-selectin	 ì	[95]		 ATP,	in	response	to	collagen	 ì	[98]		 Thromboxane	A2	metabolites	in	urine	and	plasma	 ì	[108]		 Thromboxane	B2	release	of	platelets,	after	stimulation	with		 	 Collagen	 ì	[98],	~	[89,96]		 	 Arachidonic	acid	 ì	[89,96,102]		 	 ADP	 ~	[89]	
Platelet	surface	expression	 		 P-selectin	 ì	[87,95]		 Glycoprotein	53	 ì	[95]		 Phosphatidylserine	 ì	[91]	
Intraplatelet	alterations	 		 Calcium	concentration,	after	stimulation	with	STA2	 ì	[108]		 cAMP	concentration	 î	[98]	
Others	 		 Platelet	microparticles	 ì	[91]		 Platelet	adhesiveness	 ì	[88,93]		 Platelet-vessel	wall	interactions	under	flow	conditions		 ~	[109]	
ì	 =	 increased;	î	 =	 decreased;	 ~	 =	 no	 difference;	 ADP	 =	 adenosine	 diphosphate;	 ATP	 =	
adenosine	 triphosphate;	 STA2	 =	 9,11-epithio-11,12-methano-thromboxane	 A2;	 cAMP	 =	
cyclic	adenosine	monophosphate	
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1.3.2.1 Changes	in	PLT	count	and	morphology	during	nephrotic	syndrome	
In	 1981,	 Walter	 et	 al	 reported	 for	 the	 first	 time	 a	 statistically	 significant	
increased	 mean	 PLT	 count	 of	 281	 x	 109/L	 in	 adult	 patients	 with	 NS	 in	
comparison	 to	 216	 x	 109/L	 in	 the	 healthy	 control	 group.[88]	 This	 was	 later	
confirmed	by	two	studies[86,89],	while	other	studies	found	a	normal	PLT	count	in	
adult	 patients	 with	 NS[91,92].	 These	 findings	 suggest	 that	 even	 if	 a	 significant	
increase	 in	 PLT	 count	 is	 present	 in	 adult	 patients	 with	 NS,	 the	 increase	 is	
limited.	Its	clinical	significance	remains	questionable.	
For	children,	several	studies	show	mean	PLT	counts	above	the	reference	values	
of	150-450	x	109/L[84,85,87],	 supporting	evidence	 for	 thrombocytosis	 in	 children	
with	NS.	PLT	counts	during	remission	after	the	start	of	corticosteroid	treatment	
and	early	after	cessation	of	corticosteroid	treatment	remain	high[84,85,87],	while	
they	normalize	during	 long-term	 remission[87].	 Contradicting	previous	 reports,	
Mittal	 et	 al	 recently	 described	 normal	 PLT	 counts	 in	 Indian	 nephrotic	
children.[90]		
An	elevated	PDW	and	a	decreased	MPV	are	present	in	children	with	NS	before	
the	 start	 of	 treatment.[84]	 Increased	 MPV	 levels	 during	 treatment	 for	 NS	 in	
adults	correlate	with	therapy	resistance	after	12	months.[94]		
	
1.3.2.2 Increased	platelet	activation	in	nephrotic	syndrome	
Numerous	 studies	 revealed	 evidence	 for	 an	 increased	 platelet	 function	 in	
idiopathic	NS.		
1.3.2.2.1	 Hyperaggregability	of	platelets		
Platelet	aggregability	has	repeatedly	been	tested	 in	patients	during	relapse	of	
NS	and	was	compared	with	platelet	aggregability	in	healthy	control	subjects	or	
in	 NS	 patients	 during	 remission.	 The	 majority	 of	 studies	 report	 increased	
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platelet	 aggregability	 both	 in	 adults	 and	 children	 in	 response	 to	 various	
agonists:	 ADP[86,89,90,93,95-97],	 collagen[89,90,93,95,96,98,99],	 AA[92,96,97]	 and	
epinephrine[100],	 and	 increased	 platelet	 agglutination	 after	 stimulation	 with	
ristocetin[101]	 (Table	 1.4).	 However,	 other	 studies	 could	 not	 find	 increased	
platelet	 aggregability	 in	 response	 to	 collagen[86],	 AA[89,90,92]	 and	 ristocetin[90].	
Spontaneous	aggregation	can	be	present	during	NS	as	well.[85,86,88,89,96,100]	
	
1.3.2.2.2	 Altered	expression	of	surface	markers	of	platelet	function	
Platelet	activation	leads	to	cell	membrane	expression	of	different	markers.	As	
described	above,	these	‘activation-dependent’	markers	can	be	used	as	markers	
for	 platelet	 activation.	 In	 NS,	 alterations	 in	 several	 platelet	 surface	 markers	
indicating	 enhanced	 platelet	 activation	 have	 been	 observed	 (Table	 1.4).	
Elevated	surface	expression	of	P-selectin	was	found	both	in	children	and	adults	
during	 relapse	 of	 NS.[87,95]	 Lysosomal	 membrane	 glycoprotein	 63	 (CD63)	
expression	in	the	platelet	cell	membrane	is	also	increased	in	NS	patients	during	
relapse.	[95]	
	
1.3.2.2.3	 Increased	release	of	active	substances	
Active	substances	released	from	platelets	upon	activation	can	be	measured	in	
the	 patient’s	 plasma	 and	 can	 then	 be	 used	 as	 surrogate	 markers	 of	 in	 vivo	
platelet	 activity.	 Increased	 levels	 of	 various	 active	 substances	 secreted	 by	
platelets	have	been	reported	 in	patients	during	relapse	of	NS,	compared	with	
healthy	control	subjects	or	with	patients	during	remission	(Table	1.4). Several	
substances	 released	 from	α-granules	 upon	 platelet	 activation	 are	 elevated	 in	
plasma	 during	 NS.	 β-thromboglobulin,	 a	 platelet-specific	 protein,	 was	
repeatedly	 found	 to	 be	 elevated	 in	 adults	 during	 NS.[88,89,95,105,106]	 Platelet-
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derived	 growth	 factor	 (PDGF)[84]	 and	 interleukin-7	 (IL-7)[107]	 are	 increased	 in	
pediatric	patients	during	NS,	while	plasma	levels	of	platelet	factor	4,	another	α-
granule	 component,	 are	 normal.[88,89]	 Plasma	 levels	 of	 the	 soluble	 form	 of	 P-
selectin	 are	 elevated	 in	 both	 adults	 and	 children	 during	 idiopathic	 NS.[95,110]	
Moreover,	 increased	 thromboxane	 formation	was	 observed	 during	 NS.	 TXA2,	
which	is	a	strong	inducer	of	platelet	activation,	is	formed	from	AA	in	activated	
platelets	by	the	COX	pathway.	TXA2	has	a	short	half-life	and	 is	metabolized	to	
thromboxane	 B2	 (TXB2)	 and	 malondialdehyde	 (MDA),	 which	 can	 be	 used	 as	
markers	of	platelet	prostaglandin	synthesis.[100]	Increased	TXA2	metabolites	are	
found	 in	plasma	and	urine	of	pediatric	patients	with	NS,	 indicating	enhanced	
TXA2	synthesis	in	platelets	and	the	kidney	in	NS.[108]		
However,	 these	 active	 substances	 released	 from	 platelets	 can	 also	 be	
measured	in	the	supernatant	following	ex	vivo	platelet	aggregation.	They	then	
directly	reflect	the	ex	vivo	platelet	activity.	Increased	levels	of	active	substances	
are	 also	 found	 in	 samples	 of	 NS	 patients	 after	 ex	 vivo	 platelet	 aggregation.	
Platelets	from	pediatric	NS	patients	release	an	 increased	amount	of	ATP	from	
dense	granules	in	response	to	collagen.[98]	The	production	of	MDA	and	TXB2	by	
platelets	following	AA	challenge	is	also	increased	in	NS,	indicating	activation	of	
the	 TXA2	signal	 transduction	 system.[89,96,102]	 TXB2	 formation	 after	 stimulation	
with	 ADP	 and	 collagen	 is	 not	 altered	 in	 adult	 patients	 with	 NS[89,96],	 while	
increased	TXB2	release	of	platelets	 in	 response	 to	 collagen	 is	 seen	 in	 children	
with	NS.[98]	
	
1.3.2.2.4	 Phosphatidylserine	exposure	
As	previously	explained,	under	normal	circumstances	PS	is	only	present	on	the	
inner	(cytosolic)	part	of	the	cell	membrane.	In	case	of	platelet	activation,	PS	is	
externalized	to	the	outer	part	of	the	membrane,	promoting	the	generation	of	
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thrombin,	 a	 central	 component	 of	 the	 coagulation	 system.[76]	 During	 this	
process,	microparticles	may	be	released	into	the	circulation.	Microparticles	are	
small	(<1	μm)	vesicular	cell	membrane	fragments.	They	originate	from	various	
cell	 types	 and	 contain	 antigens	 from	 their	 parent	 cells	 including	 surface	
proteins	 and	 cytoplasmic	 materials.	 Increased	 platelet	 microparticles	 were	
found	 to	 be	 a	 marker	 of	 platelet	 activation.[111]	 Elevated	 levels	 of	 platelet	
microparticles	and	increased	PS	exposure	are	present	in	pediatric	and	adult	NS	
patients	during	relapse.[87,91]	
	
1.3.2.3 	Pathogenesis	of	platelet	abnormalities	in	nephrotic	syndrome	
The	etiology	of	the	observed	platelet	abnormalities	in	NS	is	poorly	understood.	
An	 important	question	remains	whether	these	platelet	changes	 in	NS	are	due	
to	an	intrinsic	defect	or	result	from	nephrotic	alterations	that	lead	to	abnormal	
levels	of	platelet-related	proteins	and	lipids	in	nephrotic	plasma.	
	
1.3.2.3.1	 Pathogenesis	of	morphologic	and	quantitative	platelet	 changes	 in	
nephrotic	syndrome	
The	 pathophysiology	 underlying	 increased	 PLT	 counts	 in	 NS	 has	 not	 been	
studied	 in	 detail.	 Hypoalbuminemia	 has	 been	 suggested	 to	 play	 a	 role	 in	
increased	 PLT	 counts.	 An	 inverse	 correlation	 between	 PLT	 count	 and	 plasma	
albumin	 levels	 was	 found	 in	 one	 study[99],	 but	 was	 not	 confirmed	 in	 a	 later	
study.[89]	Hypercholesterolemia	has	 also	been	proposed	 to	be	 involved	 in	 the	
pathogenesis.	However,	non-nephrotic	hypercholesterolemic	patients	have	an	
increased	megakaryocyte	ploidy,	but	 they	do	not	have	altered	PLT	counts.[112]	
Moreover,	 PLT	 count	 do	 not	 correlate	 with	 cholesterol	 levels	 in	 nephrotic	
patients.[84]		
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1.3.2.3.2	 Pathogenesis	of	functional	platelet	changes	in	nephrotic	syndrome	
1.3.2.3.2.1 Stimulation	of	the	COX	pathway	
In	 1973,	 Bang	 et	 al	 suggested	 that	 urinary	 losses	 of	 proteins	 responsible	 for	
inhibition	of	platelet	function	in	glomerular	disease,	lead	to	enhanced	platelet	
function.[99]	 Proteinuria	 was	 found	 to	 correlate	 with	 the	 level	 of	
hyperaggregability,	 spontaneous	 platelet	 aggregation	 and	 platelet	
adhesiveness.[88,99]	 Addition	 of	 concentrated	 urine	 proteins	 from	 nephrotic	
patients	 indeed	 inhibits	platelet	aggregation,	while	addition	of	normal	plasma	
diminishes	 the	 production	 of	 prostaglandin	 metabolites	 MDA	 and	 TXB2	 by	
nephrotic	platelets.[99]	Addition	of	nephrotic	plasma	leads	to	the	stimulation	of	
production	of	 those	prostaglandin	metabolites	 in	normal	platelets.[102]	Hence,	
platelet	hyperactivation	seems	to	be	due	to	plasma	alterations	rather	than	to	
an	intrinsic	defect.		
Because	 albuminuria	 and	 hypoalbuminemia	 are	 prominent	 features	 in	 NS,	
albumin	was	suggested	to	exert	a	suppressive	effect	on	platelet	function.	The	
proposed	 mechanism	 of	 platelet	 inhibition	 is	 the	 binding	 of	 AA	 by	 albumin,	
preventing	it	to	be	metabolized	to	TXA2	and	endoperoxides,	which	are	potent	
proaggregating	substances.[92,96,102,113]	The	effect	of	human	albumin	addition	to	
patient	samples	was	studied	to	further	elucidate	the	role	of	hypoalbuminemia	
in	platelet	hyperactivation.	Some	studies	 in	adult	nephrotic	patients	 reported	
that	 addition	 of	 human	 albumin	 indeed	 causes	 inhibition	 of	 platelet	
aggregation	 in	 response	 to	 collagen[96,113],	 AA[92,96,97]	 and	 spontaneous	
aggregation[96].	 However,	 platelet	 hyperaggregation	 in	 response	 to	 AA	 in	
nephrotic	children,	 is	not	 inhibited	by	albumin.[92]	Addition	of	human	albumin	
inhibits	MDA	 formation	and	 release	of	 TXB2	 and	AA	 from	platelets	of	 control	
subjects	and	patients	with	NS.[102,113]	 Jackson	et	al	 reported	that	albumin	only	
inhibits	TXB2	production	in	response	to	AA,	but	not	to	collagen.[96]	The	relation	
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between	albuminemia	and	platelet	activation	markers	was	further	studied.	An	
inverse	 correlation	 between	 serum	 albumin	 levels	 and	 platelet	 aggregation,	
both	spontaneous	and	in	response	to	various	aggregation	inducers,	was	found	
in	some	studies[88,89,92,99,114],	but	was	not	confirmed	in	others[89,96,115,116].	Inverse	
correlations	 were	 also	 observed	 between	 serum	 albumin	 levels	 and	 several	
markers	of	platelet	activation,	such	as	β-thromboglobulin	levels[105,114],	PDGF[84],	
TXB2	generation	in	response	to	AA[96]	and	platelet	adhesiveness[88].	But	the	net	
conversion	 to	 TXB2	 is	 not	 dependent	 on	 albumin	 concentration	 in	 normal	
platelets.[100]		
Certain	proteins	and	lipids	are	slightly	increased	in	NS,	probably	due	to	hepatic	
hyperfunction	 in	 response	 to	 hypoalbuminemia.	 Platelet	 hyperfunction	 could	
also	 be	 a	 consequence	 of	 increased	 levels	 of	 platelet	 activating	 substances.	
Hypercholesterolemia,	 another	 main	 feature	 in	 NS,	 could	 cause	 platelet	
hyperfunction	by	affecting	diglyceride	 lipase	and	phospholipase	A2,	which	are	
involved	 in	 the	 release	 of	 AA	 from	 platelet	 phospholipids.[117,118]	 However,	
hypercholesterolemia	 in	 non-nephrotic	 subjects	 is	 associated	 with	 increased	
platelet	expression	of	GP	IIIa,	but	not	with	an	altered	expression	of	P-selectin	
and	CD63.[112]	The	effect	of	hypercholesterolemia	on	platelet	function	in	NS	is	
not	well	investigated.	Some	studies	reported	correlations	between	cholesterol	
levels	and	platelet	aggregation	in	NS[88,89],	but	later	studies	did	not	confirm	this	
correlation[87,89,98].		
	
1.3.2.3.2.2 Other	pathways	
Because	no	increase	in	production	of	TXB2	was	seen	after	stimulation	with	ADP,	
collagen	or	ristocetin,	it	was	proposed	that	at	least	part	of	the	platelet	function	
disturbances	 seen	 in	 NS	 are	 independent	 of	 the	 AA	 pathway	 of	 platelet	
activation.[89,92]	 Also,	 indomethacin	 prevents	 TXB2	 release	 after	 stimulation	 of	
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NS	platelet-rich	plasma	 (PRP)	with	AA,	but	no	effect	 is	 seen	after	 stimulation	
with	 ristocetin.[92]	 These	 observations	 indicate	 that	 another	 pathway	 apart	
from	the	COX	pathway	may	play	a	role	in	platelet	alterations	in	NS.		
Elevated	plasma	levels	of	high	molecular	weight	platelet	binding	proteins	such	
as	 vWF	 and	 fibrinogen	 are	 found	 in	 patients	 with	 NS,	 due	 to	 hepatic	
hyperfunction.[119]	 Given	 their	 major	 contribution	 to	 platelet	 adhesion	 and	
aggregation	respectively,	vWF	and	fibrinogen	probably	play	an	 important	role	
in	 increased	 platelet	 activation	 during	 NS.	 Serum	 fibrinogen	 levels	 correlate	
with	 aggregation	 in	 response	 to	 ADP,	 spontaneous	 aggregation	 and	 IL-7	
levels.[89]	 However,	 aggregation	 in	 response	 to	 collagen	 and	 AA,	 as	 well	 as	
percentages	of	platelet-platelet	aggregates	and	surface	expression	of	P-selectin	
do	 not	 correlate	with	 fibrinogen	 levels.[87,89]	 The	 effect	 of	 increased	 levels	 of	
vWF	on	platelet	alterations	in	NS	has	never	been	studied.		
Turi	et	al	suggested	that	an	intraplatelet	mechanism	via	calcium	release	could	
lead	to	increased	platelet	activation	in	NS,	apart	from	low	serum	albumin	levels	
or	 hypercholesterolemia.	 They	 observed	 reduced	 intraplatelet	 cAMP	
concentrations	in	nephrotic	children.[98]		
	
1.3.2.4 Role	of	platelet	abnormalities	in	nephrotic	syndrome	
As	 described	 above,	 several	 signs	 of	 platelet	 hyperaggregation	 and	
hyperactivity	 were	 found	 in	 patients	 with	 NS.	 The	 question	 remains	 if	 the	
platelet	 alterations	 seen	 in	 NS	 are	 a	 substantially	 contributing	 factor	 for	 the	
occurrence	of	thromboembolic	phenomena.	The	pathophysiological	processes	
underlying	 venous	 and	 arterial	 thrombosis	 are	 distinct.	 Disturbances	 of	
coagulation	or	fibrinolytic	factors,	and	abnormalities	of	blood	vessels	and	blood	
flow	 are	 important	 in	 the	 pathogenesis	 of	 venous	 thrombosis.	 As	 described	
above,	 alterations	 in	 plasma	 levels	 of	 pro-	 and	 anticoagulant	 factors	 are	
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present	 in	 patients	 with	 NS,	 explaining	 the	 increased	 risk	 of	 venous	
thrombosis.[64,120]	Arterial	thrombosis	on	the	other	hand,	depends	on	platelets	
and	vessel	wall	defects.[121]	The	fact	that	the	risk	of	arterial	thrombosis	 is	also	
elevated	 in	 NS	 patients,	 points	 to	 an	 additional	 role	 for	 blood	 platelets.	
Moreover,	recent	studies	suggest	a	role	for	platelets	in	the	pathophysiology	of	
venous	 thrombosis.[122,123]	 Platelet	 activation	 and	 increased	 PLT	 counts	 are	
significant	 risk	 factors	 for	 the	 occurrence	 of	 venous	 thromboembolism	 in	
patients	 with	 cancer.[124,125]	 Increased	 PLT	 count	 is	 also	 independently	
associated	 with	 venous	 thromboembolism	 in	 hospitalized	 patients.[126]	
Furthermore,	aspirin	is	effective	in	the	prevention	not	only	of	arterial,	but	also	
of	 venous	 thromboembolic	 events,	 supporting	 evidence	 that	 platelets	
contribute	to	the	initiation	and	progression	of	venous	thrombosis.[122,123]		
Children	 with	 NS	 have	 an	 overall	 risk	 for	 thromboembolism	 of	 around	 3%,	
mostly	 venous	 thrombosis.[60,127]	 The	 epidemiology	 of	 venous	 thrombosis	 has	
recently	 been	 reviewed	 in	 detail.[127]	 The	 incidence	 of	 arterial	 thrombosis	 in	
adult	patients	with	NS	is	8	times	higher	than	that	in	the	control	population.[64]	
Few	recent	epidemiologic	data	regarding	the	incidence	of	arterial	thrombosis	in	
childhood	idiopathic	NS	are	available,	but	a	2009	study	of	Kerlin	et	al	observed	
25.8	thromboembolic	events	per	1000	patient-years	 in	pediatric	patients	with	
NS,	with	0.68	arterial	thrombotic	events	per	1000	patient-years.[120]	Hence,	the	
absolute	incidence	rate	of	arterial	thrombosis	seems	to	be	low	in	children	with	
NS.	 However,	 arterial	 thrombosis	 is	 extremely	 rare	 in	 healthy	 children.	
Epidemiologic	 data	 are	 sparse,	 but	 in	 2011	 a	 Danish	 study	 reported	 an	
incidence	 rate	 for	 arterial	 non-cerebral	 thrombosis	 in	 the	 total	 pediatric	
population	of	0.0029	per	1000	person-years.[128]	Even	though	cerebral	arterial	
thrombotic	events	are	not	included	in	this	study,	based	on	these	data,	pediatric	
patients	with	NS	seem	to	have	a	very	high	relative	risk	of	this	potentially	 life-
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threatening	 complication	 compared	 to	 the	 general	 pediatric	 population.	 This	
risk	 is	even	much	higher	than	the	8-fold	 increase	 in	relative	risk	seen	 in	adult	
NS	patients.[64]	These	data	suggest	that	NS	has	a	strong	influence	on	the	risk	of	
both	arterial	and	venous	thrombosis.	
Large	epidemiologic	studies	 investigating	risk	 factors	 for	thrombosis	 in	NS	are	
lacking,	 especially	 in	 children.	 One	 pediatric	 study	 reported	 ‘high	 degree	 of	
proteinuria’	 and	 ‘age	 above	 12	 years’	 as	 risk	 factors	 for	 thrombosis.[120]	 In	
adults,	 proteinuria/serum	 albumin	 ratio	 was	 found	 to	 be	 a	 risk	 factor	 for	
venous	 thrombosis	 and	 age,	 sex,	 hypertension,	 diabetes,	 smoking	 and	
estimated	 glomerular	 filtration	 rate	 (eGFR)	 are	 risk	 factors	 for	 arterial	
thrombosis.[64]	However,	the	findings	are	not	specific	for	idiopathic	NS,	as	also	
patients	with	nephrotic	range	proteinuria	from	other	etiologies	were	included	
in	this	study.	Only	one	study	reported	the	relation	between	platelet	alterations	
and	 occurrence	 of	 thrombosis	 in	 NS.	 A	 higher	 incidence	 of	 thromboembolic	
events	 was	 seen	 in	 membranous	 nephropathy	 compared	 to	 other	 histologic	
lesions	and	 the	only	difference	between	 those	groups	was	hyperaggregability	
of	 platelets	 in	 55%	 vs.	 20%	 of	 patients,	 while	 all	 other	 studied	 coagulation	
parameters	did	not	differ.[86]	The	latter	suggests	a	contributing	role	for	platelet	
hyperactivity	in	the	occurrence	of	thrombosis	in	NS.		
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Chapter	2:	 Objectives	and	hypothesis	of	
this	study	
Nephrotic	 syndrome	 (NS)	 is	 a	 rare	 disease	 defined	 by	 severe	 proteinuria,	
hypoalbuminemia,	 edema	 and	 hyperlipidemia.	 NS	 is	 associated	 with	 a	
significantly	 elevated	 risk	 of	 thrombotic	 events,	 including	 both	 deep	 venous	
and	arterial	 thrombosis,	which	 significantly	 increases	morbidity	 and	mortality	
rates.	 Alterations	 in	 plasma	 levels	 of	 pro-	 and	 anticoagulant	 factors,	 as	 a	
consequence	 of	 nephrosis,	 are	 involved	 in	 the	 pathophysiology	 of	 venous	
thrombosis	 in	NS.	However,	 the	 fact	 that	 the	risk	of	both	venous	and	arterial	
thrombosis	 is	 elevated	 in	NS	 points	 to	 an	 additional	 role	 for	 blood	 platelets.	
Increased	platelet	counts	and	platelet	hyperactivity	have	indeed	been	observed	
in	 nephrotic	 children.[129]	 The	 underlying	 molecular	 mechanisms	 for	 these	
changes	in	platelet	count	and	function	in	NS	are	still	unknown.		
Recently,	 a	 role	 for	 PACAP	 as	 an	 inhibitor	 of	 megakaryopoiesis	 and	 platelet	
function	was	 identified	 in	our	 institution.	 In	a	 study	 in	patients	with	elevated	
PACAP	plasma	levels	because	of	PACAP	overexpression	due	to	a	partial	trisomy	
18p,	 and	 in	 transgenic	 mice	 with	 megakaryocyte-specific	 PACAP	
overexpression,	 it	 was	 demonstrated	 that	 PACAP	 inhibits	 megakaryopoiesis	
and	 platelet	 function,	 via	 its	 VPAC1	 receptor.[10,11]	 In	 contrast,	 stimulation	 of	
platelet	 function	 and	 megakaryopoiesis	 was	 obtained	 in	 wild-type	 mice	
injected	 with	 a	 PACAP	 antagonist	 PACAP(6-38)	 or	 a	 monoclonal	 inhibitory	
antibody	 against	 PACAP	or	 its	 receptor	VPAC1,	 as	well	 as	 in	 PACAP	 knockout	
mice.	 Moreover,	 a	 thrombopoietic	 effect	 of	 VPAC1	 inhibition	 in	
thrombocytopenia	murine	models	was	found.		
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The	 first	 aim	 of	 this	 Ph.D.	 thesis	 was	 to	 study	 a	 possible	 role	 for	 PACAP	 in	
increased	 platelet	 counts	 and	 hyperreactivity	 observed	 in	 NS	 patients.	 We	
hypothesized	 that	 urinary	 loss	 of	 PACAP	 in	 severe	 NS	 could	 lead	 to	 plasma	
PACAP	deficiency	 and	be	 a	 cause	of	 increased	megakaryopoiesis	 and	platelet	
activation.		
	
A	 nephroprotective	 effect	 of	 PACAP	 has	 been	 demonstrated	 in	 a	 variety	 of	
renal	 disease	 models.	 Changes	 induced	 by	 PACAP	 include	 inhibition	 of	
upregulated	apoptotic	pathways	 in	proximal	 tubular	epithelial	cells,	 increased	
cell	 survival	 and	 decreased	 production	 of	 proinflammatory	 and	 profibrotic	
substances.[20]	However,	 little	is	known	about	the	expression	of	PACAP	and	its	
receptors	 in	 the	 human	 kidney.	 Moreover,	 no	 data	 exist	 about	 the	 role	 of	
PACAP	 in	 proteinuric	 conditions.	 Chronic	 proteinuria	 leads	 to	 apoptosis	 of	
proximal	 tubular	 cells	 and	 to	 secretion	 of	 pro-inflammatory	 and	 profibrotic	
substances,	 causing	 tubulointerstitial	 damage,	 leading	 to	progression	of	 renal	
disease.[130]	 Since	 PACAP	 has	 been	 shown	 to	 be	 cytoprotective	 for	 proximal	
tubular	 epithelial	 cells,	we	hypothesized	 that	 it	 could	 also	 influence	proximal	
tubular	response	to	proteinuria.	
Hence,	 the	 expression	of	 PACAP	 and	 its	 receptors	 in	 the	 kidney,	 as	well	 as	 a	
possible	 nephroprotective	 effect	 of	 PACAP	 in	 proteinuric	 conditions,	 are	 the	
second	aim	of	this	Ph.D.	thesis.	
	
The	following	research	questions	will	be	addressed	in	this	thesis:	
1. Is	PACAP	deficiency	present	in	patients	with	Finnish-type	congenital	NS,	
a	 rare	 but	 very	 severe	 form	 of	 NS?	 Does	 PACAP	 deficiency	 in	 these	
conditions	 play	 a	 role	 in	 the	 increased	 platelet	 count	 and	
hyperaggregability?	 Can	 the	 findings	 in	 congenital	 NS	 patients	 be	
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reproduced	 in	 other,	 more	 common	 forms	 of	 childhood	 NS?	 These	
questions	are	addressed	in	chapter	3.	
2. Can	 a	 zebrafish	 NS	 model	 be	 developed	 to	 further	 study	 the	 role	 of	
PACAP	 loss	 for	enhanced	megakaryopoiesis?	This	question	 is	addressed	
in	chapter	4.	
3. Are	 PACAP	 and	 its	 receptors	 expressed	 in	 the	 human	 kidney	 and	 in	
human	 renal	 cell	 lines?	 Is	 there	a	 role	 for	PACAP	 in	proteinuria	 related	
proximal	tubular	damage?	These	questions	are	addressed	in	chapter	5.	
In	 chapter	6,	a	general	discussion	 is	provided,	 summarizing	 the	 results	of	our	
studies	and	future	perspectives.	
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Chapter	3:	 PACAP	deficiency	as	a	cause	
of	increased	platelet	count	and	
aggregability	in	nephrotic	syndrome	
	
Based	on:	
Eneman	 B,	 Freson	 K,	 van	 den	 Heuvel	 L,	 van	 Hoyweghen	 E,	 Collard	 L,	 Vande	
Walle	J,	Van	Geet	C,	Levtchenko	E.	PACAP	deficiency	associated	with	increased	
platelet	count	and	aggregability	in	nephrotic	syndrome.	Journal	of	Thrombosis	
and	Hemostasis.	2015	May;13(5):755-67.	
	
Objective:	The	pituitary	adenylate	 cyclase-activating	polypeptide	 (PACAP)	was	
recently	 identified	 as	 an	 inhibitor	 of	 megakaryopoiesis	 and	 platelet	
aggregability.	 We	 studied	 PACAP	 levels	 in	 children	 with	 nephrotic	 syndrome	
(NS),	which	 is	associated	with	thrombocytosis,	platelet	hyperaggregability	and	
an	increased	risk	for	thrombosis.	
Patients/Methods:	In	4	children	with	congenital	NS	(CNS)	and	24	children	with	
idiopathic	NS	(INS),	plasma	and	urine	levels	of	PACAP	and	ceruloplasmin	were	
measured,	 as	 well	 as	 platelet	 counts	 and	 platelet	 aggregation	 responses	 to	
collagen.	 In	 CNS	 patients,	 in	 vitro	megakaryopoiesis	 and	 NF-κB	 expression	 in	
platelet	lysates	were	also	measured.	All	tests	were	performed	during	nephrotic	
and	non-nephrotic	state.	
Results:	Urinary	 losses	of	PACAP	and	ceruloplasmin	were	observed	during	the	
nephrotic	 state	 and	 disappeared	 in	 the	 non-nephrotic	 state.	 Plasma	 PACAP	
deficiency	was	more	pronounced	in	CNS	compared	to	INS.	Thrombocytosis	was	
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observed	in	all	CNS	and	in	11/29	cases	with	INS	during	nephrotic	state.	During	
the	 PACAP-deficient	 state,	 in	 vitro	 megakaryopoiesis	 was	 increased	 for	 CNS	
patients	 and	 this	 effect	 could	 be	 reversed	 by	 the	 addition	 of	 recombinant	
PACAP.	Platelet	hyperaggregability	was	observed	during	nephrotic	state	in	both	
CNS	and	 INS.	 In	 INS	patients,	 the	addition	of	 recombinant	PACAP	to	patients’	
platelets	was	 studied	and	 resulted	 in	decreased	aggregation	during	nephrotic	
state.	Platelet	aggregation	correlated	 inversely	with	plasma	PACAP	 levels,	but	
not	with	serum	albumin	levels. 
Conclusions:	 We	 demonstrate	 urinary	 losses	 of	 PACAP	 and	 plasma	 PACAP	
deficiency	 in	 children	 with	 NS,	 associated	 with	 thrombocytosis	 and	 platelet	
hyperaggregability. 
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3.1 Introduction	
3.1.1 PACAP	as	an	inhibitor	of	megakaryopoiesis	and	platelet	function	
The	 pituitary	 adenylate	 cyclase-activating	 polypeptide	 (PACAP)	 is	 a	 highly	
conserved	 neuropeptide,	 which	 was	 first	 isolated	 in	 1989	 from	 ovine	
hypothalamic	 tissue	 and	 was	 identified	 to	 stimulate	 cAMP	 formation	 in	 rat	
pituitary	cells.[1,3]	The	ADCYAP1	gene	is	located	on	chromosome	18p11.32	and	
encodes	a	176-amino	acid	prepro-protein	of	PACAP	(18.8	kDa),	from	which	two	
active	 PACAP	 peptides	 are	 processed:	 PACAP(1-38)	 (4.5	 kDa)	 and	 its	 shorter	
variant	 PACAP(1-27)	 (3	 kDa).	 In	 human	 plasma,	 PACAP	 is	 bound	 to	
ceruloplasmin	(132	kDa),	which	prevents	it	from	rapid	degradation.[4]	PACAP	is	
widely	 expressed	 in	 the	 nervous	 system	 and	 in	 several	 peripheral	 tissues.	 It	
plays	a	role	as	a	neurotransmitter/neuromodulator	and	takes	part	 in	multiple	
biological	 processes,	 including	 stimulation	 of	 cell	 multiplication	 and	
differentiation	and	prevention	of	apoptosis.[3]	Three	G-protein	coupled	PACAP	
binding	 receptors	 have	 been	 identified:	 PAC1,	which	 is	 PACAP-specific	 and	 is	
coupled	 to	 several	 transduction	 systems,	 and	 VPAC1	 and	 VPAC2,	which	 bind	
both	PACAP	and	vasoactive	intestinal	peptide	(VIP)	and	are	coupled	to	adenylyl	
cyclase.[6-8]	
A	role	for	PACAP	as	an	inhibitor	of	megakaryopoiesis	and	platelet	function	was	
identified.	 Kis	 et	 al	 reported	 an	 inhibitory	 effect	 of	 PACAP	 on	 the	
cyclooxygenase	pathway	in	rat	platelets	via	a	PACAP	receptor-activated,	cAMP	
dependent	pathway.[9]	 Freson	 et	al	 reported	 in	patients	with	elevated	PACAP	
plasma	 levels	 due	 to	 a	 partial	 trisomy	 18p	 and	 in	 transgenic	 mice	 with	
megakaryocyte-specific	 PACAP	 overexpression,	 that	 PACAP	 inhibits	
megakaryopoiesis	 and	 platelet	 function	 and	 prolongs	 the	 bleeding	 time,	 via	
activation	 of	 adenylyl	 cyclase	 coupled	 VPAC1	 on	 platelets	 and	
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megakaryocytes.[10,11]	 On	 the	 contrary,	 stimulation	 of	 platelet	 function	 and	
megakaryopoiesis	 was	 obtained	 in	 wild-type	 mice	 injected	 with	 a	 PACAP	
antagonist	 PACAP(6-38)	 or	 a	 monoclonal	 antibody	 against	 PACAP	 or	 its	
receptor	 VPAC1,	 as	well	 as	 in	 PACAP	 knockout	mice.	 Peeters	et	 al	 showed	 a	
thrombopoietic	 effect	 of	 VPAC1	 inhibition	 in	 thrombocytopenia	 murine	
models.[12]		Recently,	Di	Michele	et	al	suggested	that	PACAP	signaling	via	VPAC1	
leads	to	interference	of	the	normal	regulation	of	apoptosis	in	megakaryocytes,	
probably	via	Nuclear	factor	kappa-light-chain-enhancer	of	activated	B	cells	(NF-
κB).[13]	
	
3.1.2 Increased	risk	of	thromboembolic	disease	in	nephrotic	syndrome	
Nephrotic	 syndrome	 (NS)	 is	 a	 disease	 defined	 by	 severe	 proteinuria	 (urinary	
protein	 levels	 >	 50	 mg/kg/day)	 due	 to	 increased	 glomerular	 permeability,	
hypoalbuminemia,	 edema	 and	 hyperlipidemia.[37]	 Damage	 of	 the	 glomerular	
filtration	 barrier	 can	 be	 caused	 by	 genetic,	 immunologic,	 infectious,	 toxic	 or	
other	unknown	factors.	Congenital	NS	(CNS)	is	a	severe	variant	of	NS,	starting	
within	3	months	after	birth	and	most	frequently	caused	by	mutations	in	NPHS1,	
NPHS2,	 WT1,	 LAMB2	 or	 PLCE1.[44,45]	 Idiopathic	 NS	 (INS)	 is	 in	 general	 a	 less	
severe	form	of	NS,	most	often	starting	after	the	age	of	1	year.	The	etiology	of	
INS	is	not	completely	understood.[131] 
NS	patients	have	an	increased	risk	for	thrombosis,	including	both	deep	venous	
and	arterial	 thrombosis.	 It	occurs	 in	20-37%	of	adults,	and	1-27%	of	children,	
depending	 on	 etiology	 and	 severity	 of	 the	 NS	 and	 on	 whether	 imaging	 to	
diagnose	thromboembolism	is	performed	in	all	patients	or	only	in	patients	with	
clinical	 symptoms.[60,63,64]	 Underlying	mechanisms	 of	 thromboembolism	 in	 NS	
are	 multifactorial.	 Several	 studies	 report	 increased	 levels	 of	 prothrombotic	
factors	 as	 factor	 V,	 factor	 VIII,	 von	 Willebrand	 factor	 and	 fibrinogen[132-135],	
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probably	 due	 to	 liver	 hyperfunction	 in	 response	 to	 hypoalbuminemia.	
Moreover,	 decreased	 plasma	 levels	 of	 antithrombotic	 factors	 such	 as	
antithrombin	and	protein	C	and	S	and	of	the	thrombolytic	factor	plasminogen	
were	found	in	NS	patients,	due	to	urinary	losses.[133-139]	Besides	this,	nephrosis	
leads	to	certain	features	predisposing	for	thromboembolic	disease,	in	particular	
intravascular	volume	depletion.[140]	Changes	in	platelet	count	and	function	are	
also	 associated	 with	 NS.	 Increased	 platelet	 counts	 were	 found	 in	 NS	
patients.[84,85,116]	 Platelet	 hyperaggregability,	 including	 the	 presence	 of	
spontaneous	 aggregation	 responses	 and	 enhanced	 sensitivity	 to	 aggregating	
agents,	 was	 also	 observed.[89,92,95,97,109,113]	 Other	 indications	 of	 higher	 platelet	
activity	 are	 the	presence	of	 increased	plasma	 levels	 of	 β-thromboglobulin,	 P-
selectin[95]	 and	 platelet-derived	 growth	 factor[84]	 and	 increased	 amounts	 of	
CD62P/CD63-positive	 platelets[95].	 However,	 the	 underlying	 molecular	
mechanisms	for	these	changes	in	platelet	count	and	function	in	NS	are	poorly	
understood	so	far.		
In	this	paper,	we	report	PACAP	deficiency	and	we	discuss	its	possible	role	in	the	
increased	platelet	count	and	aggregability	in	CNS.		
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3.2 Material	and	Methods	
3.2.1 Patient	description		
Approval	 by	 the	 institutional	 ethical	 board	 was	 obtained	 for	 all	 participating	
centers	 (S52866),	 according	 to	 the	 Declaration	 of	 Helsinki.	 All	 participants	
above	12	years	and	all	parents	of	participants	gave	written	informed	consent.	
 
3.2.1.1 Congenital	nephrotic	syndrome	patients	
Four	 infants	 with	 Finnish-type	 CNS,	 which	 is	 caused	 by	 autosomal	 recessive	
mutations	in	the	nephrin	gene	NPHS1,	were	studied.[141]	Because	of	the	risk	for	
thrombosis,	 these	patients	were	continuously	 treated	with	acetylsalicylic	acid	
and	 indomethacin,	 and	 therefore,	 platelet	 testing	 was	 only	 possible	 when	
these	 drugs	 were	 discontinued	 for	 reasons	 of	 medical	 interventions	 (e.g.	
surgery	or	renal	biopsy).	Patient	characteristics	and	the	age	at	blood	sampling	
are	described	in	Table	3.1.	Only	the	platelet	aggregation	tests	were	performed	
at	 different	 time	 points,	 as	 indicated	 in	 the	 Results.	 Patient	 D	 was	 lost	 to	
follow-up	 after	 the	 first	 samples,	 because	 of	 follow-up	 in	 another	 center.	
Control	samples	were	taken	from	healthy	children	not	taking	any	medication.		
	
3.2.1.2 Idiopathic	nephrotic	syndrome	patients	
Children	 between	 1	 and	 16	 years	 old	 with	 a	 first	 episode	 or	 relapse	 of	
idiopathic	 steroid	 sensitive	NS	were	 prospectively	 included	 from	March	 2011	
until	 June	 2014.	 A	 multicenter	 study	 was	 performed	 in	 3	 Belgian	 hospitals	
(University	hospitals	of	Leuven,	Liège	and	Gent).	The	diagnosis	of	NS	was	made	
based	 on	 proteinuria	 >	 50	 mg/kg/day	 and	 serum	 albumin	 levels	 <	 30	 g/L.	
Exclusion	 criteria	 were	 the	 current	 use	 of	 steroid	 treatment	 (to	 exclude	 an	
effect	 on	 platelet	 count	 or	 function),	 steroid	 resistance	 or	 impaired	 renal	
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function.	Samples	were	taken	at	3	different	time	points:	during	relapse	before	
start	of	corticosteroid	treatment	(methylprednisolone),	4	weeks	after	the	onset	
of	 remission,	 and	 4	 weeks	 after	 stop	 of	 corticosteroids	 (still	 in	 remission)	
(Figure	3.6).	Remission	was	defined	as	3	consecutive	days	without	proteinuria.		
	
3.2.2 NPHS1	mutation	analysis	
Genomic	DNA	was	extracted	from	blood.	Intronic	oligonucleotide	primers	were	
designed	 according	 to	 public	 sequences	 (Genbank	 accession	 number	
AF190637-AF035835)	to	flank	the	coding	sequences	and	exon-intron	junctions	
of	individual	exons.	The	open	reading	frame	and	splice	sites	of	the	NPHS1	gene	
were	 investigated	 by	 polymerase	 chain	 reaction	 (PCR),	 followed	 by	
bidirectional	 fluorescent	DNA-sequencing.	Potential	pathogenic	 consequences	
for	 the	 missense	 mutations	 were	 predicted	 by	 Align,	 Polyphen	 and	 SIFT	
mutation	prediction	software.	
	
3.2.3 Routine	biochemical	investigations	
Following	 blood	 and	 urine	 analyses	 were	 performed	 in	 our	 routine	 clinical	
laboratory:	 platelet	 count,	 plasma	 albumin,	 serum	 ceruloplasmin	 and	
creatinine,	and	urine	protein	and	creatinine.	
	
3.2.4 Western	blot	analysis	of	patients’	plasma	and	urine	samples	
Patients’	blood	was	collected	using	trisodium	citrate.	Plasma	was	obtained	by	
centrifugation	 (200	 g	 for	 15	 minutes).	 Patients’	 urine	 was	 collected	 and	
centrifuged	(1750	g	 for	5	minutes).	Equal	amounts	of	sample	 (1	μL	of	plasma	
and	10	μL	of	urine	for	PACAP	blots;	1	μL	of	a	1/100	dilution	of	plasma	and	1	μL	
of	a	1/20	dilution	of	urine	for	ceruloplasmin	blots)	were	resolved	by	SDS-PAGE	
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and	transferred	to	Hybond	nitrocellulose	membranes	(Amersham	Biosciences,	
Freiburg,	Germany).	Plasma	and	urine	blots	were	revealed	with	a	monoclonal	
antibody	 against	 PACAP	 (PP1A4,	 produced	 in	 our	 laboratory,	 as	 previously	
described	 by	 Freson	 et	 al[10]).	 Urine	 blots	 were	 also	 revealed	 with	 a	 1:1000	
antibody	against	human	ceruloplasmin	(Dako,	Glostrup,	Denmark).	Blots	were	
stained	 with	 Western	 blotting	 electrochemiluminescence	 (ECL)	 detection	
reagent	 (Thermo	 Scientific,	 Rockford,	 IL,	 USA).	 Detection	 of	 signal	 and	
measuring	 of	 band	 intensity	were	 performed	with	 Bio-Rad	Molecular	 Imager	
Chemi	 DocTM	 XRS	 and	 Image	 Lab	 software	 version	 4.0.	 As	 there	 are	 no	
reference	 values	 for	 PACAP	 plasma	 levels,	 the	 quantified	 values	 were	
compared	to	a	control	plasma	pool	from	10	healthy	children	between	0	and	15	
years.	The	PACAP	level	in	this	plasma	pool	was	considered	as	100%.		
Urine	PACAP	and	ceruloplasmin	 levels	were	expressed	as	a	percentage	of	 the	
described	plasma	pool,	as	it	was	not	detected	in	the	urine	of	healthy	controls.	
Pooled	 urine	 of	 5	 healthy	 children	 between	 0	 and	 4	 years	 was	 used	 as	 a	
negative	control.	All	Western	blots	were	performed	in	triplicate.		
	
3.2.5 Differentiation	and	quantification	of	megakaryocyte	colonies		
Patients’	 blood	 was	 collected	 using	 ethylenediaminetetraacetic	 acid	 (EDTA)	
tubes.	CD34+	hematopoietic	stem	cells	were	isolated	from	peripheral	blood	by	
magnetic	 cell	 sorting	 (Miltenyi	 Biotec,	 Auburn,	 CA).	 Cells	 were	 suspended	 in	
Iscove’s	 MDM	 with	 2%	 fetal	 bovine	 serum	 (StemCell	 Technologies).	 5x	 103	
CD34+	 cells	 were	 cultured	 in	 35	 mm	 petri	 dishes	 in	 MegaCult-C	 collagen	
medium	supplemented	with	cytokines	(StemCell	Technologies,	Vancouver,	BC)	
according	 to	 the	manufacturer’s	 instructions.	 The	 number	 of	 colony	 forming	
unit	megakaryocytes	(CFU-MKs)	was	counted	after	11	days	as	described.[11]	100	
μL	 phosphate	 buffered	 saline	 (PBS),	 1	 μM	 recombinant	 PACAP	 (Bachem,	
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Bubendorf,	 Switzerland)	 in	 PBS	or	 patients’	 plasma	was	 added	 to	 the	 culture	
dish	 on	 days	 0,	 6	 and	 8.	 Each	 condition	was	 performed	 at	 least	 in	 triplicate,	
using	blood	from	the	same	sample.		
	
3.2.6 Platelet	aggregation	tests	
Patients’	 blood	was	 anticoagulated	 using	3.8%	wt/vol	 trisodium	 citrate	 (9:1).	
Treatments	with	anti-platelet	medication	and	ACE-inhibitors	were	discontinued	
at	 least	 10	 days	 before	 testing.	 Platelet-rich	 plasma	 (PRP)	 was	 obtained	 by	
centrifugation	(200	g	for	15	minutes	at	RT)	and	platelet-poor	plasma	(PPP)	was	
obtained	 by	 recentrifugation	 of	 PRP	 (1750	 g	 for	 15	minutes	 at	 RT).	 PPP	was	
added	 to	 PRP	 to	 adjust	 platelet	 count	 in	 PRP	 to	 250x	 106	 platelets	 per	 mL.	
Platelet	 aggregation	 tests	 were	 performed	 on	 two	 dual-channel	 Chrono-Log	
aggregometers	 (Chrono-Log	 Corp.,	 Havertown,	 Pennsylvania,	 USA)	 by	
simultaneous	recording	of	four	trackings,	using	different	concentrations	(0.25-2	
µg/mL)	of	Horm	Collagen	(Nycomed	Arzenmittel,	Munich,	Germany).	
Mixed	 platelet	 aggregation	 after	 resuspending	 washed	 control	 platelets	 in	
patients’	plasma	was	performed.	A	washed	platelet	pellet	of	control	platelets	
was	obtained	after	addition	of	 two	volumes	of	acid	citrate	dextrose	 (ACD:	93	
mM	 trisodium	 citrate,	 7	 mM	 citric	 acid,	 140	 mM	 dextrose)	 to	 PRP	 before	
centrifugation.	 The	 pellet	was	 resuspended	 in	 the	 patients’	 plasma	 to	 obtain	
the	 concentration	 of	 250x	 106	 platelets	 per	 mL	 and	 incubated	 during	 15	
minutes	 before	 testing.	 Fresh	 platelets	 from	 a	 single	 healthy	 donor	 and	
defrosted	plasma	samples	were	used.	
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3.2.7 Western	blot	analysis	of	washed	platelet	lysates	
Patients’	 blood	was	 anticoagulated	 in	 trisodium	citrate.	 PRP	was	obtained	by	
centrifugation	 (200	g	 for	15	minutes).	Then,	2.0	vol	of	ACD	was	added	to	 the	
PRP	 and	 this	 was	 centrifuged	 (1000	 g	 for	 10	 minutes)	 to	 obtain	 a	 purified	
platelet	pellet.	 The	platelet	pellet	was	washed	a	 second	 time	 in	1	mL	of	ACD	
and	centrifuged	(1000	g	for	10	minutes).	The	platelet	pellet	was	resuspended	in	
lysis	 buffer	 (Igepal	 1%,	 ethylenediaminetetraacetic	 acid	 0.3%,	Dithioerythritol	
0.3%	 and	 a	 complete	 protease	 inhibitor	 cocktail	 in	 PBS).	 Then	 3	 freeze-thaw	
cycles	were	performed	and	the	platelet	 lysate	was	centrifuged	(3000	g	 for	10	
minutes	at	room	temperature).	Equal	amounts	(100	microgram)	of	the	washed	
platelet	 lysate	 proteins	 were	 resolved	 by	 SDS-PAGE	 gels.	Membranes	 were	
incubated	overnight	at	4°C	with	1:500	rabbit	anti-NF-κB	p50,	and	1:1000	rabbit	
anti-SP1	 primary	 antibodies	 (Santa	 Cruz	 Biotechnologies,	 Santa	 Cruz,	 CA).	
Secondary	 goat	 anti-rabbit	 antibodies	 were	 from	 Dako.	 Quantified	 patients’	
results	were	compared	with	platelets	from	5	control	subjects	between	3	and	24	
months.	Western	blots	were	performed	in	duplicate.		
	
3.2.8 Statistics	
IBM	 SPSS	 Statistics	 software	 version	 22	 was	 used	 for	 statistical	 analysis.	 All	
tests	 were	 two-tailed	 and	 P	 <	 0.05	 was	 regarded	 as	 statistically	 significant.	
Because	 the	 explorative	 set-up	 of	 the	 study,	 no	 systematic	 correction	 for	
multiple	testing	was	used.		
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3.2.8.1 Congenital	nephrotic	syndrome	
Continuous	variables	were	compared	using	two-tailed	Student	t	test	for	paired	
or	unpaired	data.	Evaluation	of	correlations	was	performed	calculating	Pearson	
correlation	coefficients	R.	
	
3.2.8.2 Idiopathic	nephrotic	syndrome	
A	linear	mixed	regression	model	was	used	to	compare	continuous	variables	at	
the	 3	 different	 time	 points.	 A	 linear	 model	 for	 repeated	 measures	 with	
unstructured	residual	covariance	matrix	was	used	in	case	of	unequal	variances	
between	 time	 points.	 Repeated	 continuous	 variables	 within	 one	 time	 point	
were	 compared	 using	 a	 Student	 t	 test	 for	 paired	 data.	 Correlations	 between	
continuous	 variables	 within	 one	 time	 point	 were	 calculated	 using	 Pearson	
correlation	coefficients	R.	Slopes	for	associations	between	platelet	aggregation	
and	 PACAP	 or	 albumin	 were	 calculated	 using	 a	 linear	 model	 for	 repeated	
measures	 (as	 different	 collagen	 concentrations	were	used)	with	unstructured	
residual	covariance	matrix.		
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3.3 Results	
3.3.1 Congenital	nephrotic	syndrome	
3.3.1.1 Clinical	description	of	congenital	nephrotic	syndrome	patients	
All	 four	 CNS	 patients	 presented	 shortly	 after	 birth	 with	 pronounced	
proteinuria,	 hypo-albuminemia	 and	 peripheral	 edema,	 pointing	 to	 the	
diagnosis	 of	 CNS	 (Table	 3.1).	 Analysis	 of	 the	 NPHS1	 gene	 demonstrated	 bi-
allelic	mutations	 in	all	patients.	Patients	A	and	B	were	sisters	while	patients	C	
and	D	were	unrelated	males.	At	the	moment	of	first	sampling,	all	patients	had	
nephrotic	 range	 proteinuria,	 thrombocytosis,	 decreased	 ceruloplasmin	 levels	
and	normal	plasma	creatinine	levels.		
Patient	A	underwent	a	nephrectomy	of	the	right	kidney	at	the	age	of	1	year	and	
a	nephrectomy	of	the	remaining	left	kidney	at	19	months,	because	of	persisting	
extremely	 severe	 proteinuria	 despite	 conservative	 treatment.	 A	 renal	
transplantation	with	cadaveric	kidney	was	performed	at	 the	age	of	2.5	years.	
Patient	 B	 and	 C	 also	 underwent	 bilateral	 nephrectomy	 because	 of	 ongoing	
severe	NS	at	 the	age	of	20	and	13	months	respectively.	Patient	D	was	 lost	 to	
follow-up	 after	 the	 first	 samples	 because	 of	 follow-up	 in	 another	 center.	
Thromboembolic	events	were	seen	in	patients	A,	B	and	C	in	the	form	of	deep	
venous	 catheter	 thromboses.	 Two	 of	 the	 thromboses	 occurred	 during	
treatment	with	 anti-platelet	medication,	while	 the	 other	 two	 occurred	when	
anti-platelet	 medication	 was	 stopped	 prior	 to	 a	 medical	 intervention.	 No	
arterial	thrombosis	was	observed.	However,	patients	were	almost	continuously	
treated	with	acetylsalicylic	acid	and	indomethacin.	
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Figure	 3.1:	 Plasma	 PACAP	 and	 urine	 PACAP	 and	 ceruloplasmin	 levels	 in	 congenital	
nephrotic	syndrome	patients	
(A)	 LEFT:	 Immunoblot	 analysis	 of	 prepro-protein	 of	 PACAP	 in	 equal	 amounts	 of	 plasma	
samples	 of	 4	 congenital	 nephrotic	 syndrome	 (CNS)	 patients	 and	 a	 control	 plasma	 pool,	
showing	 a	 decreased	 level	 of	 PACAP	 in	 CNS	 patients	 compared	 to	 controls.	 RIGHT:	
Quantification	 of	 protein	 signal	 intensities	 of	 Western	 blots	 as	 a	 percentage	 of	 signal	
intensity	 observed	 for	 the	 plasma	pool	 of	 10	 healthy	 children.	 Bars	 represent	means	 +	 SD	
from	 respectively	 the	 4	 CNS	 patients	 and	 the	 10	 healthy	 controls.	 The	 experiment	 was	
repeated	3	times	on	the	same	samples.	
(B)	LEFT:	Immunoblot	analysis	of	prepro-protein	of	PACAP	in	equal	amounts	of	urine	of	4	CNS	
patients	 and	 a	 control	 urine	 pool	 of	 5	 healthy	 controls,	 showing	 PACAP	 in	 urine	 of	 CNS	
patients,	while	no	PACAP	is	detectable	in	control	urine.	The	control	plasma	pool	was	loaded	
as	a	positive	control.	RIGHT:	Quantification	of	protein	signal	intensities	from	Western	blot	as	
a	percentage	of	signal	intensity	compared	to	a	10	times	lower	volume	of	control	plasma	pool.	
Bars	represent	means	+	SD	from	respectively	the	4	CNS	patients	and	the	5	healthy	controls.	
The	experiment	was	repeated	3	times	on	the	same	samples.		
(C)	LEFT:	Immunoblot	analysis	of	ceruloplasmin	in	equal	amounts	of	urine	in	3	CNS	patients	
and	a	control	urine	pool,	showing	ceruloplasmin	present	 in	urine	of	CNS	patients,	while	no	
ceruloplasmin	is	detectable	in	control	urine.	The	control	plasma	pool	was	loaded	as	a	positive	
control.	RIGHT:	Quantification	of	protein	signal	intensities	from	Western	blot	as	a	percentage	
of	 signal	 intensity	 compared	 to	 a	 5	 times	 lower	 volume	 of	 control	 plasma	 pool.	 Bars	
represent	means	+	SD	from	respectively	the	4	CNS	patients	and	the	5	healthy	controls.	The	
experiment	was	repeated	3	times	on	the	same	samples.	
Legend:	A-D	=	patients	A-D;	CoP	=	control	plasma	pool;	CoU	=	control	urine	pool.	*	P	<	0.05	in	
comparison	to	controls	(two-tailed	unpaired	Student	t	test).	
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3.3.1.2 PACAP	levels	in	plasma	and	urine	
PACAP	levels	were	measured	by	Western	blot	in	plasma	and	urine	samples.	All	
CNS	patients	showed	significantly	decreased	plasma	PACAP	levels,	with	a	mean	
value	 of	 26%	 compared	 to	 the	 control	 plasma	 pool	 from	10	 healthy	 children	
(Figure	 3.1	 A).	 There	were	 no	 significant	 differences	 between	 PACAP	 plasma	
levels	 between	 the	 individual	 control	 children	 (individual	 data	 not	 shown).	
PACAP	and	ceruloplasmin	were	 found	 in	 the	urine	of	 the	CNS	patients,	while	
both	were	 absent	 in	 the	 urine	 pool	 from	 5	 healthy	 children	 (Figure	 3.1	 B-C).	
These	data	indicate	urinary	loss	of	PACAP	and	its	binding	protein	ceruloplasmin	
in	CNS	patients.	
	
3.3.1.3 Biochemical	changes	after	bilateral	nephrectomy	
Serum	ceruloplasmin,	plasma	PACAP	and	blood	platelet	counts	were	measured		
during	the	nephrotic	state	and	after	bilateral	nephrectomy	in	patients	A,	B	and	
C.	 Serum	 ceruloplasmin	 and	 plasma	 PACAP	 significantly	 increased	 after	
bilateral	nephrectomy,	while	platelet	counts	significantly	decreased	(Figure	3.2	
Ai-iii).	 Correlations	 were	 found	 between	 serum	 ceruloplasmin	 and	 plasma	
PACAP	 levels	 (Pearson	 correlation	 coefficient	 R	 =	 0.84)	 and	 between	 serum	
ceruloplasmin	 and	 plasma	 albumin	 levels	 (R	 =	 0.94)	 (Bi-ii).	 A	 strong	 inverse	
correlation	was	 found	between	plasma	PACAP	 levels	and	platelet	 counts	 (R=-
0.98)	(Figure	3.2	Biii).	In	patient	A,	who	underwent	a	nephrectomy	of	the	right	
kidney	at	the	age	of	1	year	and	a	nephrectomy	of	the	left	kidney	at	the	age	of	
19	 months,	 plasma	 samples	 were	 collected	 just	 before	 the	 second	
nephrectomy	and	daily	during	the	first	6	days	after	the	nephrectomy	and	after	
14	months.	An	 increase	 in	plasma	PACAP	 levels	over	 time	was	seen,	 reaching	
~60%	of	control	PACAP	plasma	levels	6	days	after	nephrectomy	(Figure	3.2	Ci-
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ii).	 Blood	 platelet	 counts	were	 elevated	 before	 the	 second	 nephrectomy	 and	
normalized	within	one	week	after	nephrectomy	(Figure	3.2	Ciii).		
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Figure	 3.2:	 Biochemical	 changes	 after	 bilateral	 nephrectomy	 in	 congenital	 nephrotic	
syndrome	patients	
(A)	 Changes	 in	 levels	of	 serum	ceruloplasmin	 (i),	 plasma	PACAP	 (ii)	 and	platelet	 count	 (iii)	
after	 bilateral	 nephrectomy	 in	 3	 congenital	 nephrotic	 syndrome	 (CNS)	 patients.	 P	 values	
were	calculated	with	two-tailed	paired	Student	t	tests.	
(B)	 Plasma	 PACAP	 in	 function	 of	 ceruloplasmin	 (i).	 Plasma	 albumin	 in	 function	 of	 serum	
ceruloplasmin	 (ii).	 Platelet	 count	 in	 function	 of	 plasma	 PACAP	 (iii).	 Pearson	 correlation	
coefficients	R	were	calculated	and	were	all	significant	at	P	<	0.05.	
(C)	Western	 blot	 of	 prepro-protein	 of	 PACAP	 in	 plasma	of	 patient	 A	 before	 and	 in	 period	
after	bilateral	nephrectomy	(i).	Quantification	of	protein	signal	intensities	from	Western	blot	
as	 a	 percentage	 of	 signal	 intensity	 of	 control	 plasma	 pool.	 Values	 represent	means	 +	 SD,	
from	 3	 repeated	 experiments	 on	 the	 same	 samples	 (ii).	 Platelet	 counts	 in	 period	 after	
nephrectomy	in	patient	A.	Normal	values	are	indicated	between	horizontal	lines	(iii).	
Legend:	D0	=	day	0,	blood	sample	just	before	nephrectomy;	D1	=	day	1	after	nephrectomy;	
CoP	=	control	plasma	pool.	
	
	
3.3.1.4 Platelet	aggregation	tests	
Platelet	aggregation	was	 tested	 in	patients	B	and	C	before	and	after	bilateral	
nephrectomy	(Figure	3.3	A).	Platelet	aggregation	tests	were	performed	at	age	9	
and	 12	months	 before	 and	 at	 age	 21	 and	 19	months	 after	 nephrectomy,	 for	
respectively	patient	B	and	C.	PACAP	levels	at	these	moments	were	in	the	same	
range	as	the	previously	mentioned	levels	(data	not	shown).	 Increased	platelet	
aggregation	 responses	 to	Horm	 collagen	were	observed	during	 the	nephrotic	
state	 compared	 to	 the	 responses	 after	 bilateral	 nephrectomy.	 Moreover,	
platelets	 of	 a	 healthy	 adult	 control	 person	 were	 resuspended	 in	 plasma	
samples	from	patients	B	and	C	before	and	after	nephrectomy	and	in	the	control	
plasma	 pool	 of	 10	 healthy	 children	 (Figure	 3.3	 B).	 A	 higher	 aggregation	
response	was	 seen	 for	 the	 control	 platelets	 resuspended	 in	 plasma	 from	 the	
CNS	patients	before	nephrectomy	compared	to	after	nephrectomy	and	to	the	
control	 plasma	 pool.	 Supplementary	 figure	 3.1	 shows	 platelet	 aggregation	
responses	to	collagen	for	an	age-matched	(age	1	year)	healthy	child.	
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Figure	3.3:	Platelet	aggregation	in	congenital	nephrotic	syndrome	patients	and	controls	
(A)	 Platelet	 aggregation	 responses	 to	 Horm	 collagen	 (0.25-2	 µg/mL)	 in	 patient	 B	 and	 C	
before	 (respective	 age	 9	 and	 12	 months)	 and	 after	 (respective	 age	 21	 and	 19	 months)	
bilateral	 nephrectomy.	 (B)	 Platelet	 aggregation	 response	 to	 collagen	0.25	µg/mL.	Platelets	
were	isolated	form	an	adult	control	subject	and	were	resuspended	in	plasma	from	patients	B	
and	C	before	and	after	nephrectomy	and	in	the	control	plasma	pool	(CoP).	
Legend:	Coll	=	collagen.	
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Supplementary	figure	3.1:	Platelet	aggregation	in	a	representative	control	subject	
Platelet	 aggregation	 responses	 to	 collagen	 (0.25-2	 µg/mL)	 in	 a	 representative	 1	 year	 old	
control	subject.	
Legend:	Coll	=	collagen.	
	
	
3.3.1.5 Differentiation	of	hematopoietic	stem	cells	into	megakaryocytes	
Since	it	was	previously	shown	that	elevated	PACAP	plasma	levels	are	associated	
with	thrombocytopenia	and	inhibition	of	the	PACAP	receptor	VPAC1	results	in	
increased	 megakaryopoiesis[11,12],	 we	 hypothesized	 that	 plasma	 PACAP	
deficiency	led	to	high	platelet	counts	in	CNS	patients.	Therefore,	in	vitro	colony	
forming	unit	megakaryocytes	(CFU-MKs)	assays	were	performed	before	(at	low	
PACAP	 plasma	 levels)	 and	 after	 nephrectomy	 (after	 normalisation	 of	 PACAP	
plasma	levels),	using	CD34+	hematopoietic	stem	cells	derived	from	peripheral	
blood	from	patient	B	and	C.	The	number	of	CD34+	cells	derived	from	peripheral	
blood	did	not	differ	significantly	before	and	after	bilateral	nephrectomy	(data	
not	 shown).	Colonies	were	counted	after	11	days	of	 culture	 (Figure	3.4	A).	 In	
both	patients,	 significantly	 reduced	numbers	of	 CFU-MK	 colonies	were	 found	
after	bilateral	nephrectomy	with	normal	plasma	PACAP	levels,	in	comparison	to	
the	 count	 during	 the	 nephrotic	 state.	 Addition	 of	 recombinant	 PACAP	 to	 the	
culture	dish	led	to	a	significantly	reduced	number	of	colonies	during	nephrotic	
state,	 in	agreement	to	published	data	showing	an	inhibitory	role	of	PACAP	on	
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megakaryopoiesis.[11]	To	investigate	if	plasma	of	CNS	patients	directly	promotes	
megakaryopoiesis,	 plasma	 from	 CNS	 patients	 before	 and	 after	 bilateral	
nephrectomy	and	 from	a	control	plasma	pool	were	added	to	 the	culture	dish	
(Figure	3.4	B).	A	significant	higher	number	of	CFU-MKs	was	seen	with	plasma	
from	 CNS	 patients	 before	 bilateral	 nephrectomy,	 compared	 to	 their	 plasma	
after	nephrectomy	and	 to	 the	 control	 plasma	pool.	No	 significant	differences	
were	 observed	 between	 addition	 of	 plasma	 from	 CNS	 patients	 after	
nephrectomy	and	the	control	plasma	pool.		
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Figure	 3.4:	 Colony	 forming	 unit	 megakaryocyte	 colonies	 in	 2	 congenital	 nephrotic	
syndrome	patients	before	and	after	bilateral	nephrectomy	and	in	control	person	
(A)	 Number	 of	 colony	 forming	 unit	 megakaryocyte	 (CFU-MK)	 colonies	 in	 patient	 B	 and	 C	
before	 and	 after	 nephrectomy,	 with	 and	 without	 addition	 of	 recombinant	 PACAP.	
Hematopoietic	stem	cells	were	isolated	from	peripheral	blood	in	patient	B	and	C	and	in	vitro	
differentiated	into	CFU-MKs.	In	one	condition	recombinant	PACAP	(1	μM)	was	added	to	the	
culture	dish	on	day	0,	6	and	8,	while	no	PACAP	was	added	in	the	other	condition.	After	11	
days	of	culture,	colonies	were	counted.	Values	are	means	+	SD	from	at	least	3	culture	dishes.		
(B)	 Number	 of	 CFU-MK	 colonies	 from	 a	 control	 adult	 person,	 with	 addition	 of	 different	
plasma	samples	to	the	culture	dish.	Hematopoietic	stem	cells	were	isolated	from	peripheral	
blood	in	the	control	person	and	 in	vitro	differentiated	 into	CFU-MKs.	 In	the	first	condition,	
plasma	from	patient	B	and	C	before	nephrectomy	was	added	to	the	culture	dish	on	day	0,	6	
and	8,	while	 in	 the	second	condition	plasma	 from	patient	B	and	C	after	nephrectomy	was	
added	and	in	the	third	condition	plasma	of	the	control	plasma	pool	was	added	on	the	same	
days.	Colonies	were	counted	after	11	days	of	culture.	Values	are	means	+	SD	from	at	least	4	
culture	dishes.	
Legend:	CNS	=	congenital	nephrotic	syndrome;	CoP	=	control	plasma	pool.	*	P	<	0.05	(two-
tailed	unpaired	Student	t	test).	
	
	
	
3.3.1.6 Analysis	of	platelet	lysates	
Previous	 findings	 suggested	 that	 high	 levels	 of	 NF-κB	 are	 present	 in	 patients	
with	 high	 PACAP	 plasma	 values	 as	 a	 potential	 factor	 that	 modulates	 their	
normal	 apoptosis	 during	 megakaryopoiesis.[13]	 Platelets	 of	 patients	 B	 and	 C	
before	 and	 after	 bilateral	 nephrectomy	 and	 of	 5	 healthy	 controls	were	 lysed	
and	analysed	by	Western	blot	for	expression	of	NF-κB	and	SP1	(a	transcription	
factor	 with	 a	 stable	 expression	 during	 megakaryopoiesis[144])	 as	 a	 loading	
control	(Figure	3.5).	NF-κB	values	in	patients’	platelets	lysates	were	significantly	
lower	 in	 parallel	 with	 low	 plasma	 PACAP	 levels	 before	 nephrectomy	 in	
comparison	 to	 after	 nephrectomy	 and	 to	 the	 healthy	 control	 subjects.	 There	
was	 no	 significant	 difference	 between	 NF-κB	 levels	 in	 platelet	 lysates	 of	
patients	after	bilateral	nephrectomy	and	the	healthy	controls.	
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Figure	3.5:	NF-κB	in	platelet	lysates	of	two	congenital	nephrotic	syndrome	patients	
(A)	Western	blot	for	NF-κB	and	Sp1	in	platelet	lysates	from	patients	B	and	C	during	nephrotic	
state	(before	bilateral	nephrectomy)	and	after	bilateral	nephrectomy.		
(B)	 Quantification	 of	 protein	 signal	 intensities	 from	 Western	 blot,	 normalized	 to	
transcription	factor	Sp1,	used	as	a	loading	control.	Values	of	congenital	nephrotic	syndrome	
(CNS)	 patients	 represent	 means	 +	 SD	 from	 values	 of	 patients	 B	 and	 C,	 from	 2	 repeated	
experiments	on	the	same	samples.	Control	value	is	the	mean	+	SD	of	the	signal	intensity	in	5	
control	subjects,	from	2	repeated	experiments	on	the	same	samples.		
Legend:	CNS	=	congenital	nephrotic	syndrome.	*	P	<	0.05	(two-tailed	paired	Student	t	 test	
for	comparison	between	CNS	patients	before	and	after	bilateral	nephrectomy	and	unpaired	
Student	 t	 test	 for	 comparison	 between	 CNS	 patients	 before	 bilateral	 nephrectomy	 and	
controls).	
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3.3.2 Idiopathic	nephrotic	syndrome	
As	CNS	 is	a	severe,	but	rare	form	of	NS,	we	performed	a	prospective	study	 in	
INS	patients,	 verifying	 if	our	 findings	 could	be	generalized	 for	patients	with	a	
more	common	type	of	NS.		
	
3.3.2.1 Patient	description	
24	children	with	INS	were	included	and	29	episodes	of	NS	were	observed.	Tests	
were	 performed	 at	 three	 different	 time	 points	 (Figure	 3.6).	 All	 29	 episodes	
were	observed	at	a	 first	 study	 time	point	 immediately	after	diagnosis,	before	
the	start	of	corticosteroid	treatment.	All	episodes	were	further	observed	at	the	
second	 time	 point,	 4	 weeks	 after	 the	 start	 of	 remission.	 For	 the	 third	 time	
point,	after	stop	of	steroid	treatment,	18	episodes	were	observed,	because	of	
loss	of	follow-up	of	2	patients	and	the	ongoing	use	of	corticosteroids	at	the	end	
of	the	study	in	9	patients.	Patient	characteristics	are	described	in	Table	3.2.	All	
patients	presented	with	pronounced	proteinuria	and	hypo-albuminemia	(Table	
3.3)	 and	 responded	 to	 steroid	 treatment.	 In	 14	 patients	 a	 renal	 biopsy	 was	
performed:	 4	 had	 a	 focal	 segmental	 glomerulosclerosis	 (FSGS)	 and	 10	 had	 a	
minimal	 change	 nephrotic	 syndrome	 (MCNS).	 No	 symptomatic	 thrombo-
embolic	events	were	observed.		
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Figure	3.6:	Overview	of	study	time	points	in	idiopathic	nephrotic	syndrome	patients	
Samples	were	taken	at	three	time	points	(red	arrows)	in	idiopathic	nephrotic	syndrome	(INS)	
patients:	(1)	immediately	after	diagnosis	and	before	the	start	of	corticosteroid	treatment;	(2)	
4	weeks	after	the	start	of	remission	and	(3)	4	weeks	after	stop	of	corticosteroid	treatment.	
	
	
	
	
Table	3.2:	Demographics	of	idiopathic	nephrotic	syndrome	patients	
 	 	
 Total	number	of	patients	(n)	 24		
 Total	number	of	observed	NS	episodes	(n)	 29		
 Mean	age	at	inclusion	(years	±	SD)	 6.3	±	4.2		
 Gender	(male/female)	 17/7		
 First	episode	versus	relapse	of	NS	 18/11		
 Histological	type	of	NS	(n)	 	
      					MCNS	 10	
 					FSGS	 4	
      					No	biopsy	 10	
 
  
INS	=	idiopathic	nephrotic	syndrome;	MCNS	=	minimal	change	nephrotic	syndrome;	FSGS	=	
focal	segmental	glomerulosclerosis	
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Table	3.3:	Biochemical	characteristics	of	idiopathic	nephrotic	syndrome	patients	
	
Nephrotic	
	
	
	
4	weeks	after	
start	of	
remission	
	
4	weeks	after	
stop	of	
corticosteroids	
	
	
	
P1	
	
	
P2	
	
Plasma	albumin	(g/L)	 21.9	±	6.0	 42.0	±	3.5	 42.7	±	3.3	 <0.001	 <0.001	
	
Urine	total	proteins	(g/L)	 13.54	±	11.08	 0.09	±	0.06	 0.12	±	0.08	 <0.001	 <0.001	
	
Urine	protein/creatinine	(g/g)	 17.81	±	15.67	 0.19	±	0.15	 0.13	±	0.05	 <0.001	 <0.001	
	
Serum	creatinine	(mg/dL)	 0.35	±	0.18	 0.40	±	0.18	 0.40	±	0.16	 0.049	 0.010	
	
Platelet	count	(10*9/L)	
	
384	±	109		 390	±	96		 350	±	91		 NS		 NS		
Data	represent	means	±	SD.	P1	=	P	value	comparing	nephrotic	state	and	time	point	4	weeks	
after	start	of	remission;	P2	=	P	value	comparing	nephrotic	state	and	time	point	4	weeks	after	
stop	 of	 corticosteroid	 treatment.	 Comparison	 of	 variables	 between	 time	 points	 was	
performed	using	a	linear	mixed	regression	model	at	significance	level	P	<	0.05.	
eGFR	=	estimated	glomerular	filtration	rate;	NS	=	not	significant.	
	
3.3.2.2 Biochemical	changes	after	remission	
Proteinuria	 and	 hypoalbuminemia	 disappeared	 when	 patients	 were	 in	
remission	 (Table	 3.3).	 Creatinine	 levels	were	normal	 at	 all	 time	points.	Mean	
platelet	counts	were	not	significantly	altered	after	remission	in	comparison	to	
during	 nephrotic	 state.	 However,	 in	 11	 of	 29	 observed	 episodes,	 a	 platelet	
count	 above	 the	 reference	 value	 of	 450	 x	 103/μL	was	 seen	 during	 nephrotic	
state,	while	only	 in	2	of	18	after	 stop	of	 treatment.	No	 correlations	between	
platelet	counts	and	plasma	PACAP	or	serum	albumin	levels	were	seen	(data	not	
shown).	 Plasma	 and	 urine	 PACAP	 levels	 and	 urine	 ceruloplasmin	 levels	 were	
measured	 at	 the	 3	 time	 points	 by	 Western	 blot	 (Figure	 3.7).	 Plasma	 PACAP	
levels	were	significantly	lower	during	nephrotic	state	than	after	remission	and	
after	 stop	 of	 corticosteroids	 (Figure	 3.8	 Ai).	 Serum	 ceruloplasmin	 was	 not	
significantly	 altered	 during	 nephrotic	 state	 (Figure	 3.8	 Aiii).	 PACAP	 and	
ceruloplasmin	were	present	 in	 the	urine	of	 INS	patients	during	NS,	while	not	
during	 remission	 (Figure	 3.8	 Aiii-iv).	 A	 significant	 correlation	 was	 observed	
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between	 urine	 PACAP	 and	 ceruloplasmin	 levels	 (Bi)	 and	 between	 plasma	
PACAP	and	albumin	(Figure	3.8	Bii)	during	nephrotic	state.		
	
Figure	 3.7:	 PACAP	 levels	 in	 plasma	 and	 urine	 and	 ceruloplasmin	 levels	 in	 urine	 of	 2	
representative	idiopathic	nephrotic	syndrome	patients	
Immunoblot	 analysis	 of	 prepro-protein	 of	 PACAP	 in	 equal	 amounts	 of	 plasma	 and	 urine	
samples	 and	 of	 ceruloplasmin	 in	 equal	 amounts	 of	 urine,	 for	 2	 representative	 idiopathic	
nephrotic	 syndrome	 (INS)	patients,	 during	nephrotic	 state	 (1),	 4	weeks	 after	 remission	 (2)	
and	4	weeks	after	 stop	of	 corticosteroids	 (3).	Control	plasma	pool	 (CoP)	and	control	urine	
pool	 (CoU)	were	 loaded	 as	 a	 positive	 and	 negative	 control	 respectively.	 For	 the	 blots	 for	
PACAP	and	 ceruloplasmin	 in	urine,	 a	 respectively	 10	 and	5	 times	 lower	 volume	of	 plasma	
was	loaded	compared	to	urine.	The	experiment	was	repeated	3	times.	
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Figure	3.8:	Urinary	 loss	of	PACAP	and	 ceruloplasmin	during	nephrotic	 state	 in	 idiopathic	
nephrotic	syndrome	patients	
(A)	Plasma	PACAP	(i),	serum	ceruloplasmin	(ii),	urine	PACAP	(iii),	and	urine	ceruloplasmin	(iv)	
levels	 during	 nephrotic	 state,	 4	 weeks	 after	 start	 of	 remission	 and	 4	 weeks	 after	 stop	 of	
corticosteroid	 treatment.	 Significant	 lower	 values	 of	 plasma	 PACAP	 were	 found	 during	
nephrotic	 state	 in	 comparison	 to	 remission	 and	 after	 stop	 of	 corticosteroids.	 Serum	
ceruloplasmin	levels	were	not	changed.	PACAP	and	ceruloplasmin	were	present	in	the	urine	
during	 nephrotic	 state,	 while	 almost	 no	 presence	 of	 these	 proteins	 was	 found	 during	
remission	and	after	stop	of	corticosteroids.	Bars	represent	means	+	SD.		
	 80	
Legend:	CoP	=	control	plasma	pool,	CS	=	corticosteroids.	*	P	<	0.05	(linear	mixed	regression	
model).	
(B)	Correlations	between	urine	PACAP	and	ceruloplasmin	(i)	and	between	plasma	PACAP	and	
plasma	 albumin	 (ii)	 during	 nephrotic	 state.	 R	 values	 represent	 Pearson	 correlation	
coefficients,	at	significance	level	P	<	0.05.		
	
3.3.2.3 Platelet	aggregation	tests	
Platelet	 aggregation	 responses	 to	 different	 collagen	 concentrations	 were	
measured	(Figure	3.9	A).	Significantly	higher	aggregation	responses	were	found	
during	 nephrotic	 state	 than	 after	 remission	 and	 after	 stop	 of	 corticosteroid	
treatment.	When	recombinant	PACAP	was	added	to	the	PRP	sample	during	the	
nephrotic	state,	decreased	aggregation	responses	were	seen	(P	<	0.05	for	0.25	
μg/mL	 collagen	 stimulation).	 Interestingly,	 platelet	 aggregation	 responses	 to	
collagen	correlated	inversely	with	plasma	PACAP	levels	during	nephrotic	state,	
while	not	with	serum	albumin	levels	(Figure	3.9	B).		
	
Figure	 3.9:	 Platelet	 aggregation	 responses	 to	 collagen	 in	 idiopathic	 nephrotic	 syndrome	
patients	
(A)	LEFT:	Platelet	aggregation	responses	to	collagen	for	different	concentrations	of	collagen	
during	 nephrotic	 state,	 during	 remission	 and	 after	 stop	 of	 treatment.	 A	 significant	 higher	
aggregation	response	was	seen	during	nephrotic	state	than	during	remission.	Bars	represent	
means	+	standard	error	of	the	mean	(SEM).	
RIGHT:	Platelet	aggregation	responses	to	collagen	for	2	concentrations	of	collagen	with	and	
without	 addition	 of	 recombinant	 PACAP	 during	 nephrotic	 state.	 A	 decreased	 aggregation	
response	was	seen	after	addition	of	recombinant	PACAP.	Bars	represent	means	+	SEM.		
Legend:	 Coll	 =	Collagen.	*	P	<	0.05	compared	 to	 the	aggregation	 in	 response	 to	 the	 same	
collagen	concentration	in	de	nephrotic	state	(linear	mixed	regression	model);	**	P	<	0.05	for	
the	collagen	concentration	of	0.25	μg/mL	(linear	mixed	regression	model).	
(B)	 Correlations	between	platelet	 aggregation	 and	plasma	PACAP	 levels	 or	 serum	albumin	
levels,	during	nephrotic	state.	Slopes	with	95%	confidence	intervals	and	P	values	are	shown.	
Slopes	were	calculated	with	a	 linear	model	 for	 repeated	measures	 (as	4	different	collagen	
concentrations	 per	 patients	 were	 used)	 with	 unstructured	 residual	 covariance	 matrix,	 at	
significance	 level	 *	 P	 <	 0.05.	 A	 significant	 correlation	 was	 observed	 between	 platelet	
aggregation	 responses	 to	 collagen	 and	 plasma	 PACAP	 levels.	 This	 result	 persisted	 after	
correction	for	plasma	albumin	levels.	There	was	no	correlation	between	platelet	aggregation	
responses	to	collagen	and	plasma	albumin	levels,	also	not	after	correction	for	PACAP	plasma	
levels.		
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3.4 Discussion		
In	this	study	we	have	demonstrated	excessive	urinary	excretion	of	PACAP	and	
its	 binding	 protein	 ceruloplasmin	 in	 nephrotic	 patients,	 leading	 to	 plasma	
PACAP	deficiency.	To	our	knowledge,	this	is	the	first	report	of	acquired	PACAP	
deficiency	 in	 humans.	We	 first	 studied	 a	 small	 group	 of	 patients	with	 CNS,	 a	
rare	 and	extremely	 severe	 form	of	NS.	Our	 findings	were	 then	 validated	 in	 a	
larger	group	of	patients	with	steroid-sensitive	INS,	a	more	common	and	usually	
less	severe	form	of	NS.	
PACAP	 has	 recently	 been	 identified	 as	 an	 inhibitor	 of	 megakaryopoiesis	 and	
platelet	 aggregation	 in	 patients	 with	 elevated	 PACAP	 plasma	 levels	 due	 to	 a	
partial	trisomy	18p	with	three	PACAP	gene	copies	and	in	transgenic	mice	with	a	
megakaryocyte-specific	 PACAP	 overexpression.[10,11]	 In	 PACAP	 knockout	 mice	
and	in	wild-type	mice	treated	with	a	PACAP	antagonist	or	a	monoclonal	PACAP	
antibody	against	PACAP	or	its	receptor	VPAC1,	stimulation	of	megakaryopoiesis	
and	 hyperaggregability	 of	 platelets	 was	 demonstrated.[10,11]	 In	 analogy	 with	
these	findings,	megakaryopoiesis	in	CNS	patients	measured	by	the	in	vitro	CFU-
MK	assay	was	significantly	increased	during	the	nephrotic	state	with	low	PACAP	
plasma	 levels	 in	 contrast	 to	 after	 bilateral	 nephrectomy	when	plasma	PACAP	
levels	 normalized.	 Importantly,	 underscoring	 the	 role	 of	 PACAP	 deficiency	 in	
upregulated	 megakaryopoiesis,	 addition	 of	 recombinant	 PACAP	 inhibited	
differentiation	 of	 hematopoietic	 stem	 cells	 into	 megakaryocytes	 during	 the	
nephrotic	 state.	 Furthermore,	 addition	 of	 plasma	 of	 CNS	 patients	 during	
nephrotic	 state	 directly	 promoted	 megakaryopoiesis	 using	 stem	 cells	 of	 a	
healthy	donor.		
After	 bilateral	 nephrectomy,	 serum	 ceruloplasmin	 and	 plasma	 PACAP	 levels	
normalized	 in	 parallel	 with	 the	 normalization	 of	 elevated	 platelet	 counts.	
PACAP	plasma	 levels	 rose	within	already	one	day	after	bilateral	nephrectomy	
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to	 ~60%	 of	 control	 levels	 and	 platelet	 counts	 normalized	 within	 one	 week,	
which	strongly	suggests	it	was	a	direct	consequence	of	disappearing	nephrosis.	
Furthermore,	 a	 strong	 inverse	 correlation	was	 found	between	plasma	PACAP	
levels	and	platelet	counts.	Because	of	the	young	age	of	the	studied	patients	the	
quantity	of	blood	samples	was	limited	and	we	could	not	perform	other	useful	
tests	as	the	analysis	of	megakaryocyte	ploidy	with	flow	cytometric	analysis.		
NF-κB	was	recently	suggested	to	act	in	a	PACAP	dependent	pathway	via	VPAC1,	
regulating	 normal	 apoptosis	 in	 megakaryocytes,	 which	 is	 necessary	 for	 the	
release	of	platelets.[13]	NF-κB	is	a	nuclear	transcription	factor	and	plays	a	role	in	
thrombopoietin	receptor	signaling	in	megakaryocytes,	but	the	exact	pathway	is	
not	yet	known.[145]	 Inhibition	of	NF-κB	has	been	shown	to	lead	to	apoptosis	in	
various	cell	types.[146,147]	We	found	a	reduced	level	of	NF-κB	in	platelet	 lysates	
during	 the	 nephrotic	 state	 in	 CNS	 patients,	 which	 normalized	 after	 bilateral	
nephrectomy.	This	suggests	that	PACAP	deficiency	in	CNS	causes	deficiency	of	
NF-κB	in	megakaryocytes,	possibly	increasing	the	normal	apoptosis	rate,	which	
is	a	necessary	step	for	platelet	release,	and	leading	to	an	increased	amount	of	
platelets.		
Consistent	 with	 the	 results	 of	 literature[84,85,90,91,116],	 the	 increase	 in	 platelet	
count	was	less	obvious	for	INS	patients.	Only	in	11	of	29	observed	episodes,	a	
platelet	count	above	the	reference	value	of	450	x	103/μL	was	observed	during	
nephrotic	 state.	 No	 correlation	 between	 platelet	 count	 and	 plasma	 PACAP	
levels	was	found.	A	possible	explanation	is	that	proteinuria	in	INS	is	less	severe	
than	 in	 CNS	 and	 that	 a	 longer	 duration	 of	 nephrosis	 might	 be	 necessary	 to	
affect	 megakaryopoiesis	 and	 platelet	 count.	 In	 our	 current	 study	 the	 mean	
value	of	urinary	protein/creatinine	ratio	was	17.8	g/g	creatinine	in	INS	patients,	
versus	 136.2	 g/g	 in	 the	 previous	 study	 in	 CNS	 patients	 (P	 <	 0.05).	Moreover,	
plasma	PACAP	levels	were	significantly	less	reduced	in	INS	than	in	CNS	(mean	±	
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SD	of	73	±	17	%	versus	26	±	11	%	of	control	values,	P	<	0.05)	and	 the	serum	
levels	of	the	binding	protein	ceruloplasmin	were	not	altered	in	INS,	while	they	
were	 severely	 decreased	 in	 CNS.[115]	 As	 nowadays	 the	 duration	 of	 nephrosis	
before	the	diagnosis	of	NS	is	made	and	treatment	is	started,	is	probably	shorter	
than	before,	it	could	explain	why	ours	and	other	recent	studies	could	not	find	
significantly	 increased	 platelet	 counts	 in	 INS.[90,91]	 However,	 the	 relation	
between	duration	of	nephrosis	and	platelet	counts	has	never	been	studied.		
Platelet	 hyperaggregability	 in	 response	 to	 collagen	 has	 been	 shown	 in	 NS	
patients	in	several	studies.[129]	Earlier	research	suggested	that	reduced	plasma	
albumin	levels	lead	to	an	increased	level	of	unbound	arachidonic	acid	(AA)	and	
as	 a	 consequence	 to	 an	 increased	 formation	 of	 thromboxane	 A2,	 which	
stimulates	 platelet	 aggregation.[113]	 An	 inverse	 correlation	 between	 serum	
albumin	 levels	 and	 collagen	 induced	 platelet	 aggregation	 was	 found	 in	 one	
study	[99],	but	was	not	confirmed	in	a	later	study[89].	A	multifactorial	genesis	of	
platelet	hyperreactivity	in	NS	was	presumed.	In	our	study,	platelet	aggregation	
in	both	CNS	and	 INS	patients	was	 increased	during	 the	nephrotic	 state,	while	
platelets	isolated	during	non-nephrotic	state	showed	normal	reactivity	towards	
collagen.	 Moreover,	 plasma	 of	 CNS	 patients	 during	 nephrotic	 state	 directly	
promoted	aggregation	of	platelets	from	a	healthy	control	subject	resuspended	
in	CNS	plasma.	In	INS	patients,	the	effect	of	addition	of	recombinant	PACAP	to	
PRP	 samples	 was	 studied	 during	 the	 nephrotic	 state	 and	 caused	 decreased	
aggregation	 responses.	 Furthermore,	 platelet	 aggregation	 responses	 to	
collagen	inversely	correlated	with	plasma	PACAP	levels	during	nephrotic	state,	
while	not	with	 serum	albumin	 levels.	 These	 findings	 strongly	 corroborate	 the	
role	of	PACAP	deficiency	in	the	platelet	hyperaggregability	in	NS.	
Patients	with	NS	have	an	enhanced	risk	for	thrombotic	disease,	including	both	
deep	 venous	 and	 arterial	 thrombosis,	 which	 significantly	 increases	morbidity	
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and	mortality	rates.[148]	As	described	above,	the	pathogenesis	of	the	increased	
risk	for	venous	thrombosis	is	already	partially	unraveled,	but	the	etiology	of	the	
increased	 platelet	 count	 and	 aggregability	 regarding	 arterial	 thrombosis	
remains	unclear.	Thrombocytosis	in	children	is	mostly	benign.[149]	However,	the	
fact	that	the	risk	 for	both	venous	and	arterial	thrombosis	 (which	 is	 in	general	
very	 rare	 in	 children)	 is	 elevated	 in	 NS,	 suggests	 a	 role	 for	 platelets	 in	 the	
prothrombotic	state.	 
Because	PACAP	exerts	many	different	biological	functions,	the	question	arises	if	
plasma	 PACAP	 deficiency	 in	 NS	 can	 lead	 to	 consequences	 in	 other	 organ	
systems.	 In	PACAP	knockout	mice	for	example,	altered	psychomotor	behavior	
has	 been	 described.[150]	 In	 NS	 patients,	 psychomotor	 development	 has	 never	
been	 extensively	 examined	 and	 warrants	 further	 study,	 although	 no	 overt	
mental	 or	 motoric	 delay	 has	 been	 demonstrated.	 Furthermore,	 a	
nephroprotective	effect	of	PACAP	has	been	reported	in	different	kidney	disease	
models.[20]	 Further	 research	 is	 needed	 to	 investigate	 the	 influence	 of	 PACAP	
deficiency	on	the	kidney	in	NS.	
In	this	study,	we	found	arguments	for	a	role	of	PACAP	deficiency	 in	 increased	
platelet	 counts	 and	 aggregability	 in	 CNS.	 However,	 to	 prove	 the	 causal	
relationship	with	 the	 occurrence	 of	 thrombosis,	 large-scale	 studies	would	 be	
required.		
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Chapter	4:	 Zebrafish	nephrotic	
syndrome	models	to	study	the	
influence	of	PACAP	deficiency	on	
megakaryopoiesis		
	
Background:	 Pituitary	 adenylate	 cyclase-activating	 polypeptide	 (PACAP)	 is	 an	
inhibitor	of	megakaryopoiesis	and	platelet	function.	Recently,	PACAP	deficiency	
was	 observed	 in	 children	 with	 nephrotic	 syndrome	 (NS),	 associated	 with	
increased	platelet	count	and	aggregability	and	an	increased	risk	of	thrombosis.		
Objective:	 To	 further	 study	 PACAP	 deficiency	 as	 cause	 of	 increased	
megakaryopoiesis	in	NS,	zebrafish	models	of	congenital	NS	were	studied.		
Material/Methods:	 Transgenic	 Tg(cd41:EGFP)	 zebrafish	 with	 GFP-labeled	
megakaryocytes	and	 thrombocytes	were	used.	 Two	models	 for	 congenital	NS	
were	 generated.	 The	 first	 model	 resulted	 from	 injection	 of	 a	 morpholino	
targeting	 nphs1,	 the	 gene	 encoding	 for	 nephrin,	 which	 is	 mutated	 in	 the	
Finnish-type	NS.	The	second	NS	zebrafish	model	was	obtained	by	exposure	to	a	
nephrotoxic	 compound	 adriamycin.	 Nephrin	 RNA	 expression	 was	 quantified	
using	 PCR	 and	 zebrafish	 embryos	were	 life	 screened	 for	 a	 pericardial	 edema	
phenotype.	Protein	levels	of	PACAP	and	its	binding	protein	ceruloplasmin	were	
measured	 by	 Western	 blot	 and	 GFP-labeled	 thrombocytes	 were	 quantified	
using	fluorescence	microscopy,	Western	blot	and	flow	cytometry.	
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Results:	Nephrin	downregulation	and	a	phenotype	of	pericardial	edema	were	
observed	 in	 both	 nephrin	 depleted	 and	 adriamycin	 exposed	 congenital	 NS	
zebrafish	models.	PACAP	deficiency	was	found	in	the	adriamycin	exposed,	but	
not	 in	 the	 nephrin	 depleted	 zebrafish	 model.	 Ceruloplasmin	 levels	 and	 the	
number	of	GFP-labeled	thrombocytes	remained	unchanged	in	both	models.		
Conclusion:	We	 report	 for	 the	 first	 time	 PACAP	 deficiency	 in	 a	 NS	 zebrafish	
model	 as	 a	 consequence	of	 adriamycin	exposure.	However,	 distinct	 from	our	
findings	 in	 human	 congenital	 NS,	 both	 NS	 zebrafish	 models	 retained	 normal	
levels	of	ceruloplasmin	and	thrombocytes.		
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4.1 Introduction	
Nephrotic	 syndrome	 (NS)	 is	 a	 disease	 of	 the	 glomerular	 filtration	 barrier,	
characterized	 by	 severe	 proteinuria,	 hypoalbuminemia,	 edema	 and	
hyperlipidemia.[37]	 Congenital	 NS	 (CNS)	 is	 a	 rare	 and	 severe	 form	 of	 NS,	
manifesting	 within	 3	 months	 of	 life,	 with	 proteinuria	 being	 present	 already	
before	birth.	CNS	is	rarely	caused	by	non-genetic	causes,	such	as	infections,	but	
most	 frequently,	 it	 is	based	on	genetic	mutations	 in	the	NPHS1,	NPHS2,	WT1,	
LAMB2[44]	or	PLCE1	gene.[45]	NPHS1	encodes	 for	nephrin,	which	 is	a	 structural	
component	 of	 the	 slit	 diaphragm.[52]	Nephrin	 also	 plays	 a	 role	 in	 intracellular	
signaling	and	interacts	with	the	podocyte	cytoskeleton.[42]	In	humans,	recessive	
NPHS1	 mutations	 and	 subsequent	 disruption	 of	 the	 slit	 diaphragm	 cause	
Finnish-type	 CNS,	 a	 very	 severe	 form	 of	 NS	 with	 extremely	 pronounced	
proteinuria.		
Patients	with	NS	have	an	increased	risk	of	thromboembolic	events,	both	deep	
venous	 and	 arterial	 thrombosis.[60,64]	 Elevated	 levels	 of	 prothrombotic	 factors	
such	 as	 factor	 V,	 factor	 VIII,	 von	 Willebrand	 factor	 and	 fibrinogen,	 and	
decreased	levels	of	antithrombotic	factors	as	antithrombin	and	protein	C	and	S	
due	 to	 nephrosis	 were	 described	 in	 NS	 patients	 and	 probably	 underlie	 the	
increased	risk	of	deep	venous	thrombosis	in	NS.[60]	However,	the	fact	that	the	
risk	 of	 both	 venous	 and	 arterial	 thrombosis	 is	 elevated	 in	 NS,	 points	 to	 an	
additional	 role	 for	 blood	 platelets.	 Increased	 platelet	 counts	 and	 platelet	
hyperaggregability	were	repeatedly	observed	 in	NS	patients.[129]	However,	the	
etiology	 of	 those	 platelet	 abnormalities	 observed	 in	 NS	 is	 not	 completely	
understood.		
Recently,	 we	 found	 evidence	 that	 deficiency	 of	 pituitary	 adenylate	 cyclase-
activating	polypeptide	 (PACAP)	plays	a	 role	 in	 the	 increased	platelet	 count	of	
CNS	 patients.[115]	 PACAP	 is	 a	 highly	 conserved	 neuropeptide.[1,3]	 In	 human	
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plasma,	PACAP	 is	bound	 to	 its	 carrier	protein	ceruloplasmin	 (132	kDa),	which	
prevents	it	from	rapid	degradation.[4]	PACAP	is	widely	expressed	in	the	nervous	
system,	 but	 also	 in	 several	 peripheral	 tissues,	 where	 it	 takes	 part	 in	 diverse	
biological	 processes.[3]	 PACAP	 can	 bind	 three	 different	 G-protein	 coupled	
receptors:	 the	 PAC1	 receptor,	 which	 is	 PACAP	 specific,	 and	 the	 VPAC1	 and	
VPAC2	 receptors,	 which	 bind	 both	 vasoactive	 intestinal	 peptide	 (VIP)	 and	
PACAP	and	are	coupled	to	adenylyl	cyclase.[6-8]	Recently,	PACAP	was	identified	
as	 an	 inhibitor	 of	megakaryopoiesis	 and	 platelet	 activation.	 Freson	 et	 al[10,11]	
studied	 patients	 with	 elevated	 PACAP	 plasma	 levels	 due	 to	 a	 partial	 trisomy	
18p	 and	 transgenic	 mice	 with	 megakaryocyte-specific	 PACAP	 overexpression	
and	 found	 that	 PACAP	 inhibits	 megakaryopoiesis	 and	 platelet	 function	 and	
prolongs	the	bleeding	time,	via	activation	of	adenylyl	cyclase	coupled	VPAC1	on	
platelets	 and	 megakaryocytes.	 The	 opposite	 phenotype	 with	 stimulation	 of	
platelet	 function	 and	 megakaryopoiesis	 was	 obtained	 in	 wild-type	 mice	
injected	 with	 a	 PACAP	 antagonist	 PACAP(6-38)	 or	 a	 monoclonal	 antibody	
against	 PACAP	 or	 its	 receptor	 VPAC1,	 as	 well	 as	 in	 PACAP	 knockout	 mice.	
Peeters	 et	 al	 further	 showed	 a	 thrombopoietic	 effect	 of	 VPAC1	 inhibition	 in	
thrombocytopenia	murine	models.[12]	 	We	 recently	 reported	urinary	 losses	of	
PACAP	and	 ceruloplasmin	 in	 children	with	CNS	due	 to	 recessive	mutations	 in	
the	 NPHS1	 gene.	 We	 further	 found	 that	 in	 vitro	 megakaryopoiesis	 was	
increased	 in	 CNS	 patients	 during	 nephrotic	 state	 in	 comparison	 to	 a	 non-
nephrotic	 state	 after	 bilateral	 nephrectomy,	 and	 that	 this	 effect	 could	 be	
reversed	by	the	addition	of	recombinant	PACAP.[115] 
To	 support	 our	 hypothesis	 that	 PACAP	 deficiency	 due	 to	 urinary	 loss	 is	 the	
cause	 of	 increased	megakaryopoiesis	 in	 CNS,	 a	 NS	 animal	model	 is	 required.	
Constitutive	nephrin	knockout	mice	are	not	available	as	the	animals	die	within	
24	 hours	 after	 birth.[151]	 Zebrafish	 larvae	 are	 currently	 widely	 used	 in	 kidney	
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research	 as	 the	 structure	 of	 the	 glomerular	 filtration	 barrier	 is	 similar	 to	 the	
mammalian	 filter,	 with	 the	 presence	 of	 fenestrated	 endothelial	 cells,	 a	
glomerular	 basement	 membrane	 and	 podocytes	 with	 a	 slit	 diaphragm.	
Moreover,	in	this	model	a	complete	maturation	of	glomeruli	is	observed	within	
3	 days	 post	 fertilization	 (dpf).[152]	 For	 our	 study,	 we	 used	 two	 previously	
characterized	CNS	zebrafish	models.	The	first	zebrafish	model	was	obtained	by	
injection	 of	 a	morpholino	 (MO)	 targeting	nphs1,	which	 is	 the	 zebrafish	 gene	
encoding	for	nephrin.[153]	Nephrin	depleted	zebrafish	were	previously	shown	to	
have	 structural	 damage	 of	 podocytes	 with	 effacement	 of	 podocyte	 foot	
processes	and	the	absence	of	a	slit	diaphragm,	in	accordance	with	observations	
for	Finnish-type	CNS	in	humans.	Moreover,	due	to	loss	of	the	podocyte	barrier	
function,	nephrin	depleted	embryos	developed	a	phenotype	of	proteinuria	and	
pericardial	edema	at	4	dpf.[153]	The	second	NS	zebrafish	model	was	obtained	by	
exposure	 to	 low	 concentrations	of	 adriamycin.[152]	 Adriamycin	 exposure	 leads	
to	 podocyte	 developmental	 defects	 and	 decreased	 nephrin	 expression,	 with	
subsequent	functional	 impairment	of	the	glomerular	filtration	barrier,	causing	
proteinuria	 and	 pericardial	 edema	 early	 after	 fertilization,	 similar	 to	 the	
observations	for	human	CNS.	We	intended	to	establish	these	two	CNS	models	
in	Tg(cd41:EGFP)	transgenic	zebrafish,	expressing	GFP-labeled	megakaryocytes	
and	 thrombocytes,	 previously	 developed	 to	 study	 megakaryopoiesis.[154]	 The	
aim	 of	 this	 study	 was	 to	 verify	 whether	 these	 CNS	 zebrafish	 models	 have	
PACAP	deficiency	and	increased	megakaryopoiesis	as	found	for	human	Finnish-
type	CNS.	
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4.2 Material	and	methods	
4.2.1 Embryo	collection	
All	 zebrafish	 experiments	 and	 protocols	 were	 approved	 by	 the	 Ethical	
Committee	 of	 the	 Catholic	 University	 of	 Leuven.	 Tg(cd41:EGFP)	 transgenic	
zebrafish	 embryos	were	 a	 gift	 from	Dr	 L.	 Zon	 (Hematology	Division,	 Brigham	
and	Women's	Hospital's,	Boston,	MA,	USA).	Embryos	were	kept	in	medium	(tap	
water	with	2	mL/L	methylene	blue	0.1%)	at	28°C.		
	
4.2.2 Morpholino	injection	
Tg(cd41:EGFP)	transgenic	Danio	rerio	embryos[154]	were	injected	at	the	one-cell	
stage	 with	 an	 exon	 splice	 donor	 sites	 targeting	 morpholino	 for	 nephrin	
(nephrinMO)	 (5ʹ-CGCTGTCCATTACCTTTCAGGCTCC-3ʹ)	 at	 50,	 100	 and	 200	 µM,	
as	previously	described[153].	The	morpholino	was	diluted	in	an	injection	solution	
(0.5	%	Phenol	red	(Sigma,	St-Louis,	MO,	USA)	1/10	in	NaCl	0.9%	(v/v)).	Embryos	
were	 collected	 at	 24,	 48,	 72	 and	120	hours	 post	 fertilization	 (hpf).	Off-target	
effects	 were	 excluded	 by	 inclusion	 of	 standard	 control	 MO	 (5’-
CCTCTTACCTCAGTTACAATTTATA-3’)	 injected	 embryos.	 The	 nephrinMO	 and	
controlMO	were	obtained	from	Gene-Tools	LLC	(Philomath,	OR,	USA).		
	
4.2.3 Embryo	exposure	to	adriamycin	
Tg(cd41:EGFP)	 transgenic	 zebrafish	 embryos[154]	were	 incubated	 in	 10	 and	 30	
μM	 adriamycin	 from	 9	 hpf	 as	 previously	 described[152].	 Adriamycin	 was	 from	
Sigma	(D1515).	Adriamycin	was	removed	from	the	medium	after	48	hours	 (at	
57	 hpf).	 Embryos	 were	 next	 washed	 several	 times	with	medium	 and	 further	
immersed	in	adriamycin-free	medium.		
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4.2.4 Phenotype	characterization	
Fluorescent	microscopy	was	used	 for	 life-screening	of	 the	embryos	at	24,	48,	
72,	96	and	120	hpf.	The	amount	of	thrombocytes	in	the	caudal	hematopoietic	
tissue	 (CHT)	of	 the	zebrafish	embryos	was	recorded	for	 the	detection	of	GFP-
labeled	thrombocytes.	Images	were	captured	using	a	Zeiss	Axiocam	HR	camera	
using	AxioVision	software	4.8	(Carl	Zeiss).	Pixel	intensity	of	fluorescent	pictures	
was	measured	using	ImageJ	software.		
	
4.2.5 Evaluation	of	glomerular	blood	filtration	
A	qualitative	 assay	was	performed	 to	 evaluate	 glomerular	 blood	 filtration,	 as	
previously	 described.[155]	 Rhodamine-labeled	 70	 kDa-dextran	 (Sigma)	 was	
injected	 into	 the	 cardiac	 venous	 sinus	 of	 75	 hpf	 old	 embryos.	 Images	 were	
captured	 5	 hours	 after	 injection	 using	 a	 Zeiss	 Axiocam	 HR	 camera	 and	
AxioVision	 software	 4.8	 (Carl	 Zeiss,	 Jena,	Germany).	 Fluorescence	 intensity	 in	
the	fish	eye	was	measured	using	ImageJ	software	(http://rsbweb.nih.gov/ij/).	
	
4.2.6 RNA	isolation,	reverse	transcription	PCR	and	quantitative	real-time	PCR		
Total	 RNA	 was	 extracted	 from	 15	 zebrafish	 embryos	 at	 various	 stages	 of	
development	 using	 Trizol	 Reagent	 (Invitrogen,	 Waltham,	 USA).	 RNA	
concentration	 was	 measured	 using	 Nanodrop	 2000c	 (Thermo	 Scientific,	
Waltham,	USA).	cDNA	was	produced	from	one	μg	of	RNA	using	SuperScript®	III	
reverse	 transcriptase	 (Life	 technologies,	 Carlsbad,	 USA),	 oligo	 (dT)	 primers,	
random	 hexamer	 primers	 and	 dNTP	 mix	 (Invitrogen).	 Polymerase	 chain	
reaction	(PCR)	products	were	separated	on	2%	agarose	gels	and	visualized	with	
GelRed	 (Biotium,	 Hayward,	 CA,	 USA).	 Pixel	 intensity	 of	 reverse	 transcription	
PCR	 (RT-PCR)	 bands	 was	 measured	 using	 ImageJ	 software	
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(http://rsbweb.nih.gov/ij/).	Quantitative	 real-time	PCR	 (qPCR)	was	 performed	
with	 platinum	 SYBR	 green	 qPCR	mix	 (Invitrogen).	 Sequences	 of	 forward	 and	
reverse	 primers	 were:	 Danio	 rerio	 nephrin	 5’-GCAAGCTACATGT-
ATGTAGACGTGT-3’	 (forward)	 and	 Danio	 rerio	 nephrin	 5’-TCCTGTGAAATG-
CTGCTGGTGTC-3’	 (reverse);	 Danio	 rerio	 elongation	 factor	 I-α	 (elfa)	
(housekeeping	gene)	5’-CTTCTCAGGCTGACTGTGC-3’	(forward)	and	Danio	rerio	
elfa	5’-CCGCTAGCATTACCCTCC-3’	(reverse).[156]	
	
4.2.7 Immunoblot	analysis	
Protein	 lysates	 were	 obtained	 from	 controlMO-	 versus	 nephrinMO-injected	
and	 from	 adriamycin	 exposed	 versus	 non-exposed	 control	 zebrafish	 embryos	
(30	deyolked	embryos	per	condition).	The	Bradford	protein	assay	was	used	for	
determination	 of	 protein	 concentrations	 (Bio-Rad,	 Hercules,	 CA,	 USA).	 Equal	
amounts	(50	μg)	of	protein	were	resolved	by	SDS-PAGE	and	then	transferred	to	
Hybond	 ECL-nitrocellulose	 membranes	 (Amersham	 Biosciences,	 Freiburg,	
Germany).	Blots	were	 incubated	with	a	rabbit	polyclonal	anti-PACAP	antibody	
(produced	 in	 our	 laboratory,	 as	 previously	 described[10]),	 a	 rabbit	monoclonal	
anti-ceruloplasmin	antibody	(Dako,	Glostrup,	Denmark),	a	goat	polyclonal	anti-
GFP	 antibody	 (Rockland	 Immunochemicals,	 Gilbertsville,	 USA)	 and	 a	 rabbit	
monoclonal	 anti-β-actin	 antibody	 (Cell	 Signaling	 Technology,	 Boston,	 USA).	
Secondary	 anti-rabbit	 and	 anti-goat	 antibodies	 were	 from	 Dako.	 Blots	 were	
stained	 with	 Western	 blotting	 electrochemiluminescence	 (ECL)	 detection	
reagent	(Thermo	Scientific,	Rockford,	USA).	Detection	of	signal	and	measuring	
of	 band	 intensity	 were	 performed	 with	 ImageJ	 software	
(http://rsbweb.nih.gov/ij/).	 The	band	 intensities	 of	 PACAP,	 ceruloplasmin	 and	
GFP	were	corrected	 for	 the	band	 intensities	of	 the	 loading	control	β-actin[157]	
and	were	expressed	as	a	percentage	of	the	control	condition.	All	Western	blots	
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were	performed	at	least	in	duplicate. 	
	
4.2.8 Flow	cytometric	analysis	of	CD41	positive	cells	
ControlMO-	 versus	 NephrinMO-injected	 Tg(cd41:EGFP)	 transgenic	 embryos	
were	 dechorionated	 72	 hpf	 and	 digested	 with	 0.02%	 trypsin/EDTA	 for	 15	
minutes	at	28°C.	The	sample	was	pipetted	10	times	up	and	down,	for	getting	a	
single	 cell	 suspension.	 Cells	 were	 filtered	 through	 a	 40	 μm	 cell	 strainer	 and	
centrifuged	 (770	 g	 for	 10	 minutes	 at	 room	 temperature).	 Pellets	 were	 then	
resuspended	 in	 phosphate	 buffered	 saline	 (PBS).	 The	 Cell	 Diva	 software	was	
used	 for	 two-colour	 immunofluorescence	 acquisition	 on	 a	 FACSCanto	 II	 flow	
cytometer	(BD	Biosciences,	San	Diego,	USA)	and	for	data	analysis	determining	
the	percentage	of	GFP-positive	thrombocytes.	
	
4.2.9 Statistics	
Relative	 nephrin	 gene	 expression	 and	 eye	 fluorescence	 intensity	 were	
compared	 using	 one-way	 analysis	 of	 variance	 (ANOVA)	 with	 Bonferroni	
correction	for	multiple	testing.	Continuous	variables	were	compared	using	two-
tailed	 Student	 t	 test	 for	 unpaired	data.	 P	<	0.05	was	 regarded	 as	 statistically	
significant.		
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4.3 Results		
4.3.1 Nephrin	depleted	CNS	zebrafish	model	
The	 first	 CNS	 zebrafish	 model	 was	 obtained	 by	 injection	 of	 Tg(cd41:EGFP)	
transgenic	 zebrafish	 with	 a	 splice	 site	 morpholino	 targeting	 nephrin	
(nephrinMO).[153]	 The	 zebrafish	 embryos	were	 life-screened	 for	 the	 nephrotic	
phenotype	 of	 pericardial	 edema	 at	 3	 and	 5	 dpf	 and	 were	 divided	 into	 3	
different	 categories:	embryos	with	a	normal	phenotype,	embryos	with	visible	
pericardial	 edema	 and	 severe	 dysmorphic	 or	 dead	 embryos	 (Figure	 4.1	 A).	 A	
phenotype	of	pericardial	edema	was	obtained	at	5	dpf	in	only	6,	20	and	28%	of	
fish	 for	nephrinMO	injections	of	50,	100	and	200	μM,	respectively	 (Figure	4.1	
B).	 Phenotypes	 at	 3	 dpf	 were	 similar	 to	 these	 observed	 at	 5	 dpf	 (data	 not	
shown).	For	increasing	concentrations	of	nephrinMO,	an	increasing	percentage	
of	 embryos	 showed	 a	 severely	 dysmorphic	 phenotype	 or	 died.	 All	 further	
experiments	were	performed	with	100	μM	nephrinMO.	RT-PCR	was	performed	
using	total	RNA	extracted	from	nephrinMO-	and	controlMO-injected	zebrafish	
at	 24,	 48	 and	72	hpf.	 Reduced	nephrin	expression	 (389	bp)	was	 seen	 in	RNA	
samples	extracted	 from	nephrinMO-injected	compared	to	controlMO-injected	
embryos	 (Figure	 4.1	 C).	 Quantification	 of	 nephrin	 expression	 in	 nephrinMO-
injected	embryos	was	57.2,	57.6	and	33.0	%	compared	 to	 control	 fish	at	1,	2	
and	 3	 dpf,	 respectively	 (significant	 reduction	 with	 P	 <	 0.05,	 using	 unpaired	
student	t	test).	Abnormal	RT-PCR	bands	of	272	and	1070	bp	were	only	detected	
for	 the	nephrinMO-injected	embryos	resulting	 from	an	exon	deletion	and	the	
retention	of	an	adjacent	intron,	respectively.	
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Figure	4.1:	Phenotype	and	nephrin	expression	in	nephrin	depleted	zebrafish		
(A)	Three	categories	of	phenotypes	were	defined	in	nephrinMO-injected	embryos:	embryos	without	
edema	 (normal),	 embryos	 with	 visible	 pericardial	 edema	 (white	 arrow)	 and	 dysmorphic	 or	 dead	
embryos.	Pictures	were	taken	at	5	dpf.		
(B)	 80	 embryos	 per	 condition	were	 life-screened	 at	 5	 dpf	 and	 assigned	 to	 a	 phenotype	 category.	
Increasing	concentrations	of	the	injected	nephrinMO	were	associated	with	an	increasing	percentage	
of	embryos	with	pericardial	edema,	but	also	with	increased	numbers	of	severely	dysmorphic	or	dead	
embryos.		
(C)	 RT-PCR	 was	 performed	 using	 total	 RNA	 extracted	 from	 nephrinMO	 (100	 μM)	 and	 controlMO-
injected	embryos	at	24,	48	and	72	hpf.	Reduced	expression	of	normal	nephrin	(389	bp)	was	found	in	
the	 nephrin	 depleted	 versus	 control	 embryos.	 Moreover,	 nephrinMO-induced	 alternative	 splicing	
resulted	 in	 272	 and	 1070	 bp	 fragments,	 resulting	 from	 an	 exon	 deletion	 and	 a	 retained	 intron,	
respectively.		
Legend:	M	=	marker;	Mo	=	morphant;	Co	=	control	morpholino	injected	
	
	
Nephrin	 depleted	 embryos	 with	 visible	 pericardial	 edema	 were	 selected	 to		
further	study	PACAP	and	ceruloplasmin	expression	using	Western	blot	analysis	
of	 total	 embryo	 lysates.	 No	 differences	 in	 PACAP	 levels	 were	 observed	 in	
nephrin	 depleted	 versus	 controls	 embryos	 (Figure	 4.2).	 Western	 blot	 for	
ceruloplasmin	 also	 showed	 no	 significant	 difference	 in	 nephrin	 depleted	 and	
control	 embryos	 at	 3	 dpf.	Western	 blots	 for	 PACAP	 and	 ceruloplasmin	 were	
repeated	at	5	dpf	with	similar	results	(data	not	shown).	
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Figure	4.2:	PACAP	and	ceruloplasmin	protein	levels	in	nephrin	depleted	zebrafish		
(A)	 Western	 blots	 for	 PACAP,	 ceruloplasmin	 and	 β-actin	 (loading	 control)	 were	 performed	 using	
whole	 zebrafish	 lysates	 at	 3	 dpf	 for	 nephrin	 depleted	 (100	 μM	NephrinMO)	 compared	 to	 control	
embryos.				
(B)	 Signal	 intensity	of	Western	blot	bands	was	measured	using	 ImageJ	 software.	Graphs	 represent	
means	+	SD	from	two	repeated	experiments.	A	representative	blot	is	shown.	Means	were	compared	
using	a	two-tailed	unpaired	Student	t	test,	but	no	significant	difference	was	observed.	
Legend:	Mo	=	nephrin	morphant;	Co	=	control	morpholino	injected	
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Tg(cd41:EGFP)	 transgenic	 zebrafish	 with	 GFP-labeled	 thrombocytes	 and	
thrombocyte	precursors	were	used	to	study	the	effect	of	nephrin	depletion	on	
megakaryopoiesis.	 Fluorescence	 microscopy	 did	 not	 show	 a	 difference	
between	 GFP-labeled	 cells	 in	 nephrinMO	 injected	 (100	 μM)	 versus	 control	
embryos	at	3	dpf	(Figure	4.3	A).	Quantification	of	GFP	expression	via	Western	
blot	analysis	also	revealed	no	differences	in	the	thrombocyte	numbers	(Figure	
4.3	B).	Finally,	flow	cytometric	analysis	of	lysates	from	whole	zebrafish	embryos	
did	not	show	any	differences	in	the	amount	of	GFP-positive	cells	(Figure	4.3	C).	
Western	blot	 and	 flow	cytometry	were	 repeated	at	5	dpf	with	 similar	 results	
(data	not	shown).	
	
	
Figure	4.3:	Quantification	of	 thrombocytes	 in	nephrin	depleted	Tg(cd41:EGFP)	 transgenic	
zebrafish	
(A)	LEFT:	GFP-labeled	thrombocytes	and	thrombocyte	precursors	are	formed	in	the	zebrafish	caudal	
hematopoietic	tissue	(CHT)	region	(white	arrows)	at	3	dpf.	Representative	pictures	of	the	CHT	region	
of	a	control	and	a	nephrin	depleted	 (100	μM	nephrinMO)	embryo	at	3	dpf	are	shown.	No	obvious	
differences	 in	 thrombocyte	 numbers	 were	 observed.	 RIGHT:	 Pixel	 intensity	 was	 measured	 using	
ImageJ	 software.	 The	 graph	 represents	 means	 +	 SD	 from	 measurements	 in	 three	 embryos	 per	
condition.	 Means	 were	 compared	 using	 a	 two-tailed	 unpaired	 Student	 t	 test,	 but	 no	 significant	
difference	was	observed	between	nephrin	depleted	and	control	embryos.	
(B)	 LEFT:	Western	 blot	 for	 GFP	 and	 β-actin	 (loading	 control)	 was	 performed	 using	 total	 zebrafish	
lysates	at	3	dpf.	The	experiment	was	repeated	twice.	A	representative	blot	 is	shown.	RIGHT:	Signal	
intensity	 was	 measured	 using	 ImageJ	 software.	 The	 graph	 represents	 means	 +	 SD	 from	
measurements	 in	 two	 repeated	 experiments.	 Means	 were	 compared	 using	 a	 two-tailed	 unpaired	
Student	 t	 test,	 but	 no	 significant	 difference	was	 observed	 between	 nephrin	 depleted	 and	 control	
embryos.	
(C)	TOP:	Fluorescence-activated	cell	sorter	(FACS)	analysis	of	total	zebrafish	lysates	was	performed	at	
3	dpf.	GFP-labeled	thrombocytes	and	thrombocyte	precursors	were	quantified.	BOTTOM:	The	graph	
shows	the	number	of	GFP-positive	cells	per	100.000	counted	cells.	For	each	zebrafish	lysate,	500.000	
cells	were	 counted	 and	 analyzed.	Graphs	 represent	means	 +	 SD	 from	 three	 repeated	 experiments	
performed	 in	 duplo.	 Means	 were	 compared	 using	 a	 two-tailed	 unpaired	 Student	 t	 test,	 but	 no	
significant	difference	was	observed	between	nephrin	depleted	and	control	embryos.	
Legend:	 Mo	 =	 morphant;	 Co	 =	 control	 morpholino	 injected;	 SCC	 =	 side	 scatter;	 GFP	 =	 green	
fluorescent	protein	
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4.3.2 Adriamycin	exposed	CNS	zebrafish	model	
The	 adriamycin	 model	 for	 NS	 in	 zebrafish	 was	 previously	 described.[152]	 We	
applied	 this	 strategy	 in	 Tg(cd41:EGFP)	 transgenic	 zebrafish	 embryos	 and	
exposed	 embryos	 at	 9	 hpf	 to	 adriamycin	 for	 48	 hours.	 Given	 the	 toxicity	 of	
adriamycin,	zebrafish	embryos	were	immersed	for	40	hours	in	adriamycin-free	
medium	 after	 adriamycin	 exposure,	 before	 further	 manipulation.	 Hence,	 all	
analyses	were	 performed	 at	 4	 instead	 of	 3	 dpf.	 The	 zebrafish	 embryos	were	
life-screened	for	the	nephrotic	phenotype	of	pericardial	edema	at	4	dpf	(Figure	
4.4	A).	A	dose	and	 time	dependent	 increase	 in	embryos	with	a	phenotype	of	
pericardial	edema	was	observed	(Figure	4.4	B).	Quantitative	polymerase	chain	
reaction	 (qPCR)	 showed	 significantly	 reduced	 expression	 of	 nephrin	 in	
adriamycin	exposed	zebrafish	embryos	compared	to	control	fish	(Figure	4.4	C).	
An	 evaluation	 of	 the	 glomerular	 function	 was	 performed	 by	 injection	 of	
rhodamine-labeled	 70	 kDa	 dextran	 in	 75	 hpf	 old	 embryos.	 In	 the	 adriamycin	
treated	 embryos,	 a	 statistically	 significant	 lower	 level	 of	 rhodamine-labeled	
dextran	 was	 detected	 5	 hours	 after	 injection	 in	 the	 eye	 of	 the	 injected	
embryos,	 indicating	increased	glomerular	permeability	and	proteinuria	(Figure	
4.4	D).		
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Figure	4.4:	Phenotype	analysis,	nephrin	expression	and	evaluation	of	glomerular	function	
in	adriamycin	exposed	zebrafish		
(A)	 Different	 categories	 of	 phenotype	were	 defined	 in	 the	 adriamycin	 exposed	 embryos	 at	 4	 dpf:	
embryos	 with	 a	 normal	 phenotype,	 embryos	 with	 visible	 pericardial	 edema	 (white	 arrow)	 and	
dysmorphic	or	dead	embryos.		
(B)	 100	embryos	per	 condition	were	 life-screened	at	 4	dpf	 and	assigned	 to	 a	phenotype	 category.	
Increasing	 adriamycin	 concentrations	 in	 the	 culture	 medium	 were	 associated	 with	 an	 increasing	
percentage	of	embryos	with	pericardial	edema.		
(C)	qPCR	was	performed	using	total	RNA	from	control	and	adriamycin	exposed	embryos	at	4	dpf.	A	
significantly	decreased	expression	of	nephrin	(corrected	for	housekeeping	gene	elfa)	was	observed	in	
the	 adriamycin	 exposed	 embryos	 compared	 to	 the	 control	 fish	 (mean	 Ct	 values	 for	 nephrin	were	
32.2,	 32.8	 and	 33.6	 for	 respectively	 0,	 10	 and	 30	 μM	 adriamycin	 exposure).	 The	 experiment	 was	
performed	 twice	 in	 triplo.	 Data	 from	 one	 representative	 experiment	 are	 shown.	 Bars	 represent	
means	+	SD.	*	P	<	0.05	in	comparison	to	condition	without	addition	of	adriamycin	(one-way	ANOVA).	
(D)	 Rhodamine-labeled	 70	 kDa	 dextran	 was	 injected	 in	 the	 cardiac	 venous	 sinus	 of	 75	 hpf	 old	
embryos.	 A	 representative	 immunofluorescence	 picture	 of	 a	 control	 embryo	 immediately	 after	
injection	 shows	 distribution	 of	 fluorescence	 through	 the	 body	 (a).	 A	 dose-dependent	 diminishing	
effect	of	adriamycin	on	fluorescence	recorded	 in	the	fish	eye	5	hours	after	 injection	was	observed.	
Representative	 images	 of	 the	 eye	 from	 0,	 10	 and	 30	 μM	 adriamycin	 treated	 embryos	 are	 shown	
(respectively	b,	c	and	d).	The	graph	shows	the	quantification	of	the	mean	fluorescence	intensity	+/-	
SD	recorded	in	the	eye	from	3	fish	per	condition	(e).	*	P	<	0.05	in	comparison	to	condition	without	
addition	of	adriamycin	(one-way	ANOVA).	
	
	
	
Similar	 to	 the	 published	 zebrafish	 model	 due	 to	 adriamycin	 exposure[152],	
reduced	 nephrin	 RNA	 expression	 was	 confirmed	 in	 our	 adriamycin	 exposed	
Tg(cd41:EGFP)	embryos.	Therefore,	this	model	was	further	analysed	for	PACAP	
and	 ceruloplasmin	 levels	 and	megakaryopoiesis.	Western	blot	 for	 PACAP	was	
performed	 using	 total	 zebrafish	 lysates	 and	 showed	 a	 reduced	 signal	 for	
nephrotic	fish	compared	to	controls	(P	<	0.05,	unpaired	student	t	test)	(Figure	
4.5).	 The	 signal	 intensity	 for	 ceruloplasmin	 on	 Western	 blot	 was	 not	
significantly	 different	 between	 nephrotic	 and	 control	 embryos.	 GFP-labeled	
thrombocytes	 quantified	 by	 fluorescence	microscopy	 revealed	 no	 differences	
after	quantification	of	pixel	 intensity	 (Figure	4.6	A)	and	Western	blot	 for	GFP	
expression	was	 similar	 in	 all	 embryo	 lysates	 (Figure	 4.6	B).	Western	blots	 for	
PACAP,	ceruloplasmin	and	GFP	were	 repeated	at	5	and	6	dpf	 to	 investigate	a	
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time	 dependent	 effect.	 However,	 these	 experiments	 remained	 similar	 to	 the	
data	obtained	for	4	dpf	(data	not	shown).	
	
	
Figure	4.5:	PACAP	and	ceruloplasmin	protein	levels	in	adriamycin	treated	zebrafish	
(A)	Western	blot	 for	PACAP,	ceruloplasmin	and	β-actin	 (loading	control)	was	performed	using	total	
zebrafish	lysates.	A	representative	blot	is	shown.		
(B)	 Pixel	 intensity	 of	Western	 blot	 bands	was	measured	 using	 ImageJ	 software.	 Graphs	 represent	
means	 +	 SD	 of	 signal	 intensity	 from	 two	 repeated	 experiments.	 *	 P	 <	 0.05	 (two-tailed	 unpaired	
Student	t	test).	
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Figure	4.6:	Quantification	of	thrombocytes	in	adriamycin	treated	zebrafish		
(A)	LEFT:	GFP-labeled	thrombocytes	and	thrombocyte	precursors	are	formed	in	the	zebrafish	caudal	
hematopoietic	tissue	(CHT).	Representative	pictures	of	the	CHT	region	at	4	dpf	of	embryos	exposed	
to	 adriamycin	 0,	 10	 and	 30	 μM	 are	 shown.	 No	 obvious	 difference	 in	 thrombocytes	was	 observed	
between	 the	 controls	 and	 the	adriamycin	exposed	 fish.	RIGHT:	 Pixel	 intensity	was	measured	using	
ImageJ	 software.	 The	 graph	 represents	 means	 +	 SD	 from	 measurements	 in	 three	 embryos	 per	
condition.	Means	were	compared	using	one-way	ANOVA,	but	no	significant	difference	was	observed	
between	adriamycin	exposed	and	control	embryos.		
(B)	 LEFT:	 Western	 blot	 for	 GFP	 and	 β-actin	 (loading	 control)	 was	 performed	 using	 total	 zebrafish	
lysates	at	4	dpf.	The	experiment	was	repeated	twice.	A	representative	blot	 is	shown.	RIGHT:	Signal	
intensity	 was	 measured	 using	 ImageJ	 software.	 The	 graph	 represents	 means	 +	 SD	 from	
measurements	in	two	repeated	experiments.	Means	were	compared	using	one-way	ANOVA,	but	no	
significant	difference	was	observed	between	adriamycin	exposed	and	control	embryos.	
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4.4 Discussion		
The	 aim	 of	 this	 study	 was	 to	 generate	 a	 NS	 animal	 model	 to	 confirm	 our	
hypothesis	 that	PACAP	deficiency	 is	a	cause	of	 increased	megakaryopoiesis	 in	
human	NS.	As	 our	 observations	 in	 humans	 showed	more	pronounced	PACAP	
deficiency	and	 increased	platelet	counts	 in	CNS	compared	to	 INS,	we	decided	
to	 use	 a	 CNS	 animal	model	 rather	 than	 a	model	mimicking	minimal	 changes	
nephrotic	 syndrome	 (MCNS)	or	 focal	 segmental	 glomerulosclerosis	 (FSGS).	As	
mentioned	above,	 transgenic	CNS	 rodent	models	 are	not	 suitable	because	of	
lethality	early	after	birth.[158]	An	endogenous	nephrin	knockout	mouse	model,	
with	 podocyte-specific,	 doxycycline-inducible	 expression	 of	 rat	 nephrin	 has	
later	 been	 developed.[159]	 Doxycycline-induced	 rat	 nephrin	 expression	
immediately	 after	 birth	 could	 rescue	 nephrin-deficient	 mice	 from	 perinatal	
lethality.	 This	 model	 shows	 proteinuria	 from	 the	 third	 week	 after	 birth,	 but	
seen	 the	 induced	 nephrin	 expression	 shortly	 after	 birth,	 it	 is	 not	 a	 pure	 CNS	
model.	 Zebrafish	 CNS	 models	 were	 applied	 for	 our	 study,	 as	 PACAP	 and	
ceruloplasmin	levels	as	well	as	thrombocyte	counts	can	be	determined	in	CNS	
early	after	maturation	of	the	pronephros	in	such	models.	
As	 a	 nephrin	 knockout	 zebrafish	 is	 not	 available,	 a	 first	 CNS	 zebrafish	model	
was	 obtained	 using	 a	 nephrin	 targeting	 morpholino.	 Nephrin	 depletion	 was	
confirmed	 in	 the	 nephrin	 depleted	 Tg(cd41:EGF)	 model,	 as	 previously	
described.[153]	Distinct	 from	our	 findings	 in	human	CNS	patients[115],	 however,	
we	did	not	observe	PACAP	deficiency	or	increased	thrombocyte	numbers	in	the	
nephrin	 depleted	 embryos.	 One	 possible	 explanation	 for	 these	 unexpected	
findings	is	glomerular	immaturity	present	during	the	first	days	post	fertilization,	
that	 might	 be	 responsible	 for	 the	 loss	 of	 small	 proteins	 present	 in	 equal	
amounts	 in	 control	 and	 nephrinMO	 injected	 fish,	 as	 has	 been	 previously	
suggested	by	Kramer-Zucker	et	al.[153]	Another	possible	explanation	is	that	the	
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short	duration	of	proteinuria	with	subsequent	mortality	of	 the	embryos	 (max	
144	hpf)	was	not	sufficient	for	developing	PACAP	and	ceruloplasmin	deficiency.	
Moreover,	 the	 phenotype	 of	 pericardial	 edema	was	 achieved	 only	 in	 a	 small	
percentage	of	nephrin	depleted	embryos.	A	large	part	of	embryos	had	a	normal	
phenotype	 at	 lower	 concentrations	 of	 injected	 nephrinMO,	 while	 high	
mortality	 was	 observed	 at	 higher	 concentrations.	 We	 hypothesized	 that	 the	
pericardial	 edema	observed	 in	 the	nephrin	depleted	model	 could	be	partially	
due	 to	 extrarenal	 effects	 of	 nephrinMO	 such	 as	 cardiac	 toxicity.	 However,	
cardiac	morphology	and	function	has	not	been	studied	in	the	nephrin	depleted	
model.	 We	 concluded	 that	 the	 nephrinMO	 injected	 Tg(cd41:EGF)	 transgenic	
zebrafish	 embryos	 are	 not	 suitable	 for	 further	 studies	 regarding	 the	 role	 of	
PACAP	and	ceruloplasmin	deficiency	in	thrombocytosis	related	to	the	CNS.		
As	the	nephrin	depleted	zebrafish	was	unsuitable,	a	second	recently	described	
CNS	zebrafish	model	was	studied.[152]	Adriamycin	exposure	 induces	decreased	
nephrin	 expression	 and	 subsequent	 functional	 impairment	 of	 the	 glomerular	
filtration	 barrier,	 causing	 proteinuria	 and	 pericardial	 edema	 early	 after	
fertilization,	 similar	 to	 the	 observations	 for	 human	 CNS.	 We	 examined	 the	
possibility	of	using	adriamycin	exposed	Tg(cd41:EGF)	 zebrafish	embryos	as	an	
alternative	model	to	study	the	effect	of	PACAP	on	megakaryopoiesis	in	NS.	We	
confirmed	 nephrin	 depletion,	 impaired	 function	 of	 the	 glomerular	 filtration	
barrier,	 and	 a	 dose	 and	 time	 dependent	 increase	 of	 pericardial	 edema	 in	
adriamycin	 exposed	 embryos,	 as	 previously	 described.[152]	 At	 4	 dpf,	 PACAP	
levels	were	 significantly	 decreased,	 but	 ceruloplasmin	 levels	 and	GFP-labeled	
thrombocyte	numbers	remained	unchanged.		
We	previously	observed	 that	 children	with	 INS	have	mildly	decreased	plasma	
PACAP	 levels,	 but	 maintain	 normal	 serum	 ceruloplasmin	 levels	 and	
demonstrate	 increased	platelet	 counts	only	 in	a	 subgroup	of	 the	patients.[115]	
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Hence,	 the	 adriamycin	 exposed	 zebrafish	 model	 seems	 to	 mimic	 the	
observations	 in	 human	 INS	 rather	 than	 CNS.	We	 hypothesized	 that	 a	 longer	
duration	 of	 nephrosis	 might	 be	 necessary	 to	 affect	 megakaryopoiesis	 and	
platelet	count.	 In	humans	with	CNS,	we	also	observed	 low	or	normal	platelet	
counts	immediately	after	birth,	slowly	increasing	within	1	or	2	weeks	until	they	
reached	 levels	 of	 500-600	 x	 109/L.[115]	 However,	 repetition	 of	 experiments	 in	
the	 adriamycin	 exposed	 zebrafish	 embryos	 at	 5	 and	 6	 dpf	 showed	 similar	
results.	
Low	 concentrations	 of	 adriamycin	 dissolved	 in	 the	 zebrafish	 medium,	
specifically	 seem	 to	 target	 the	 pronephros.[152]	 Like	 other	 cytotoxic	 drugs,	
adriamycin	 can	 cause	 myelosuppression	 in	 humans.	 Leukopenia	 is	 the	 most	
common,	but	moderate	thrombocytopenia	can	also	rarely	occur	and	is	a	dose-
dependent	 effect.[160]	 Hence,	 a	 direct	 inhibitory	 effect	 of	 adriamycin	 on	
megakaryopoiesis	 in	 this	 zebrafish	 model	 cannot	 be	 excluded.	 A	 dose-
dependent	 decrease	 of	 GFP-positive	 thrombocytes	 might	 then	 be	 expected,	
and	could	counteract	the	effect	of	PACAP	deficiency.		
As	 adriamycin	 can	 also	 cause	 cardiomyopathy	 in	 humans[161]	 and	 adult	
zebrafish[162],	 the	 question	 arose	 if	 the	 observed	 pericardial	 edema	 in	 the	
adriamycin	 exposed	 fish	 could	 be	 explained	 by	 cardiac	 toxicity,	 besides	
proteinuria.	 However,	 the	 cardiac	 phenotype	 in	 this	 model	 was	 previously	
studied	 in	 detail.	 Embryos	 exposed	 to	 low	 concentrations	 of	 adriamycin	 (less	
than	 30	 μM)	 did	 not	 show	 any	 signs	 of	 cardiac	 toxicity	 or	 vascular	
abnormalities.	 Only	 higher	 concentrations	 gave	 rise	 to	 morphological	 and	
functional	 cardiac	 changes	 and	 dysmorphic	 blood	 vessels.	 Moreover,	 dose	
dependent	 proteinuria,	 associated	 with	 increasing	 cardiac	 edema	 was	
demonstrated,	 enforcing	 the	 causal	 relationship	 between	 proteinuria	 and	
edema	in	this	model.[152]		
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An	other	plausible	explanation	 for	 the	 fact	 that	our	 findings	 in	humans	could	
not	be	reproduced	in	zebrafish	CNS	models,	could	be	found	in	the	differences	
in	thrombocytes	and	thrombocyte	formation	in	zebrafish	compared	to	humans.	
The	 zebrafish	 thrombocyte	 is	 the	 functional	 equivalent	 of	 the	 mammalian	
platelet.	 The	 early	 process	 of	 hematopoiesis,	 including	 the	 formation	 of	
hematopoietic	stem	cells	and	megakaryocytes	(or	thrombocyte	progenitors	for	
the	 zebrafish),	 is	 comparable	 in	 both	 zebrafish	 and	 humans.[163]	 However,	
zebrafish	 thrombocytes	 are	 different	 from	 human	 platelets,	 as	 they	 remain	
nucleated.[164]	 The	 final	 maturation	 process	 from	 megakaryocyte	 to	
thrombocyte	 seems	 to	 be	 different	 between	 zebrafish	 and	 mammals.	 The	
existence	 of	 a	 zebrafish	 equivalent	 of	 the	 mammalian	 proplatelet-forming	
megakaryocyte	 that	 undergoes	 fragmentation	 of	 its	 cytoplasm	 to	 produce	
platelets	 has	 never	 been	 demonstrated.	 If	 PACAP	 deficiency	 exerts	 its	 effect	
during	 this	 late	 stage	of	megakaryopoiesis,	 this	 could	be	another	 reason	why	
our	 observations	 in	 humans	 were	 not	 reproducible	 in	 the	 studied	 zebrafish	
models	of	CNS.	
	
4.5 Conclusion	
In	 this	 study,	 two	 different	 CNS	 models	 were	 established	 in	 Tg(cd41:EGFP)	
transgenic	 zebrafish,	 by	 injection	 of	 a	 nephrin	 morpholino	 or	 exposure	 to	
adriamycin.	 In	 the	 nephrin	 depleted	 zebrafish	 model,	 no	 severe	 PACAP	
deficiency	nor	increased	thrombocyte	counts	were	observed.	PACAP	deficiency	
was	observed	in	the	adriamycin	exposed	model.	However,		thrombocyte	counts	
were	not	increased.	We	conclude	that	none	of	both	CNS	zebrafish	models	are	
suitable	 for	 studying	 the	 role	 of	 PACAP	 and	 ceruloplasmin	 deficiency	 in	
megakaryopoiesis	in	CNS.	Animal	models	for	other	forms	of	NS,	as	for	example	
puromycin	 aminonucleoside	 treated	 rats[158],	 should	 be	 further	 studied.	
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Chapter	5:	 Distribution	and	function	of	
PACAP	and	its	receptors	in	the	healthy	
and	nephrotic	kidney	
	
Based	on:	
Eneman	B,	Freson	K,	Van	Geet	C,	Dijkman	H,	van	den	Heuvel	L,	Levtchenko	E.	
Distribution	 and	 function	 of	 PACAP	 and	 its	 receptors	 in	 the	 healthy	 and	
nephrotic	kidney.	Nephron	Experimental	Nephrology,	under	revision.	
	
Background:	 Plasma	 deficiency	 of	 pituitary	 adenylate	 cyclase	 activating	
polypeptide	 (PACAP)	 due	 to	 urinary	 loss	 was	 recently	 demonstrated	 for	
children	with	nephrotic	syndrome	(NS).	Previous	studies	have	also	reported	a	
nephroprotective	 effect	 of	 PACAP	 on	 kidney	 proximal	 tubules	 in	 a	 variety	 of	
renal	disease	models.	However,	little	is	known	about	the	expression	of	PACAP	
and	its	receptors	in	the	human	kidney.	Furthermore,	the	role	of	PACAP	in	renal	
health	for	the	NS	has	never	been	studied.		
Objective:	The	aim	of	this	study	was	to	explore	the	expression	of	PACAP	and	its	
receptors	PAC1,	VPAC1	and	VPAC2	in	healthy	and	nephrotic	kidney	tissue	and	
to	determine	if	PACAP	has	an	effect	on	renal	proximal	tubular	cells	exposed	to	
albumin.		
Material/Methods:	 Expression	 of	 PACAP	 and	 its	 receptors	 PAC1,	 VPAC1	 and	
VPAC2	was	 studied	with	 immunofluorescence	 using	 kidney	 tissue	 from	 three	
healthy	children,	two	children	with	congenital	and	five	children	with	acquired	
NS.	The	expression	of	PACAP	and	its	receptors	was	additionally	studied	in	three	
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human	 renal	 cell	 lines	 (conditionally	 immortalized	 glomerular	 microvascular	
endothelial	 cells,	 conditionally	 immortalized	 podocytes	 and	 proximal	 tubular	
epithelial	 HK-2	 cells)	 with	 RT-PCR,	 qPCR,	Western	 blot	 and	 immunostainings.	
cAMP	 levels	were	measured	 in	HK-2	 cells	 after	 stimulation	with	 recombinant	
PACAP,	to	test	the	functionality	of	the	VPAC1	receptor.	Cell	viability	and	TGF-β1	
expression	 were	 measured	 in	 HK-2	 cells	 exposed	 to	 albumin,	 mimicking	
proteinuria	 related	 damage,	 with	 and	 without	 the	 addition	 of	 recombinant	
PACAP.		
Results:	VPAC1	expression	was	detected	in	the	tubular	proximal	epithelial	cells	
and	 in	 the	glomeruli	of	healthy	and	nephrotic	 renal	 tissue.	PACAP	expression	
was	upregulated	 in	the	proximal	 tubules	of	renal	sections	of	children	with	NS	
compared	 to	healthy	 renal	 sections,	 probably	due	 to	 the	 reuptake	of	 filtered	
PACAP.	 VPAC1	 expression	 was	 demonstrated	 in	 glomerular	 microvascular	
endothelial	 cells	 and	 HK-2	 cells.	 Functionality	 of	 the	 VPAC1	 receptor	 in	 HK-2	
cells	was	confirmed	by	demonstrating	increased	cAMP	levels	after	stimulation	
with	recombinant	PACAP,	which	could	be	inhibited	by	VPAC1	antagonist	PG	97-
269.	Finally,	we	demonstrated	that	the	addition	of	recombinant	PACAP	to	the	
cell	medium	of	HK-2	cells	exposed	to	albumin,	did	not	alter	cell	viability	or	TGF-
β1	expression.		
Conclusion:	Our	observations	provide	new	insights	in	the	expression	of	PACAP	
and	 its	 receptors	 in	 the	healthy	and	nephrotic	human	kidney	tissue.	VPAC1	 is	
the	 predominant	 receptor	 in	 the	 human	 kidney.	 The	 enhanced	 presence	 of	
PACAP	 in	 proximal	 tubular	 epithelial	 cells	 in	 nephrotic	 kidneys	 points	 to	 the	
reabsorption	of	filtered	PACAP.	On	short	term,	no	in	vitro	effect	of	PACAP	was	
found	 on	 proximal	 tubular	 epithelial	 cells	 exposed	 to	 high	 concentrations	 of	
albumin.	
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5.1 Introduction	
Pituitary	 adenylate	 cyclase-activating	 polypeptide	 (PACAP)	 is	 a	 widespread	
neuropeptide	 that	belongs	 to	 the	 vasoactive	 intestinal	 peptide	 (VIP)-secretin-
growth	 hormone	 releasing	 hormone-glucagon	 family.	 The	 ADCYAP1	 gene	
encodes	a	176-amino	acid	prepro-protein,	from	which	two	active	peptides	are	
formed:	PACAP-38	and	PACAP-27.[3]	PACAP	is	widely	expressed	in	the	nervous	
system	 and	 in	 several	 peripheral	 organs,	 notably	 the	 genital,	 respiratory	 and	
gastro-intestinal	 tracts	 and	 the	 endocrine	 organs.[3]	 PACAP	 was	 initially	
identified	 to	 stimulate	 cAMP	 formation	 in	 pituitary	 cells.[1]	 Later,	 numerous	
functions	 of	 PACAP	 in	 the	 nervous	 system	 and	 peripheral	 organs	 were	
discovered.[3]	PACAP	plays	a	 role	as	a	neurotransmitter,	hormone	and	trophic	
factor	and	takes	part	in	diverse	biological	processes,	such	as	neurotransmitter	
release,	 apoptosis	 prevention	 and	 stimulation	 of	 cell	 multiplication	 and	
differentiation.[3]	 In	 human	 plasma,	 PACAP	 is	 bound	 to	 ceruloplasmin,	 which	
prevents	its	rapid	degradation.[4]	Three	different	receptors	can	be	activated	by	
PACAP.	 PAC1	 is	 a	 PACAP-specific	 receptor,	 which	 is	 coupled	 to	 several	
transduction	 systems.	 Activation	 of	 PAC1	 stimulates	 cAMP	 production	 via	
adenylyl	 cyclase,	 activates	 phospholipase	 C,	 and	 leads	 to	 increased	 calcium	
levels.[6,165]	 VPAC1	 and	 VPAC2	 are	 PACAP/VIP-indifferent	 receptors,	 primarily	
coupled	to	adenylyl	cyclase	(AC).[7,8]	The	PAC1	receptor	 is	especially	abundant	
in	 the	 brain	 and	 peripheral	 nervous	 system,	 while	 the	 VPAC1	 and	 VPAC2	
receptors	 are	 particularly	 expressed	 in	 peripheral	 organs,	 as	 for	 example,	 	 in	
lung,	gonads	and	spleen.[3]		
Little	is	known	about	the	expression	and	function	of	PACAP	and	its	receptors	in	
the	kidney.	Recently,	several	studies	have	revealed	a	nephroprotective	effect	of	
PACAP	 in	 different	 in	 vitro	 and	 in	 vivo	models	 of	 kidney	pathology.[20]	 PACAP	
protects	 proximal	 tubular	 epithelial	 cells	 in	 vitro	 against	 myeloma	 light	
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chain[19,25],	cisplatin[21,22],	cyclosporine	A[23]	and	hypoxia[24].	Changes	due	to	the	
addition	 of	 recombinant	 PACAP	 include	 increased	 cell	 survival,	 inhibition	 of	
upregulated	 apoptotic	 pathways	 and	 decreased	 production	 of	 pro-
inflammatory	and	profibrotic	substances.[20]	Data	from	in	vivo	animal	studies	in	
rodents	confirm	a	nephroprotective	effect	of	PACAP	 in	 ischemia	caused	 renal	
damage[24,26-28],	 multiple	 myeloma[19,29],	 diabetic	 nephropathy[29],	 contrast	
induced	 nephropathy[31]	 and	 renal	 damage	 due	 to	 cisplatin[21,22]	 and	
cyclosporine	 A[23].	 PACAP	 administration	 in	 those	 in	 vivo	 models	 leads	 to	
improvement	 of	 renal	 function,	 decreased	 tubulointerstitial	 damage	 and	
decreased	 expression	 of	 inflammatory	 and	 fibrotic	 markers.[20]	 A	
nephroprotective	 effect	 of	 PACAP	 administration	 has	 been	 confirmed	 in	 a	
patient	with	multiple	myeloma.[30]		
No	 data	 exist	 about	 the	 role	 of	 PACAP	 in	 proteinuric	 conditions.[115]	 Chronic	
proteinuria	 has	 been	 demonstrated	 as	 an	 independent	 disease	 progression	
factor	 in	 numerous	 kidney	 disorders.[130]	 The	 overload	 of	 albumin	 and	 other	
plasma	proteins	 in	 the	proximal	 tubules	 causes	apoptosis	of	proximal	 tubular	
epithelial	 cells	 and	 the	 production	 of	 proinflammatory	 and	 profibrotic	
substances,	 such	 as	 interleukin-8	 (IL-8)	 and	 transforming	 growth	 factor-β1	
(TGF-β1),	 causing	 tubulointerstitial	 damage	 and	 the	 progression	 of	 renal	
disease.[130,166-168]	 Since	we	 previously	 found	 plasma	 PACAP	 deficiency	 due	 to	
urinary	loss	in	infants	and	children	with	NS[115],	we	questioned	whether	PACAP		
would	have	any	effect	on	renal	proximal	tubular	epithelial	cells	simultaneously	
exposed	to	high	albumin	concentrations	mimicking	proteinuric	conditions.	
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5.2 Material	and	methods	
5.2.1 Cell	culture	
Human	conditionally	 immortalized	glomerular	microvascular	endothelial	 cells,	
transduced	with	the	temperature-sensitive	SV40-T	gene	and	telomerase,	were	
cultured	in	endothelial	growth	medium	2	-	microvascular	(EGM2-MV,	Cambrex,	
Wokingham,	UK)	supplemented	with	fetal	bovine	serum	(FBS)	5%	and	growth	
factors	as	supplied,	as	previously	described.[169]	Cells	were	grown	to	confluence	
at	 33°C,	 and	 then	differentiated	 for	 14	days	 at	 37°C. AB	podocytes,	 a	 human	
conditionally	immortalized	podocyte	cell	line	transduced	with	the	temperature-
sensitive	SV40-T	gene,	were	a	kind	gift	of	Prof.	Dr.	Moin	Saleem	(University	of	
Bristol,	United	Kingdom).	Cells	were	grown	as	previously	described[170]	at	33°C	
and	 differentiated	 for	 14	 days	 at	 37°C	 in	 DMEM-HAM’s/F12	medium	 (Lonza,	
Basel,	 Switzerland)	 supplemented	 with	 FBS	 10%	 (Gibco,	 Carlsbad,	 USA),	 50	
IU/mL	 penicillin	 and	 50	 μg/mL	 streptomycin	 (Lonza)	 and	 ITS	 (insulin,	
transferrin,	selenite	5	mL	in	500	mL	medium,	Sigma	Chemicals,	Dorset,	United	
Kingdom).	 The	 human	 kidney	 proximal	 tubular	 epithelial	 HK-2	 cell	 line	 was	
obtained	 from	 the	 American	 Type	 Culture	 Collection	 (ATCC,	Manassas,	 USA).	
Cells	 were	 grown	 in	 DMEM-HAM’s/F12	 medium	 (Lonza)	 supplemented	 with	
FBS	10%	(Gibco),	50	IU/mL	penicillin	and	50	μg/mL	(Lonza).	Cells	were	cultured	
in	 T75	 flasks	 at	 37°C.	Human	megakaryocytic	 CHRF-288–11	 cells	 (ATCC)	were	
grown	 as	 previously	 described,	 in	 RPMI1640	 medium	 (Lonza)	 supplemented	
with	FBS	10%	(Gibco),	50	IU/mL	penicillin	and	50	μg/mL	streptomycin	(Lonza),	4	
mM	L-glutamine,	1	mM	sodium	pyruvate	and	nonessential	amino	acids	(Gibco),	
at	37	°C.[13]	Human	neuroblastoma	HTB-11	cells	(ATCC)	were	grown	in	DMEM-
HAM’s/F12	 medium	 (Lonza)	 supplemented	 with	 FBS	 10%	 (Gibco),	 50	 IU/mL	
penicillin	and	50	μg/mL	streptomycin	(Lonza)	and	4	mM	L-glutamine	(Gibco)	at	
37	°C.	All	cells	were	grown	in	a	humidified	atmosphere	of	5%	CO2	in	air. 
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5.2.2 Immunostaining	
5.2.2.1 Cells	
Cells	 were	 grown	 in	 eight	 chamber	 Lab-Tek	 cover	 slips	 (Thermo	 Scientific,	
Waltham,	 USA).	 Conditionally	 immortalized	 cell	 lines	 were	 cultured	 at	 33	 °C	
until	 confluence	and	 then	differentiated	at	37	 °C	 for	14	days.	Other	 cell	 lines	
were	 cultured	 to	 confluence	 at	 37°C.	 Medium	 was	 removed	 and	 cells	 were	
washed	with	 phosphate	 buffered	 saline	 (PBS).	 Then	 cover	 slips	were	 fixed	 in	
cold	paraformaldehyde	4%	 in	PBS	 (Alfa	Aesar,	Ward	Hill,	USA).	After	washing	
and	permeabilization	with	0.1%	triton	X-100	in	PBS	(Sigma),	nonspecific	binding	
sites	were	blocked	for	60	min	with	blocking	buffer	(PBS	containing	2%	FBS,	2%	
bovine	 serum	 albumin	 (BSA)	 and	 0.2%	 gelatin).	 Next,	 slides	 were	 incubated	
overnight	at	4°C	with	the	following	primary	antibodies	1/100	in	blocking	buffer:	
PACAP	(PP1A4,	produced	in	our	lab	as	previously	described[10]),	PAC1	(SC32776,	
Santa	Cruz	Biotechnology,	Texas,	USA),	VPAC1	(polyclonal	antibody	produced	in	
our	 lab	 as	 previously	 described[10])	 and	 VPAC2	 (SC30020,	 Santa	 Cruz	
Biotechnology).	 Subsequently,	 slides	 were	 washed	 with	 PBS	 and	 then	
incubated	 for	 one	 hour	 with	 alexa	 fluor	 goat	 anti	 rabbit	 or	 goat	 anti	mouse	
antibodies	 (Invitrogen,	 Waltham,	 USA).	 Cover	 slips	 were	 mounted	 on	 glass	
slides	with	FluorSave	mounting	medium	(Calbiochem,	La	Jolla,	USA),	containing	
4ʹ,6-Diamidine-2ʹ-phenylindole	dihydrochloride	(DAPI)	1/1000	for	DNA	staining.	
Images	 were	 captured	 with	 a	 Zeiss	 Axiocam	 HR	 camera	 using	 AxioVision	
software	4.8	(Carl	Zeiss,	Jena,	Germany).	
	
5.2.2.2 Tissue	
Renal	tissue	was	obtained	from	the	tissue	databank	of	the	university	hospitals	
of	 Leuven,	 with	 permission	 from	 the	 local	 ethical	 board,	 according	 to	 the	
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Declaration	of	Helsinki	 (S55577).	Renal	 tissue	 from	a	 total	of	10	 children	was	
studied.	Control	renal	tissue	was	obtained	from	three	children	between	1	and	
13	years	old,	who	underwent	a	partial	nephrectomy	because	of	a	benign	renal	
tumor.	 The	healthy	 tissue	 surrounding	 the	 tumor	was	 used	 as	 control	 tissue.	
Renal	 tissue	 of	 7	 children	 with	 nephrotic	 syndrome	 (NS)	 between	 0	 and	 12	
years	old	was	 further	studied.	Two	children	had	a	Finnish-type	congenital	NS,	
while	 five	had	acquired	 idiopathic	NS	 (three	had	minimal	 change	NS	and	 two	
had	 focal	 segmental	 glomerulosclerosis).	 All	 patients	 had	 a	 normal	 renal	
function.	All	nephrotic	patients	had	nephrotic	proteinuria	(urine	protein	levels	
>	 2	 g/g	 creatinine)	 on	 the	moment	 of	 renal	 biopsy.	 Supplementary	 table	 5.1	
provides	an	overview	of	studied	patients.		
For	 immunofluorescence	 stainings,	 kidney	 fragments	 were	 frozen	 in	 liquid	
nitrogen,	 and	 2	 μm	 cryostat	 sections	 were	 made.	 Slices	 were	 then	 fixed	 in	
acetone	 during	 10	minutes	 and	 air-dried.	 Subsequently,	 sections	 were	
incubated	with	the	primary	antibodies	against	PACAP	(PP1A4,	produced	in	our	
lab	 as	 previously	 described[10]),	 PAC1	 (SC32776,	 Santa	 Cruz	 Biotechnology),	
VPAC1	(polyclonal	antibody	produced	in	our	lab	as	previously	described[10])	and	
VPAC2	 (SC30020,	 Santa	Cruz	Biotechnology)	 for	1	hour	at	 room	 temperature.	
Primary	 antibody	 dilution	 was	 1/50	 in	 PBS	 with	 1%	 BSA.	 Next,	 slices	 were	
washed	with	PBS	and	incubated	with	a	secondary	goat	anti-rabbit	or	goat	anti-
mouse	Alexa	Fluor	488	antibody	(Invitrogen),	diluted	1/100	in	PBS	with	1%	BSA	
for	 30	 minutes	 at	 room	 temperature.	 Tissue	 slices	 were	 mounted	 with	
Fluoromount-G	(SouthernBiotech,	Birmingham,	USA).	Sections	were	examined	
using	a	Zeiss	Axiocam	HR	camera	and	AxioVision	software	4.8	(Carl	Zeiss,	Jena,	
Germany).	Healthy	human	prostate	tissue	was	used	as	a	positive	control.[171,172]	
For	 immunohistochemical	 stainings,	 kidney	 fragments	 were	 fixed	 in	 4%	
buffered	formaldehyde	for	24	hours	and	embedded	in	paraffin.	4	μm	sections	
	 118	
were	 incubated	 overnight	with	 the	 primary	monoclonal	 anti-PACAP	 antibody	
(PP1A4)	1/50	 in	PBS	with	1%	BSA	at	4°C.	Subsequently,	 slices	were	 incubated	
for	 60	 minutes	 in	 a	 biotinylated	 horse	 anti-mouse	 antibody	 (Vector	
Laboratories,	 Burlingame,	 USA)	 diluted	 1/100	 in	 PBS	 with	 1%	 BSA,	 at	 room	
temperature.	The	Vectastain	ABC	kit	with	peroxidase	as	detection	enzyme	was	
used	(Vector	Laboratories),	and	diaminobenzidine	was	used	as	a	substrate.	
	
5.2.3 RNA	isolation,	reverse	transcription	PCR	and	quantitative	real-time	PCR		
Reverse	 transcriptase	PCR	 (RT-PCR)	 and	quantitative	 real-time	PCR	 (qPCR)	 for	
mRNA	expression	of	PACAP	receptors	
Cells	were	grown	in	T75	flasks	 in	their	standard	culture	medium,	as	described	
above.	 Conditionally	 immortalized	 cell	 lines	 were	 cultured	 at	 33	 °C	 until	
confluence	and	then	differentiated	at	37	°C	 for	14	days.	Other	cell	 lines	were	
cultured	to	confluence	at	37°C.	RNA	was	extracted	with	the	RNeasy	Plus	minikit	
(Quiagen,	 Hilden,	 Germany)	 according	 to	 the	 manufacturer’s	 protocol.	 RNA	
extracted	 from	 a	 control	 human	 kidney	 lysate	 was	 used	 as	 a	 control.	 RNA	
concentration	 was	 measured	 using	 Nanodrop	 2000c	 spectrophotometer	
(Thermo	 Scientific).	 cDNA	 was	 produced	 from	 one	 μg	 of	 RNA	 using	
SuperScript®	 III	 reverse	 transcriptase	 (Life	 technologies,	 Carlsbad,	 USA),	 oligo	
(dT)	 primers,	 random	 hexamer	 primers	 and	 dNTP	 mix	 (Invitrogen).	 PCR	
products	 were	 separated	 on	 2%	 agarose	 gels	 and	 visualized	 with	 GelRed	
(Biotium,	Hayward,	CA,	USA).	Quantitative	real-time	PCR	(qPCR)	was	performed	
with	platinum	SYBR	green	qPCR	mix	(Invitrogen),	in	the	StepOne	Real-Time	PCR	
system	(Life	technologies).	Specific	forward	and	reverse	primers	were	from	IDT	
Technologies	 (San	 Jose,	USA).	 Primers	were	 added	 to	 the	 qPCR	mix	 together	
with	 the	 cDNA	 solution	 and	 subsequently	 run	 on	 the	 cycler	 according	 to	 the	
manufacturer’s	 protocol.	 Supplementary	 table	 5.2	 provides	 an	 overview	 of	
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primer	sequences	for	PAC1,	VPAC1,	VPAC2	and	GAPDH.	Human	megakaryocytic	
CHRF-288-11	 cells	 were	 used	 as	 a	 positive	 control	 for	 VPAC1,	 while	 human	
neuroblastoma	 HTB-11	 cells	 were	 used	 as	 a	 positive	 control	 for	 PAC1	 and	
VPAC2.	 Relative	 expression	 of	 the	 gene	 of	 interest	 versus	 GAPDH	 expression	
was	calculated	with	the	comparative	Ct	method.	
	
qPCR	for	mRNA	expression	of	TGF-β1	on	albumin	treated	HK-2	cells	
HK-2	 cells	 were	 grown	 at	 37	 °C	 in	 6	 wells-plates	 at	 a	 density	 of	 300.000	
cells/well	for	24	hours	in	standard	culture	medium.	Cells	were	next	pretreated	
with	recombinant	PACAP-38	 in	standard	culture	medium.	PACAP-38	was	from	
Bachem	(Bubendorf,	Switzerland).	After	two	hours,	the	medium	was	removed	
and	 replaced	 by	 standard	 culture	 medium	 containing	 BSA	 0,	 1,	 10	 or	 100	
mg/mL	and	recombinant	PACAP	0	nM,	10	nM,	100	nM	or	1	μM.	BSA	was	from	
Sigma	(A7906)	and	was	fatty	acid	and	endotoxin	free.	Cells	were	incubated	for	
12	hours	at	37°C.	RNA	was	extracted	and	qPCR	was	performed	as	mentioned	
above.	Supplementary	table	5.2	provides	an	overview	of	primer	sequences	for	
GAPDH	and	TGF-β1.	
	
5.2.4 Western	blot	for	PACAP	
HK-2	 cells	 were	 cultured	 in	 T75	 flasks	 and	 incubated	 in	 standard	 culture	
medium	with	or	without	BSA	100	mg/mL	for	72	hours.	BSA	was	from	Sigma	and	
was	 fatty	acid	and	endotoxin	 free.	Cells	were	 lysed	and	homogenized	 in	RIPA	
buffer	 (1%	 igepal	 CA630,	 0.5%	 sodiumdeoxycholate,	 0.1%	 SDS,	 0.01%	
phenylmethane	 sulphonylfluoride,	 3%	 aprotinin,	 and	 1	 mM	
sodiumorthovanadate).	 Human	 plasma	 was	 used	 as	 a	 positive	 control.[115]	
Protein	concentrations	were	determined	using	the	Bradford	protein	assay	(Bio-
Rad,	 Hercules,	 CA,	 USA).	 Equal	 amounts	 (50	 μg)	 of	 protein	 sample	 were	
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separated	by	12%	SDS-PAGE	and	then	transferred	to	Hybond	ECL-nitrocellulose	
membranes	(Amersham	Biosciences,	Freiburg,	Germany).	Blots	were	incubated	
with	 a	 mouse	 monoclonal	 anti-PACAP	 antibody	 PP1A4	 (produced	 in	 our	
laboratory,	 as	 previously	 described[10])	 and	 a	 commercial	 antibody	 against	
GAPDH	(Abcam).	The	secondary	anti-mouse	antibody	was	from	Bio-Rad.	Blots	
were	stained	with	Western	blotting	electrochemiluminescence	(ECL)	detection	
reagent	(Thermo	Scientific).	
	
5.2.5 cAMP	measurements	
HK-2	cells	were	plated	 in	a	96-well	plate	at	a	density	of	5000	cells/well.	Cells	
were	grown	for	24	hours	in	standard	culture	medium	at	37°C.	Cells	were	then	
treated	with	 recombinant	PACAP-38	0	nM,	10	nM	and	1	μM	with	or	without	
VPAC1	 receptor	 antagonist	 PG	 97-269	 1	 μM	 in	 serum	 free	 medium.	
Recombinant	PACAP-38	and	VPAC1	antagonist	PG	97-269	were	from	Bachem.	
The	phosphodiesterase	 inhibitor	 3-isobutyl	 1-methylxanthine	 (IBMX)	was	 also	
added	to	the	culture	medium	(100	μM	final	concentration).	After	15	minutes	of	
incubation,	cAMP	 levels	were	measured	using	a	cAMP	enzyme	 immunoassay,	
according	 to	 the	 manufacturer’s	 protocol	 (GE	 Healthcare	 Life	 Sciences,	
Uppsala,	Sweden).		
	
5.2.6 Cell	viability	assay	
HK-2	cells	 (passages	10-15)	were	plated	 in	96-well	plates	at	a	density	of	7500	
cells/well.	Cells	were	grown	for	24	hours	 in	standard	culture	medium	at	37°C.	
Cells	 were	 next	 pretreated	 with	 recombinant	 PACAP-38	 in	 standard	 culture	
medium.	 PACAP-38	 was	 from	 Bachem.	 After	 two	 hours,	 the	 medium	 was	
removed	and	replaced	by	standard	culture	medium	containing	BSA	0,	1,	10	or	
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100	mg/mL	and	recombinant	PACAP	0	nM,	10	nM,	100	nM	or	1	μM.	Cells	were	
incubated	for	3	days	at	37°C.	PACAP	addition	was	repeated	every	24	hours.	72	
hours	 after	 the	 start	 of	 BSA	 treatment,	 the	 medium	 was	 removed	 and	 cells	
were	washed	 twice	with	 PBS.	 A	water	 soluble	 tetrazolium	 salt-1	 (WST-1)	 cell	
viability	 assay	 was	 performed,	 according	 to	 the	 manufacturer’s	 protocol	
(Roche,	Basel,	Switzerland).	
	
5.2.7 Statistics	
Relative	 gene	 expression,	 cAMP	 levels	 and	 viability	 measurements	 were	
compared	 using	 analysis	 of	 variance	 (ANOVA)	 with	 Bonferroni	 correction	 for	
multiple	testing	at	significance	level	P	<	0.05.	
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5.3 Results	
5.3.1 Expression	of	PACAP	and	 its	 receptors	 in	human	kidney	and	renal	cell	
lines	
As	 little	 is	 known	 about	 the	 expression	 of	 PACAP	 receptors	 in	 the	 kidney,	
immunofluorescence	 stainings	 for	 PAC1,	 VPAC1	 and	 VPAC2	 were	 initially	
performed	on	normal	renal	 tissue	from	three	children.	VPAC1	expression	was	
detected	 in	 the	 proximal	 tubular	 epithelial	 cells	 and	 in	 the	 glomerular	
endothelium	(Figure	5.1),	while	VPAC2	was	only	found	in	the	renal	blood	vessel	
walls	 and	 PAC1	 expression	 could	 not	 be	 demonstrated	 (data	 not	 shown).	
Expression	of	PACAP	receptors	was	then	investigated	in	renal	tissue	from	two	
children	 with	 congenital,	 three	 with	 minimal	 change	 NS	 and	 two	 with	 focal	
segmental	 glomerulosclerosis	 (FSGS).	 The	 same	 expression	 pattern	 was	
observed	for	nephrotic	children	as	for	healthy	children.	Representative	images	
from	one	healthy	 child	 and	 from	one	 child	 of	 each	NS	 subtype	 are	 shown	 in	
Figure	5.1.	
The	 human	 kidney	 sections	 were	 further	 investigated	 for	 the	 expression	 of	
PACAP.	 For	 the	 healthy	 children,	 no	 expression	 of	 PACAP	 was	 found	 in	 the	
glomeruli	(data	not	shown)	and	a	very	weak	signal	was	found	in	the	tubules.	In	
the	 sections	 from	 children	 with	 nephrotic	 syndrome	 (NS),	 strong	 PACAP	
expression	was	 observed	 in	 proximal	 tubular	 epithelial	 cells,	 probably	 due	 to	
reabsorption	 of	 filtered	 PACAP	 (Figure	 5.2	 A).	 Because	 endogenous	 PACAP	
expression	 by	 proximal	 tubular	 epithelial	 cells	 could	 be	 upregulated	 due	 to	
proteinuria,	PACAP	expression	 in	human	proximal	tubular	epithelial	HK-2	cells	
upon	 albumin	 exposure	 was	 investigated.	 HK-2	 cells	 neither	 showed	 PACAP	
expression	 at	 basal	 conditions,	 nor	when	 exposed	 to	 a	 high	 concentration	 of	
albumin	(100	mg/mL)	(Figure	5.2	B).	
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Figure	5.1:	Expression	of	VPAC1	receptor	in	the	healthy	and	nephrotic	human	kidney	
Immunofluorescence	stainings	for	VPAC1	were	performed	on	renal	tissue	from	healthy	and	
nephrotic	 children.	 Representative	 pictures	 from	 a	 healthy	 child	 and	 children	 with	
respectively	minimal	 change	 nephrotic	 syndrome,	 focal	 segmental	 glomerulosclerosis	 and	
Finnish-type	 congenital	 nephrotic	 syndrome	 are	 depicted.	 A	 strong	 signal	 for	 VPAC1	 was	
observed	 in	 the	glomeruli	with	 a	 staining	pattern	of	 glomerular	 endothelial	 cells,	 for	both	
healthy	and	nephrotic	renal	tissue	(a-d).	A	rather	weak	signal	was	observed	in	proximal	renal	
tubules,	both	for	control	and	nephrotic	patients	(e-h).	Magnification	200x.	
Legend:	Co	=	control;	MCNS	=	minimal	change	nephrotic	syndrome;	FSGS	=	focal	segmental	
glomerulosclerosis;	CNS	=	congenital	nephrotic	syndrome.	
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Figure	5.2:	PACAP	in	the	healthy	and	nephrotic	kidney	
(A)	Representative	immunofluorescence	(a	and	c)	and	peroxidase	(b	and	d)	stainings	of	renal	
proximal	 tubules	 with	 PP1A4	 monoclonal	 antibody	 against	 PACAP.	 While	 little	 or	 no	
expression	of	 PACAP	was	 seen	 in	 tubules	of	 healthy	 controls	 (a	 and	b),	 a	 clear	 signal	was	
seen	in	the	tubules	of	nephrotic	patients,	especially	apically	(c	and	d).	Representative	images	
from	a	3	years	old	healthy	child	(Co)	and	a	minimal	change	nephrotic	syndrome	patient	aged	
2	years	(NS)	are	shown.	Magnification	200x	(a	and	c)	and	400x	(b	and	d).	
(B)	 Immunoblot	analysis	for	PACAP	in	HK-2	cells	and	human	plasma	(as	a	positive	control),	
showing	no	expression	of	PACAP	in	HK-2	cells,	neither	in	basal	condition	nor	when	exposed	
to	albumin	 (100	mg/mL	during	96	hours).	 Immunoblot	analysis	 for	 the	housekeeping	gene	
GAPDH	was	performed	as	a	control.	
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To	 further	 confirm	 the	 expression	 of	 PACAP	 receptors	 in	 the	 human	 kidney,	
three	 human	 renal	 cell	 lines	 were	 studied:	 conditionally	 immortalized	
glomerular	 microvascular	 endothelial	 cells	 (ciGMVEC),	 conditionally	
immortalized	podocytes	and	proximal	tubular	epithelial	HK-2	cells.	In	line	with	
the	observation	in	human	kidney	tissue,	VPAC1	mRNA	expression	was	observed	
in	 ciGMVEC	 and	 HK-2	 cells	 (Figure	 5.3	 A).	 Both	 qPCR	 and	 RT-PCR	 were	
performed	for	all	 receptors	and	PACAP	 in	 the	three	cell	 lines	 (only	qPCR	data	
for	 VPAC1	 are	 shown).	 Expression	 of	 VPAC2	was	 not	 observed	 in	 any	 of	 the	
tested	 cell	 lines	 (data	 not	 shown).	 Expression	 of	 PAC1	 was	 very	 weak,	 with	
mean	Ct	values	of	35.6,	37.5	and	36.8	for	ciGMVEC,	podocytes	and	HK-2	cells	
respectively	(data	not	shown).	PACAP	expression	was	not	detected	in	the	three	
tested	cell	 lines	(data	not	shown).	Expression	of	VPAC1	by	ciGMVEC	and	HK-2	
cells	was	confirmed	on	the	protein	level	(Figure	5.3	B).	Since	PACAP	stimulates	
cAMP	 formation	 via	 binding	 the	 Gs-coupled	 receptor	 VPAC1,	 functionality	 of	
the	 VPAC1	 receptor	 on	 HK-2	 cells	 was	 examined	 by	 measuring	 cAMP	 levels	
under	basal	conditions	and	after	stimulation	with	recombinant	PACAP	 (Figure	
5.3	C).	The	addition	of	recombinant	PACAP	significantly	increased	cAMP	levels	
in	HK-2	cells.	The	addition	of	 the	VPAC1	receptor	antagonist	PG	97-269	could	
inhibit	 this	 increase	 in	 cAMP	 levels,	 proving	 the	 functionality	 of	 the	 VPAC1	
receptor	in	HK-2	cells.	
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Figure	5.3:	VPAC1	expression	in	renal	cell	lines	
(A)	 A	 quantitative	 real-time	 PCR	 for	 VPAC1	 was	 performed	 on	 three	 renal	 cell	 lines.	 The	
graph	shows	the	relative	gene	expression	of	VPAC1,	as	a	percentage	of	VPAC1	expression	in	
CHRF	 cells,	 used	 as	 a	 positive	 control	 (mean	 Ct	 value	 for	 CHRF	 cells	 was	 31.2).	 Gene	
expression	 was	 corrected	 for	 GAPDH	 (housekeeping	 gene).	 VPAC1	mRNA	 expression	 was	
observed	in	ciGMVEC	and	HK-2	cells,	while	not	in	AB	podocytes.	RNA	isolated	from	a	renal	
cortex	 lysate	 also	 showed	 expression	 of	 VPAC1.	 The	 experiment	 was	 performed	 twice	 in	
triplicate.	Data	from	one	representative	experiment	are	shown.	Bars	represent	means	+	SD.	
(B)	 Immunofluorescence	 staining	 with	 a	 polyclonal	 VPAC1	 antibody	 (green)	 shows	
expression	of	VPAC1	in	ciGMVEC	(left)	and	HK-2	cells	(right).	DAPI	was	used	for	the	nuclear	
staining	(blue).	Magnification	400x.	
(C)	Measurements	of	cAMP	levels	in	HK-2	cells	under	basal	conditions	and	after	stimulation	
with	PACAP	10	nM	and	1	μM	are	 shown.	The	experiment	was	performed	 in	 triplicate	and	
was	 repeated	 twice.	Bars	 represent	 the	means	plus	SD	 from	all	measurements.	*	P	<	0.05	
(one-way	ANOVA	with	Bonferroni	correction).	
Legend:	 CHRF	 =	megakaryocytic	 CHRF-288-11	 cells;	 ciGMVEC	 =	 conditionally	 immortalized	
glomerular	 microvascular	 endothelial	 cells;	 GAPDH	 =	 glyceraldehyde	 3-phosphate	
dehydrogenase;	cAMP	=	cyclic	adenosine	monophosphate	
	
5.3.2 Effects	of	PACAP	on	HK-2	cells	exposed	to	albumin	
To	 mimic	 proteinuria	 related	 cell	 damage,	 HK-2	 cells	 were	 exposed	 to	 a	
concentration	 range	of	 albumin.	 Cell	 viability	 tests	 using	 a	WST-1	 assay	were	
optimized	and	showed	a	concentration	dependent	decrease	of	cell	viability	 in	
HK-2	cells	 treated	with	albumin	during	 three	days,	while	 the	daily	addition	of	
recombinant	 PACAP	 did	 not	 influence	 cell	 viability	 (Figure	 5.4	 A).	 Also	 when	
PACAP	was	added	twice	daily,	or	when	cell	viability	was	measured	after	1,	2,	4	
or	5	days	of	albumin	exposure,	no	toxic	nor	protective	effect	of	PACAP	addition	
on	cell	 viability	was	observed	 (data	not	 shown).	Since	TGF-β1	expression	was	
previously	 found	 to	 be	 upregulated	 in	 albumin	 exposed	 proximal	 tubular	
epithelial	 cells[167],	 and	PACAP	was	 shown	 to	 lead	 to	decreased	expression	of	
TGF-β1	 in	 proximal	 tubular	 cells	 in	 several	 in	 vitro	 and	 in	 vivo	 renal	 disease	
models[20],	 the	 effect	 of	 treatment	 with	 recombinant	 PACAP	 on	 TGF-β1	
expression	in	albumin	exposed	HK-2	cells	was	measured.	We	found	that	TGF-β1	
expression	was	upregulated	after	12	hours	in	HK-2	cells	for	increasing	albumin	
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concentrations,	 whereas	 the	 addition	 of	 recombinant	 PACAP	 did	 not	 lead	 to	
altered	TGF-β1	expression	(Figure	5.4	B).	Longer	or	shorter	incubation	of	HK-2	
cells	 with	 albumin	 was	 investigated,	 but	 no	 effect	 of	 PACAP	 on	 TGF-β1	
expression	was	observed	after	6,	24	or	72	hours	of	albumin	exposure	(data	not	
shown).	
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Figure	5.4:	Effect	of	PACAP	on	cell	viability	and	TGF-β1	expression	of	albumin	exposed	HK-
2	cells	
(A)	Cell	viability	of	HK-2	cells	exposed	to	different	concentrations	of	recombinant	PACAP	and	
bovine	 serum	 albumin	 (BSA)	 was	 assessed	 with	 a	 WST-1	 cell	 viability	 assay.	 Cells	 were	
exposed	 to	 BSA	 and	 recombinant	 PACAP	 at	 different	 concentrations	 during	 72	 hours.	
Increasing	 BSA	 concentrations	 caused	 a	 significant	 decrease	 in	 cell	 viability,	 whereas	 the	
addition	of	 recombinant	PACAP	did	not	 influence	cell	 viability.	Bars	 represent	means	+	SD	
from	two	repeated	experiments	performed	in	triplo.	Means	were	compared	using	two-way	
ANOVA	with	Bonferroni	correction	for	multiple	tests	at	significance	level	P	<	0.05.	
(B)	 mRNA	 expression	 of	 TGF-β1	 was	 measured	 in	 HK-2	 cells	 exposed	 during	 12	 hours	 to	
different	concentrations	of	recombinant	PACAP	and	bovine	serum	albumin	(BSA),	using	the	
comparative	Ct	method.	Increasing	BSA	concentrations	caused	a	significant	increase	in	TGF-
β1	mRNA	expression,	whereas	 the	 addition	of	 recombinant	 PACAP	had	no	 influence.	 Bars	
represent	means	 +	 SD	 from	 two	 repeated	 experiments	 performed	 in	 duplo.	Means	 were	
compared	using	two-way	ANOVA	with	Bonferroni	correction	for	multiple	tests	at	significance	
level	P	<	0.05.		
Legend:	BSA	 =	 bovine	 serum	albumin;	 TGF-β1	 =	 transforming	 growth	 factor-β;	 *	 P	 <	 0.05	
compared	 to	 the	 condition	with	 the	 same	 PACAP	 concentration	 for	 BSA	 concentrations	 0	
and	1	mg/mL.	**	P	<	0.05	compared	to	the	condition	with	the	same	PACAP	concentration	for	
BSA	concentrations	of	0,	1	and	10	mg/mL.	
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5.4 Discussion	
PACAP	recently	gained	our	attention	as	it	was	demonstrated	that	is	has	a	major	
role	 in	 inhibiting	 platelet	 formation	 and	 activation,	 and	 that	 urinary	 PACAP	
losses	lead	to	thrombocytosis	and	platelet	hyperreactivity	in	NS.[10,11,115]	On	the	
other	 hand,	 PACAP	 plays	 a	 nephroprotective	 role	 in	 a	 variety	 of	 models	 of	
kidney		pathology[20],	while	 little	 is	known	about	the	expression	of	PACAP	and	
its	 receptors	 in	 the	 kidney.	 Hence,	 in	 this	 study	 we	 aimed	 to	 study	 the	
expression	 of	 PACAP	 and	 its	 receptors	 in	 healthy	 and	 nephrotic	 kidneys	 and	
studied	 its	 effect	 on	 renal	 proximal	 tubular	 epithelial	 cells	 simultaneously	
exposed	 to	 albumin	 and	 PACAP,	 mimicking	 the	 situation	 in	 proteinuric	
conditions.		
First,	we	detected	VPAC1	expression	in	proximal	tubular	epithelial	cells	and	in	
the	 glomerular	 endothelium	 in	 both	 healthy	 and	 nephrotic	 renal	 tissue.	 This	
finding	 confirms	 earlier	 research	 results,	 in	 which	 RNA	 expression	 of	 VPAC1	
was	 demonstrated	 in	 the	 human	 kidney.[7]	 Later,	 VPAC1	 was	 shown	 to	 be	
expressed	 particularly	 in	 the	 glomeruli,	 using	 in	 vitro	 receptor	
autoradiography.[15]	 Second,	 we	 observed	 that	 the	 presence	 of	 VPAC2	 was	
restricted	 to	 renal	 blood	 vessel	walls,	 in	 accordance	with	 a	 previous	 study	 in	
mice.[17]	We	could	not	detect	the	third	PACAP	receptor,	PAC1,	in	human	renal	
tissue.	One	study	previously	showed	expression	of	PAC1	by	radioimmunoassay	
(RIA)	in	the	rat	kidney[18],	but	it	was	never	demonstrated	in	humans.		
PACAP	expression	was	also	studied	in	the	human	kidney.		One	previous	study	in	
rats	showed	PACAP	expression	in	the	kidney	by	RIA.[14]	In	our	experiments,	we	
detected	weak	 expression	 of	 PACAP	 in	 the	 proximal	 tubules	 of	 healthy	 renal	
tissue.	In	comparison,	a	much	stronger	signal	was	observed	in	the	renal	tissue	
of	children	with	NS,	pointing	to	a	reabsorption	of	filtered	PACAP.	Theoretically,	
PACAP	expression	by	proximal	tubular	epithelial	cells	could	also	be	upregulated	
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due	to	a	harmful	stimulus	as	proteinuria.	 It	was	previously	shown	that	PACAP	
expression	in	the	renal	cortex	reacts	to	renal	 ischemia/reperfusion	injury	with	
an	 initial	 decrease	 followed	 by	 an	 increase	 of	 PACAP	 levels.[14]	 To	 further	
distinguish	 between	 increased	 production	 or	 reuptake	 of	 PACAP	 in	 proximal	
tubular	 cells,	 we	 investigated	 PACAP	 expression	 by	 Western	 blot	 in	 normal	
human	 proximal	 tubular	 epithelial	 HK-2	 cells	 and	 in	 HK-2	 cells	 exposed	 to	
albumin.	HK-2	cells	did	not	express	PACAP,	also	not	after	exposure	to	albumin.	
This	supports	the	idea	that	PACAP	would	be	reabsorbed	in	the	proximal	tubular	
epithelial	cell	due	to	an	overload	of	PACAP	present	 in	the	proximal	tubules	 in	
NS.	However,	the	exact	mechanism	and	the	physiological	importance	of	PACAP	
reuptake	 by	 proximal	 tubular	 cells	 remain	 unknown.	 Ceruloplasmin,	 the	 132	
kDa	binding	protein	of	PACAP,	 is	also	excreted	 into	the	urine	of	children	with	
congenital	 and	 idiopathic	 NS.[4,115]	 In	 diabetic	 patients,	 increased	 glomerular	
filtration	and	urinary	excretion	of	ceruloplasmin	was	previously	shown.[173]	As	a	
strong	 correlation	 between	 PACAP	 and	 ceruloplasmin	 urine	 levels	 was	
demonstrated	 in	 children	 with	 NS,	 and	 seen	 the	 short	 half-life	 of	 unbound	
PACAP,	 it	 was	 suggested	 that	 PACAP	 would	 be	 filtered	 bound	 to	
ceruloplasmin.[115]	 Data	 about	 possible	 reuptake	 of	 filtered	 ceruloplasmin,	
however,	 are	 lacking.	 It	 is	 not	 clear	 if	 ceruloplasmin	 or	 PACAP	 are	 ligands	 of	
megalin	or	cubulin,	the	multiligand	receptors	responsible	for	the	reabsorption	
of	 a	 wide	 variety	 of	 proteins	 in	 proximal	 tubules.[174]	 Furthermore,	 as	 the	
sample	 size	of	 our	 study	was	 small,	we	were	not	 able	 to	discuss	 the	 relation	
between	the	severity	of	proteinuria	and	the	presence	of	PACAP	in	the	proximal	
tubules.	 Further	 research	 is	 necessary	 to	 unravel	 the	 mechanisms	 of	 PACAP	
filtration	and	reabsorption	in	NS.	
To	further	investigate	the	expression	of	PACAP	receptors	in	the	human	kidney,	
three	 human	 renal	 cell	 lines	 were	 studied:	 ciGMVEC,	 conditionally	
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immortalized	 podocytes	 and	 proximal	 tubular	 epithelial	 HK-2	 cells.	 VPAC1	
mRNA	expression	was	observed	in	ciGMVEC	and	HK-2	cells,	while	expression	of	
PAC1	was	 very	 low	and	VPAC2	was	 not	 observed	 in	 the	 three	 cell	 lines.	One	
previous	 report	 mentions	 RNA	 expression	 of	 PACAP	 receptors	 in	 an	 SV40	
immortalized	 human	 proximal	 tubular	 epithelial	 cell	 line:	 RNA	 expression	 of	
VPAC1	 and	 PAC1	 was	 demonstrated	 while	 VPAC2	 was	 not	 expressed.[19]	 We	
confirmed	expression	of	VPAC1	in	ciGMVEC	and	HK-2	cells	on	the	protein	level	
by	immunofluorescence	stainings.		
As	 we	 demonstrated	 reduced	 plasma	 PACAP	 levels	 and	 excessive	 urinary	
PACAP	 levels	 in	proximal	 tubules	 in	NS	patients[115]	 and	 since	PACAP	exerts	 a	
protective	effect	on	proximal	tubular	epithelial	cells	in	a	variety	of	renal	disease	
models[20],	 we	 further	 aimed	 to	 investigate	 the	 effect	 of	 PACAP	 on	 human	
proximal	 tubular	 epithelial	HK-2	 cells.	We	 showed	 functionality	 of	 the	VPAC1	
receptor	 on	 HK-2	 cells	 by	 demonstrating	 increased	 cAMP	 levels	 after	
stimulation	with	 recombinant	PACAP,	which	 could	be	 inhibited	by	 the	VPAC1	
receptor	 antagonist	 PG	 97-269.	 This	 finding	 is	 important	 as	 it	 suggests	 that	
VPAC1	is	the	main	active	PACAP	receptor	in	HK-2	cells.	PAC1	can	possibly	play	
an	additional	role,	since	PAC1	signaling	is	coupled	to	a	variety	of	transduction	
systems	 besides	 the	 cAMP	 pathway.	 However,	 we	 showed	 that	 PAC1	
expression	 in	 HK-2	 cells	 is	 very	 low.	 If	 VPAC1	 signaling	 is	 indeed	 the	 main	
pathway	 underlying	 the	 cytoprotective	 effect	 of	 PACAP	 on	 proximal	 tubular	
cells	 observed	 in	 several	 renal	 disease	 models[20]	 should	 be	 further	
investigated,	 studying	 the	 effect	 of	 antagonists	 and	 agonists	 of	 the	 PACAP	
receptors.	
We	 further	 investigated	 the	 effect	 of	 PACAP	 on	 albumin	 exposed	 HK-2	 cells,	
mimicking	proteinuria	related	cell	damage.	Cell	viability	and	TGF-β1	expression	
were	studied.	We	chose	for	those	two	parameters,	because	albumin	exposure	
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causes	cell	death	and	 leads	to	 increased	expression	of	the	profibrotic	TGF-β1,	
both	playing	a	role	in	the	ongoing	tubulointerstitial	damage	and	fibrosis	due	to	
chronic	proteinuria[130,167].	Furthermore,	PACAP	was	shown	in	a	variety	of	renal	
disease	models	 to	 inhibit	 cell	 death	 and	 increased	 TGF-β1	 expression.[20]	We	
confirmed	 that	 increasing	 albumin	 concentrations	 indeed	 induced	 decreasing	
cell	 viability	 and	 increasing	 TGF-β1	 expression.	 However,	 the	 addition	 of	
recombinant	 PACAP	 did	 not	 influence	 cell	 viability	 or	 TGF-β1	 expression.	
Hence,	 PACAP	does	 not	 seem	 to	 play	 a	 protective	 role	 in	 proteinuria	 related	
damage	 of	 proximal	 tubular	 epithelial	 cells	 as	 it	 does	 in	 other	 renal	 disease	
models,	at	least	for	the	currently	tested	parameters.	Furthermore,	no	harmful	
effect	of	PACAP	was	observed.		
A	 shortcoming	of	 this	 study	 is	 that	HK-2	 cells	were	only	 exposed	 to	 albumin,	
while	 for	 in	 vivo	 proteinuria	 related	damage,	 proximal	 tubular	 epithelial	 cells	
are	 evidently	 exposed	 to	 many	 other	 proteins	 present	 in	 the	 glomerular	
ultrafiltrate.	 We	 cannot	 exclude	 a	 PACAP	 effect	 when	 proximal	 tubular	
epithelial	cells	would	be	exposed	to	a	mixture	of	proteins	reflecting	the	in	vivo	
situation.	 Furthermore,	 in	 this	 in	 vitro	 model,	 it	 was	 only	 possible	 to	 study	
short-term	effects	of	PACAP.	To	exclude	in	vivo	effects	of	PACAP	on	proteinuria	
related	proximal	 tubular	epithelial	damage,	 the	evolution	of	proximal	 tubular	
damage	in	a	NS	animal	model	treated	with	PACAP	should	be	studied.	
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5.5 Conclusions	
Our	 observations	 provide	 new	 insights	 in	 the	 expression	 of	 PACAP	 and	 its	
receptors	 in	 the	 healthy	 and	 nephrotic	 kidney	 in	 humans.	 VPAC1	 is	 the	
predominant	receptor	in	human	glomerular	endothelium	and	proximal	tubular	
epithelial	 cells.	 Enhanced	 presence	 of	 PACAP	 in	 tubular	 epithelial	 cells	 in	
nephrotic	 kidneys	 is	 probably	 due	 to	 the	 reabsorption	 of	 filtered	 PACAP.	
Simultaneous	 exposure	 of	 human	 proximal	 tubular	 epithelial	 cells	 to	 PACAP	
and	albumin	had	similar	effects	compared	to	albumin	only,	suggesting	that	at	
least	 on	 short	 term	 PACAP	 had	 no	 detrimental	 or	 protective	 effect	 upon	
proteinuric	conditions.			
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Supplementary	table	5.1:	Overview	of	study	patients	
	
Patient	number	
	
Type	of	NS	
	
Age	at	biopsy		
(years)	
	
Protein/creatinine	ratio	
(g/g)	
	Patient	1	 None	 3.3		 0.14		Patient	2	 None	 9.3		 0.14		Patient	3	 None	 13.5		 0.06		Patient	4	 MCNS	 2.2		 12.38		Patient	5	 MCNS	 6.2		 3.42		Patient	6	 MCNS	 5.3		 42.75		Patient	7	 FSGS	 6.3		 10.03		Patient	8	 FSGS	 12.8		 12.28		Patient	9	 Finnish-type	CNS	 0.7		 553.18		Patient	10	 Finnish-type	CNS	 1.1		 254.44		
MCNS	 =	minimal	 change	 nephrotic	 syndrome;	 FSGS	 =	 focal	 segmental	 glomerulosclerosis;	
CNS	=	congenital	nephrotic	syndrome	
	
Supplementary	table	5.2:	Overview	of	PCR	primer	sequences		 	Forward	(5’	è	3’)	 	Reverse	(5’	è	3’)		 	PCR	product	(bp)	
	
GAPDH	
	GAGTCAACGGATTTGGTCGTAT	 	CAGGAGGCATTGCTGATGATCT	 	436		
PAC1	 TCTACACGGTTGGCTACAGCACAT	 TATCCCAGCAGCCTGTGTCATCAA	 429		
VPAC1	 TCAAAGACTTGGCCCTCTTCGACA	 TGTCCCAGCACCCATAATCCTCAA	 282		
VPAC2	 AGATTTCGTCGATGCCTGTGGCTA	 GATGCTGATGGGAAACACGGCAAA	 745		
TGF-β1	 CACATCAGAGCTCCGAGAAGCG	 TAGTGAACCCGTTGATGTCCACT	 314		
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Chapter	6:	 General	discussion	and	
future	perspectives	
	
Patients	 with	 nephrotic	 syndrome	 (NS)	 have	 an	 enhanced	 risk	 for	
thromboembolic	disease,	including	both	deep	venous	and	arterial	thrombosis.	
Thromboembolic	complications	 lead	to	a	significant	 increase	 in	morbidity	and	
mortality	 rates	 for	NS	patients.[148]	 The	mechanisms	underlying	 the	 increased	
risk	of	venous	 thrombosis	have	already	partially	been	unraveled,	but	 the	 fact	
that	also	the	arterial	risk	is	elevated	for	NS,	points	to	a	role	for	platelets	in	the	
pathophysiology	 of	 the	 prothrombotic	 state.	 Elevated	 platelet	 counts	 and	
enhanced	 platelet	 function	 have	 indeed	 repeatedly	 been	 observed	 in	 NS	
patients	during	relapse.[129]	However,	the	mechanisms	underlying	these	platelet	
alterations	 in	 NS	 remain	 unclear.	 A	 better	 understanding	 of	 the	
pathophysiology,	 could	 help	 to	 identify	 patients	 at	 risk	 for	 thromboembolic	
disease,	and	new	strategies	for	the	prevention	and	treatment	of	thrombosis	in	
NS	patients.	
Recently,	PACAP	was	identified	as	an	inhibitor	of	megakaryopoiesis	and	platelet	
aggregation.	In	patients	with	elevated	PACAP	plasma	levels	because	of	PACAP	
overexpression	 and	 in	 transgenic	 mice	 with	 megakaryocyte-specific	 PACAP	
overexpression,	 PACAP	 was	 demonstrated	 to	 inhibit	 megakaryopoiesis	 and	
platelet	 function	 via	 the	 VPAC1	 receptor.	 In	 contrast,	 stimulation	 of	 platelet	
function	and	megakaryopoiesis	was	obtained	in	wild-type	mice	injected	with	a	
PACAP	antagonist	or	inhibitory	antibodies	against	PACAP	or	its	receptor	VPAC1,	
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as	well	as	in	PACAP	knockout	mice.[10,11]	Moreover,	a	thrombopoietic	effect	of	
VPAC1	inhibition	in	thrombocytopenia	murine	models	was	demonstrated.[12]	
The	first	aim	of	this	Ph.D.	thesis	is	the	study	of	a	possible	role	for	plasma	PACAP	
deficiency	in	increased	platelet	count	and	hyperreactivity	observed	in	NS.	Two	
studies	 in	NS	 patients	were	 performed.	 First,	 a	 small-scale	 study	was	 set	 up,	
investigating	 PACAP	 and	 ceruloplasmin	 levels,	 as	 well	 as	 platelet	
characteristics,	 in	 4	 patients	 with	 Finnish-type	 congenital	 NS	 (CNS).	 Three	 of	
these	patients	underwent	bilateral	nephrectomy	because	of	ongoing	extremely	
severe	 proteinuria	 despite	 conservative	 treatment,	 providing	 the	 opportunity	
to	perform	tests	in	a	nephrotic	and	non-nephrotic	state.	Our	findings	were	next	
validated	in	a	prospective,	multicenter	study,	investigating	a	larger	group	of	24	
patients	with	steroid-sensitive	idiopathic	NS	(INS),	a	more	common	and	usually	
less	 severe	 form	of	NS.	Tests	were	performed	 in	 these	patients	at	3	different	
time	points:	during	nephrotic	state	before	the	start	of	corticosteroid	treatment,	
4	weeks	after	the	onset	of	remission,	and	4	weeks	after	stop	of	corticosteroids	
(still	 in	 remission).	 In	 addition,	we	 have	 studied	 the	 relation	 between	 PACAP	
and	thrombocyte	counts	using	two	established	zebrafish	CNS	models.	
	
Furthermore,	a	nephroprotective	effect	of	PACAP	has	been	demonstrated	in	a	
variety	of	renal	disease	models.	The	protective	effect	of	PACAP	has	particularly	
been	 shown	 in	 proximal	 tubular	 epithelial	 cells.	 Changes	 induced	 by	 PACAP	
include	 inhibition	 of	 upregulated	 apoptotic	 pathways,	 increased	 cell	 survival	
and	 decreased	 production	 of	 proinflammatory	 and	 profibrotic	 substances.[20]	
Little	is	known	however	about	the	expression	of	PACAP	and	its	receptors	in	the	
kidney.	 Moreover,	 no	 data	 exist	 about	 the	 role	 of	 PACAP	 in	 proteinuric	
conditions.	Chronic	proteinuria	leads	to	apoptosis	of	proximal	tubular	cells	and	
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to	 secretion	 of	 pro-inflammatory	 and	 profibrotic	 substances,	 causing	
tubulointerstitial	damage,	leading	to	progression	of	renal	disease.[130]		
A	second	aim	of	this	Ph.D.	thesis	is	the	study	of	the	expression	of	PACAP	and	its	
receptors	 in	the	healthy	and	nephrotic	kidney,	as	well	as	to	define	the	role	of	
PACAP	 in	 proteinuria	 related	 proximal	 tubular	 damage.	 Therefore,	 the	
expression	 of	 PACAP	 and	 its	 receptors	 was	 investigated	 in	 renal	 tissue	 of	
healthy	 and	 nephrotic	 children	 and	 in	 human	 renal	 cell	 lines.	 The	 effect	 of	
PACAP	on	albumin	exposed	human	proximal	tubular	epithelial	HK-2	cells,	as	a	
model	for	proteinuria	related	cell	damage,	was	further	investigated.	
	
1.	Plasma	PACAP	deficiency	in	patients	with	nephrotic	syndrome	
Plasma	PACAP	deficiency	due	to	excessive	urinary	excretion	was	first	observed	
in	4	patients	with	Finnish-type	CNS,	a	rare	and	extremely	severe	variant	of	NS.	
The	 plasma	 PACAP	 deficiency	 was	 next	 confirmed	 in	 a	 group	 of	 24	 children	
during	a	first	episode	or	relapse	of	steroid-sensitive	INS,	a	more	common	form	
of	NS.	However,	PACAP	deficiency	was	much	 less	severe	for	 INS	compared	to	
CNS	 patients,	 probably	 due	 to	 the	 shorter	 duration	 and	 the	 milder	 form	 of	
nephrosis.	Plasma	PACAP	levels	normalized	for	both	patient	groups	during	the	
non-nephrotic	phase.	
Ceruloplasmin,	 the	 binding	 protein	 of	 PACAP,	was	 also	 excreted	 in	 the	 urine	
during	 nephrotic	 state	 in	 both	 patient	 groups.	 As	 urine	 ceruloplasmin	 levels	
correlated	 well	 to	 urine	 PACAP	 levels,	 it	 is	 possible	 that	 both	 are	 excreted	
proportionally.	 Excessive	 ceruloplasmin	 excretion	 caused	 decreased	 serum	
levels	 in	CNS	patients,	while	 in	 INS	patients	normal	ceruloplasmin	 levels	were	
observed.	 The	 reason	 for	 this	 difference	 is	 probably	 due	 to	 the	 fact	 that	 INS	
patients	 suffer	 from	 a	milder	 proteinuria	 and	 shorter	 existence	 of	 nephrosis	
compared	to	CNS	patients.	
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Although	nephrotic	proteinuria	leads	to	increased	excretion	of	several	different	
proteins,	 a	 proteomic	 study	 in	 childhood	 INS	 showed	 that	 from	388	 proteins	
detected	in	normal	plasma,	only	18	were	altered	in	the	plasma	of	children	with	
NS.[175]	For	other	proteins,	compensatory	mechanisms	as	hepatic	hyperfunction	
seem	 to	 be	 sufficient	 to	 keep	 plasma	 levels	 constant.	 The	 observation	 of	
plasma	 PACAP	 deficiency	 in	 children	 with	 NS	 is	 a	 novel	 finding	 and,	 to	 our	
knowledge,	it	is	the	first	report	of	acquired	PACAP	deficiency	in	humans.	
	
2.	PACAP	deficiency	as	a	cause	of	platelet	alterations	in	nephrotic	syndrome	
As	we	observed	plasma	PACAP	deficiency	in	NS	patients,	the	next	step	was	the	
investigation	of	 its	role	 in	the	 increased	platelet	count	and	hyperaggregability	
observed	for	NS	patients.	Increased	megakaryopoiesis	and	platelet	count	were	
demonstrated	 in	 CNS	 patients	 during	 nephrotic	 state,	 normalizing	 after	
bilateral	 nephrectomy	 together	 with	 plasma	 PACAP	 levels.	 Platelet	 counts	
normalized	within	one	week,	which	strongly	suggests	the	elevation	was	a	direct	
consequence	 of	 nephrosis.	 Furthermore,	 a	 strong	 inverse	 correlation	 was	
found	 between	 plasma	 PACAP	 levels	 and	 platelet	 counts.	 Above	 this,	 the	
addition	 of	 plasma	 of	 CNS	 patients	 during	 nephrotic	 state	 directly	 promoted	
megakaryopoiesis	using	stem	cells	of	a	healthy	donor.	Moreover,	underscoring	
the	role	of	PACAP	deficiency	in	upregulated	megakaryopoiesis	for	CNS,	addition	
of	 recombinant	 PACAP	 inhibited	 differentiation	 of	 hematopoietic	 stem	 cells	
into	megakaryocytes	during	the	nephrotic	state.		
The	pathways	by	which	PACAP	exerts	its	inhibitory	effect	on	megakaryopoiesis	
are	not	 completely	 understood.	 The	 initial	 hypothesis	was	 that	 PACAP	would	
interfere	 with	 gene	 expression	 by	 increasing	 intracellular	 cAMP	 levels	 that	
could	 influence	 genes	 with	 cAMP	 response	 element-binding	 protein	 (CREB)	
recognition	sites	 in	their	promoters.	However,	potent	stimulation	of	cAMP	by	
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the	 addition	 of	 forskolin	 to	 in	 vitro	 megakaryocyte	 cultures	 could	 not	
completely	mimic	PACAP	effects.[11]	 Therefore,	other	pathways	besides	 cAMP	
increase	 were	 presumed.	 NF-κB	 was	 recently	 suggested	 to	 act	 in	 a	 PACAP	
dependent	 pathway	 via	 VPAC1,	 regulating	 normal	 apoptosis	 in	
megakaryocytes,	 which	 is	 necessary	 for	 the	 release	 of	 platelets.[13]	 In	 our	
current	 study,	we	observed	 reduced	 levels	of	NF-κB	 in	platelet	 lysates	during	
the	nephrotic	state	in	CNS	patients	when	plasma	PACAP	levels	were	low,	which	
normalized	after	bilateral	nephrectomy.	This	suggests	that	PACAP	deficiency	in	
CNS	would	cause	deficiency	of	NF-κB	in	megakaryocytes,	increasing	the	normal	
apoptosis	rate,	which	is	a	necessary	step	for	platelet	release,	and	leading	to	an	
increased	amount	of	platelets.	
Consistent	 with	 the	 results	 of	 literature[84,85,90,91,116],	 the	 increase	 in	 platelet	
count	was	less	obvious	for	INS	patients.	No	correlation	between	platelet	count	
and	plasma	PACAP	levels	was	found.	Megakaryopoiesis	was	not	studied	in	INS	
patients.	 Proteinuria	was	much	 less	 severe	 in	 INS	 compared	 to	 CNS	patients,	
with	a	mean	value	of	urinary	protein/creatinine	ratio	of	17.8	g/g	versus	136.2	
g/g,	 respectively.	 Plasma	 PACAP	 levels	were	 also	 significantly	 less	 reduced	 in	
INS	 compared	 to	 CNS	 (mean	 ±	 SD	 of	 73	 ±	 17	%	 versus	 26	 ±	 11	%	 of	 control	
values).	A	possible	explanation	for	the	lack	of	an	effect	on	platelet	count	for	INS	
patients,	is	that	more	severe	proteinuria	and/or	a	longer	duration	of	nephrosis	
might	 be	 necessary	 to	 affect	 megakaryopoiesis	 and	 platelet	 counts.	 As	
nowadays	 the	 duration	 of	 proteinuria	 before	 the	 diagnosis	 of	 NS	 is	made,	 is	
probably	 shorter	 than	 before,	 it	 could	 explain	 why	 ours	 and	 other	 recent	
studies	 could	 not	 find	 significantly	 increased	 platelet	 counts	 in	 INS.[90,91]	
However,	the	effect	of	duration	of	nephrosis	on	platelet	counts	has	never	been	
studied.		
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Platelet	 hyperaggregability	 in	 response	 to	 collagen	 has	 repeatedly	 been	
demonstrated	 in	NS.[89,90,95,99]	 Earlier	 research	 suggested	 that	 reduced	 plasma	
albumin	levels	lead	to	an	elevated	level	of	unbound	arachidonic	acid	(AA)	in	the	
plasma	 and,	 as	 a	 consequence,	 to	 increased	 formation	 of	 thromboxane	 A2	
(TXA2),	 which	 stimulates	 platelet	 aggregation.[113]	 An	 inverse	 correlation	
between	serum	albumin	 levels	and	collagen	 induced	platelet	aggregation	was	
found	 in	 one	 study	 [99],	 but	 was	 not	 confirmed	 in	 a	 following	 study.[89]	 Later	
studies	showed	that	at	least	part	of	the	platelet	function	disturbances	seen	in	
NS	 were	 independent	 of	 the	 AA	 pathway	 of	 platelet	 activation.[129]	 A	
multifactorial	cause	for	the	platelet	hyperreactivity	in	NS	was	presumed.	In	our	
study,	we	confirmed	that	platelet	aggregation	in	both	CNS	and	INS	patients	was	
increased	 during	 the	 nephrotic	 state,	 while	 platelets	 isolated	 during	 non-
nephrotic	state	showed	normal	reactivity	towards	collagen.	Moreover,	plasma	
of	 CNS	 patients	 during	 nephrotic	 state	 directly	 promoted	 aggregation	 of	
platelets	 from	 a	 healthy	 control	 subject	 resuspended	 in	 CNS	 plasma.	 This	
confirms	 the	 idea	 that	 increased	 levels	 of	 platelet	 stimulating	 or	 decreased	
levels	of	platelet	 inhibiting	substances	are	present	 in	nephrotic	plasma.	In	INS	
patients,	 the	 effect	 of	 addition	 of	 recombinant	 PACAP	 to	 platelets	 was	
investigated	 ex	 vivo	 during	 the	 nephrotic	 state	 and	 caused	 significantly	
decreased	aggregation	responses.	Furthermore,	platelet	aggregation	responses	
to	 collagen	 inversely	 correlated	 with	 plasma	 PACAP	 levels	 during	 nephrotic	
state,	but	not	with	serum	albumin	 levels.	These	 findings	 strongly	corroborate	
the	role	of	PACAP	deficiency	in	the	platelet	hyperaggregability	for	NS.		
The	 pathway	 underlying	 the	 effect	 of	 plasma	 PACAP	 deficiency	 on	 platelet	
aggregability	 in	 NS	 is	 probably	 via	 a	 reduction	 of	 intraplatelet	 cAMP	 levels,	
leading	 to	 increased	platelet	activation	by	stimulation	of	calcium	release.	The	
presence	 of	 the	 VPAC1	 receptor,	 coupled	 to	 adenylate	 cyclase,	 was	
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demonstrated	in	megakaryocytes	and	platelets,	while	VPAC2	and	PAC1	are	not	
expressed.[10]	 Elevated	 levels	 of	 basal	 cAMP	 were	 observed	 in	 platelets	 of	
patients	with	PACAP	overexpression	due	to	partial	trisomy	18p,	explaining	the	
reduced	 platelet	 activation,	 as	 intracellular	 cAMP	 antagonizes	 platelet	
activation	by	inhibition	of	calcium	release.	In	our	current	studies,	cAMP	levels	
were	 not	 measured	 in	 platelet	 lysates	 of	 NS	 patients,	 but	 a	 previous	 study	
reported	reduced	intraplatelet	cAMP	concentrations	in	nephrotic	children.[98]	
	
Limitations	and	future	perspectives:	
In	 this	 study,	 we	 found	 experimental	 evidence	 for	 a	 role	 of	 acquired	 PACAP	
deficiency	 for	 increased	 platelet	 counts	 and	 aggregability	 in	 NS.	 However,	
large-scale	 prospective	 epidemiologic	 studies	 are	 needed	 to	 investigate	 the	
relation	 between	 platelet	 alterations	 and	 the	 incidence	 of	 thrombotic	
complications	in	NS	patients.		
One	of	the	limitations	of	this	study	is	the	low	number	of	patients	studied.	The	
low	incidences	of	congenital	and	childhood	idiopathic	NS	form	a	burden	in	this	
perspective.	 It	 would	 be	 interesting	 to	 extend	 our	 observations	 to	 adult	
patients	with	NS.	Adult	patients	with	membranous	nephropathy	would	be	an	
interesting	 study	 population,	 as	 these	 patients	 have	 an	 even	 higher	 risk	 for	
thromboembolic	disease	than	other	nephrotic	patients.[63]		
Controversy	 exists	 concerning	 the	 need	 of	 prophylactic	 treatment	 for	 the	
prevention	 of	 thromboembolic	 events	 in	 NS.	 Prophylactic	 treatment	 could	
include	 anticoagulants[176],	 but	 also	 antiplatelet	 agents	 such	 as	 acetylsalicylic	
acid[177].	 Some	 early	 reports	 support	 the	 use	 of	 antiplatelet	 medication,	
showing	normalization	of	 in	vitro	platelet	aggregation	 in	NS	during	 treatment	
with	 acetylsalicylic	 acid.[88,99]	 However,	 no	 controlled	 trials	 are	 available	
demonstrating	an	effect	of	antiplatelet	agents	on	the	incidence	of	thrombotic	
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complications	 in	 children	 with	 NS.	 Furthermore,	 it	 should	 be	 noted	 that	
cyclooxygenase	 (COX)	 inhibition	 could	 have	 direct	 negative	 consequences	 on	
renal	 health.	 It	 was	 shown	 that	 low-dose	 acetylsalicylic	 acid	 effectively	
suppressed	 TXA2	 synthesis	 in	 platelets,	 without	 affecting	 renal	 prostacyclin	
synthesis.[178]	Some	authors,	however,	have	suggested	that	in	NS	patients	with	
hypovolemia,	non-steroidal	anti-inflammatory	drugs	(NSAID)	could	increase	the	
risk	 of	 acute	 renal	 failure.[37]	 Hence,	 antiplatelet	 medication	 is	 not	 generally	
recommended	 for	 routine	 prophylactic	 therapy	 in	 patients	 with	 NS.	
Furthermore,	 it	 is	 not	 clear	whether	 the	presence	of	 certain	 clinical	 features,	
such	 as	 the	 degree	 of	 PACAP	 deficiency,	 hypoalbuminemia,	 proteinuria	 or	
thrombocytosis	and	alterations	in	platelet	function	tests,	could	predict	the	risk	
for	 thromboembolism	 and	 would	 justify	 prophylactic	 measures	 in	 selected	
patients.	If	a	role	for	PACAP	deficiency	in	the	occurrence	of	thrombosis	for	NS	
would	 be	 confirmed	 in	 large-scale	 studies,	 measuring	 plasma	 PACAP	 levels	
could	 possibly	 be	 of	 help	 in	 clinical	 decisions	 regarding	 the	 need	 for	
prophylactic	measures	in	NS	patients.	 
Because	PACAP	exerts	many	different	biological	functions,	the	question	arises	if	
plasma	 PACAP	 deficiency	 in	 NS	 could	 lead	 to	 consequences	 in	 other	 organ	
systems	 besides	 platelets.	 For	 example,	 altered	 psychomotor	 behavior	 has	
been	 described	 in	 PACAP	 knockout	 mice.[150]	 In	 NS	 patients,	 psychomotor	
development	has	never	been	extensively	examined	and	warrants	further	study,	
although	no	overt	mental	or	motoric	delay	has	been	demonstrated.	Moreover,	
a	 nephroprotective	 effect	 of	 PACAP	 has	 been	 reported	 in	 different	 kidney	
disease	 models.[20]	 Further	 research	 is	 needed	 to	 investigate	 long-term	
influence	of	PACAP	deficiency	on	renal	health	in	NS.		
	
	
	 145	
3.	 Zebrafish	 nephrotic	 syndrome	 models	 to	 study	 the	 influence	 of	 PACAP	
deficiency	on	thrombocyte	formation	
Aiming	to	further	elucidate	the	role	of	PACAP	deficiency	in	platelet	alterations	
for	NS,	 two	 established	 zebrafish	 CNS	models	were	 used.	 The	main	 research	
question	was:	can	a	NS	zebrafish	model	be	developed	to	further	study	the	role	
of	PACAP	 loss	 in	enhanced	megakaryopoiesis?	As	our	observations	 in	humans	
showed	more	pronounced	PACAP	deficiency	 and	 increased	platelet	 counts	 in	
Finnish-type	 CNS	 compared	 to	 INS,	 we	 preferred	 to	 use	 a	 Finnish-type	 CNS	
animal	model	rather	than	a	model	for	INS.	Constitutive	nephrin	knockout	CNS	
rodent	models	could	not	be	used	because	of	lethality	early	after	birth.[158]	Two	
previously	 characterized	 CNS	 zebrafish	 models,	 a	 nephrin	 depleted	 and	 an	
adriamycin	 exposed	 model,	 were	 generated	 using	 the	 transgenic	
Tg(cd41:EGFP)	 model	 with	 GFP-labeled	 thrombocytes.	 Different	 from	 our	
findings	 in	 human	 CNS	 patients	 however,	 we	 did	 not	 observe	 increased	
thrombocytes	 in	 those	 models.	 PACAP	 deficiency	 was	 observed	 in	 the	
adriamycin	 exposed,	 but	 not	 in	 the	 nephrin	 depleted	 model.	 We	 concluded	
that	none	of	these	CNS	zebrafish	models	were	suitable	for	the	investigation	of	
the	role	of	PACAP	and	ceruloplasmin	deficiency	in	megakaryopoiesis	in	CNS.		
	
Limitations:	
Some	study	limitations	could	possibly	explain	why	the	observations	in	humans	
were	not	 reproducible	 in	 the	zebrafish	models.	One	 limitation	 is	 that	 it	 is	not	
proven	that	the	pericardial	edema	in	the	nephrin	depleted	Tg(cd41:EGF)	model	
was	 due	 to	 proteinuria.	 It	 could	 be	 partially	 caused	 by	 extrarenal	 effects	 of	
nephrinMO	such	as	cardiac	toxicity.	However,	cardiac	morphology	and	function	
were	not	 studied	 in	 this	model.	As	no	PACAP	deficiency	or	 increased	platelet	
counts	were	observed,	we	concluded	that	this	model	could	not	be	used	for	our	
	 146	
purposes,	and	did	not	perform	any	 further	experiments.	Another	 limitation	 is	
the	relatively	short	duration	of	observation	(maximum	6	dpf).	A	longer	duration	
of	nephrosis	might	be	necessary	to	affect	megakaryopoiesis	and	platelet	count.	
Furthermore,	 a	 direct	 inhibitory	 effect	 of	 adriamycin	 on	megakaryopoiesis	 in	
zebrafish	 cannot	 be	 excluded.	 A	 dose-dependent	 decrease	 of	 GFP-positive	
thrombocytes	 might	 then	 be	 expected,	 and	 could	 counteract	 the	 effect	 of	
PACAP	 deficiency.	 A	 last	 limitation	 of	 this	 study,	 is	 the	 difference	 in	
thrombocytes	 and	 thrombocyte	 formation	 in	 zebrafish	 compared	 to	 humans.	
The	final	maturation	process	from	megakaryocyte	to	thrombocyte	seems	to	be	
different	between	zebrafish	and	mammals.	If	PACAP	deficiency	exerts	its	effect	
during	 this	 late	 stage	of	megakaryopoiesis,	 this	 could	be	another	 reason	why	
our	 observations	 in	 humans	 were	 not	 reproducible	 in	 the	 studied	 zebrafish	
models	of	CNS.	
	
Future	perspectives:		
Better	 understanding	 of	 the	 pathophysiology	 of	 platelet	 alterations	 and	
increased	risk	for	thrombosis	in	NS	could	help	in	taking	clinical	decisions	about	
prophylaxis	 and	 treatment	 of	 thrombotic	 complications.	 Besides	 induced	
zebrafish	 models,	 no	 other	 suitable	 Finnish-type	 CNS	 animal	 models	 are	
currently	 available.	 Therefore,	 animal	 models	 for	 other	 forms	 of	 NS,	 as	 for	
example	 puromycin	 aminonucleoside	 treated	 rats[158]	 or	 podocin	 deficient	
mice[179],	should	be	further	studied.		
	
4.	 Distribution	 and	 function	 of	 PACAP	 and	 its	 receptors	 in	 the	 healthy	 and	
nephrotic	kidney	
As	 PACAP	 seems	 to	 play	 an	 important	 nephroprotective	 role	 in	 a	 variety	 of	
models	of	renal	pathology[20]	and	little	is	known	about	the	expression	of	PACAP	
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and	its	receptors	in	the	kidney,	we	investigated	the	expression	of	PACAP	and	its	
receptors	 in	 human	 renal	 tissue	 and	 renal	 cell	 lines.	 VPAC1	 expression	 was	
detected	 in	 the	proximal	 tubules	and	 in	 the	glomeruli	of	healthy	 renal	 tissue,	
confirming	 the	 results	 of	 previous	 studies.[7,15]	 The	VPAC2	 and	PAC1	 receptor	
were	 not	 detected	 in	 glomeruli	 or	 tubules	 of	 healthy	 renal	 tissue.	 The	 same	
expression	 pattern	 of	 PACAP	 receptors	 was	 demonstrated	 in	 renal	 tissue	 of	
children	 with	 NS.	 Furthermore,	 weak	 expression	 of	 PACAP	 was	 found	 in	 the	
proximal	 tubules	 of	 healthy	 renal	 tissue,	 while	 a	 much	 stronger	 signal	 was	
observed	 in	 the	 renal	 sections	 of	 children	 with	 NS.	 We	 hypothesized	 that	
increased	expression	of	PACAP	in	proximal	tubules	in	NS	is	due	to	reabsorption	
of	increased	levels	of	filtered	PACAP,	which	was	supported	by	the	fact	that	HK-
2	cells	did	not	express	PACAP,	nor	at	basal	conditions,	neither	after	exposure	to	
albumin.	We	further	demonstrated	expression	of	a	functional	VPAC1	receptor	
in	 human	 proximal	 tubular	 epithelial	 HK-2	 cells.	 Expression	 of	 VPAC2	 was	
absent	and	PAC1	was	very	low	in	HK-2	cells,	suggesting	that	VPAC1	is	the	main	
active	PACAP	receptor	in	HK-2	cells.		
As	we	demonstrated	reduced	plasma	PACAP	levels	and	excessive	PACAP	levels	
in	proximal	tubules	in	NS	patients	and	since	PACAP	exerts	a	protective	effect	on	
proximal	 tubular	 epithelial	 cells	 in	 a	 variety	 of	 renal	 disease	 models[20],	 we	
further	 aimed	 to	 investigate	 the	 effect	 of	 PACAP	 on	 albumin	 exposed	 HK-2	
cells,	mimicking	proteinuria	related	cell	damage.	We	found	that	the	addition	of	
recombinant	PACAP	did	not	influence	decreased	cell	viability	or	increased	TGF-
β1	expression	due	to	albumin	exposure.	Hence,	PACAP	does	not	seem	to	play	a	
protective	 role	 in	 proteinuria	 related	 damage	 of	 proximal	 tubular	 epithelial	
cells	as	it	does	in	other	renal	disease	models,	at	least	in	these	conditions	for	the	
currently	 tested	 parameters.	 Furthermore,	 no	 harmful	 effect	 of	 PACAP	 was	
observed.	
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Future	perspectives:	
To	 exclude	 in	 vivo	 effects	 of	 PACAP	 on	 proteinuria	 related	 proximal	 tubular	
epithelial	 damage,	 the	 evolution	 of	 proximal	 tubular	 damage	 in	 a	 NS	 animal	
model	 treated	 with	 PACAP	 should	 be	 studied.	 Furthermore,	 a	 better	
understanding	 of	 the	 molecular	 pathways	 underlying	 the	 nephroprotective	
effect	of	PACAP	in	other	renal	disease	models	is	 important.	The	use	of	PACAP	
receptor	antagonists	concomitant	with	PACAP	administration	in	in	vitro	and	in	
vivo	 models	 can	 help	 to	 further	 explore	 the	 respective	 importance	 of	 the	
receptors	 in	 the	 nephroprotective	 effects	 of	 PACAP	 in	 conditions	 of	 proximal	
tubular	 damage.	 Finally,	 to	 further	 evaluate	 the	 physiologic	 importance	 of	
PACAP	 reuptake	 by	 proximal	 tubular	 cells,	 the	 mechanisms	 of	 glomerular	
filtration	and	reabsorption	should	be	further	studied.		
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Samenvatting	
	
Patiënten	met	nefrotisch	syndroom	(NS)	hebben	een	verhoogd	risico	zowel	op	
diepe	 veneuze	 als	 arteriële	 trombose,	 hetgeen	 de	 morbiditeit	 en	 mortaliteit	
significant	 doet	 toenemen.	 Herhaaldelijk	 werd	 aangetoond	 dat	 bloedplaatjes	
van	 patiënten	 met	 nefrotisch	 syndroom	 hyperactief	 zijn	 en	 dat	 hun	 aantal	
verhoogd	is.	De	mechanismen	die	aan	de	basis	 liggen	van	deze	veranderingen	
in	 aantal	 en	 functionaliteit	 van	 bloedplaatjes	 in	 NS	 werden	 echter	 nog	 niet	
opgehelderd.	 Een	 tiental	 jaar	 geleden	 werd	 ontdekt	 dat	 pituitary	 adenylate	
cyclase-activating	 polypeptide	 (PACAP)	 een	 inhibitor	 is	 van	 megakaryopoiese	
en	bloedplaatjesaggregatie,	en	dat	inhibitie	van	PACAP	of	de	PACAP	receptoren	
leidt	 tot	 stimulatie	 van	 bloedplaatjesproductie	 en	 -activatie.	 In	 deze	
doctoraatsthesis	werd	de	rol	van	PACAP	bestudeerd	in	het	toegenomen	aantal	
en	de	hyperactivatie	van	bloedplaatjes	in	kinderen	met	NS.		
Eerst	 werd	 een	 kleinschalige	 studie	 uitgevoerd	 in	 4	 patiënten	met	 Fins	 type	
congenitaal	 NS	 (CNS).	 Daarna	 werden	 onze	 bevindingen	 gevalideerd	 in	 een	
prospectieve	multicentrische	studie	in	een	groep	van	24	patiënten	met	steroïd-
sensitief	idiopathisch	nefrotisch	syndroom	(INS).	Zowel	in	CNS	als	INS	patiënten	
vonden	we	plasma	PACAP	deficiëntie	terug	tijdens	het	nefrotisch	stadium,	als	
gevolg	van	excessieve	urinaire	excretie.	De	plasma	PACAP	deficiëntie	was	meer	
uitgesproken	in	de	CNS	dan	INS	patiënten.	We	stelden	verder	vast	dat	in	vitro	
megakaryopoïese	 verhoogd	was	 gedurende	 het	 PACAP	 deficiënte	 stadium	bij	
CNS	patiënten,	en	dat	dit	effect	kon	tegengegaan	worden	indien	recombinant	
PACAP	 werd	 toegevoegd.	 Trombocytose	 werd	 geobserveerd	 in	 alle	 CNS	
patiënten	en	in	sommige	patiënten	met	INS	tijdens	de	nefrotische	fase.	Verder	
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werd	aangetoond	dat	NF-κB,	een	downstream	target	van	PACAP,	verlaagd	was	
in	 bloedplaatjeslysaten	 van	 CNS	 patiënten.	Ook	 bloedplaatjeshyperaggregatie	
werd	 vastgesteld	 bij	 CNS	 en	 INS	 patiënten	 in	 de	 nefrotische	 fase.	 In	 INS	
patiënten	 werd	 verder	 gezien	 dat	 de	 toevoeging	 van	 recombinant	 PACAP	
tijdens	de	nefrotische	fase	aan	het	bloeplaatjesstaal,	leidt	tot	een	vermindering	
van	 de	 bloedplaatjesaggregatie.	 Bovendien	 werd	 een	 omgekeerd	 correlatie	
aangetoond	 tussen	bloedplaatjesaggregatie	 en	 plasma	PACAP	waarden,	maar	
niet	 tussen	 bloedplaatjesaggregatie	 en	 serum	 albumine	 concentratie.	 Onze	
observaties	 wijzen	 sterk	 op	 een	 rol	 voor	 plasma	 PACAP	 deficiëntie	 in	 de	
verhoogde	megakaryopoïese	en	de	toegenomen	bloedplaatjesactivatie	in	NS.	
Om	 het	 effect	 van	 PACAP	 deficiëntie	 op	 bloedplaatjes	 in	 NS	 verder	 te	
bestuderen,	 werden	 twee	 CNS	 zebravis	 modellen	 onderzocht.	 Twee	 vroeger	
reeds	gekarakteriseerde	CNS	modellen,	één	op	basis	van	depletie	van	nefrine	
en	een	ander	op	basis	van	blootstelling	aan	adriamycine,	werden	bekomen	in	
Tg(cd41:EGFP)	 transgene	 zebravis	 embryos.	 PACAP	 deficiëntie	 werd	 enkel	
bevestigd	 in	 het	 adriamycine	 model.	 Anders	 dan	 in	 onze	 bevindingen	 bij	 de	
mens	 echter,	 vonden	 we	 geen	 verhoogd	 bloedplaatjesaantal	 terug	 in	 deze	
zebravismodellen.	 Deze	 modellen	 konden	 dus	 niet	 verder	 gebruikt	 worden	
voor	de	studie	van	de	rol	van	PACAP	deficiëntie	in	megakaryopoïese	in	CNS.		
	
Verder	 werd	 vroeger	 ook	 aangetoond	 in	 verschillende	 renale	 pathologie	
modellen,	 dat	 PACAP	 ook	 een	 nefroprotectief	 effect	 uitoefent.	 Er	 is	 echter	
weinig	geweten	over	de	expressie	van	PACAP	en	zijn	receptoren	in	de	nier.	Ook	
is	 er	 niets	 bekend	 over	 de	 rol	 van	 PACAP	 in	 proteïnurie	 gerelateerde	
nierschade.	 In	 deze	 doctoraatsthesis	 werd	 de	 expressie	 van	 PACAP	 en	 zijn	
receptoren	bestudeerd	in	de	gezonde	en	nefrotische	nier.	Bovendien	werd	de	
rol	 van	 PACAP	 nagegaan	 in	 proteïnurie	 gerelateerde	 schade	 van	 proximale	
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tubulaire	 cellen.	 Expressie	 van	 de	 VPAC1	 receptor	 werd	 aangetoond	 in	 de	
proximale	 tubuli	 en	 glomeruli	 van	 gezond	 en	 nefrotisch	 humaan	nierweefsel.	
Verder	werd	ook	een	 zeer	 zwakke	expressie	 van	PACAP	 teruggevonden	 in	de	
proximale	tubuli	van	gezond	nierweefsel,	terwijl	een	veel	sterker	signaal	werd	
gezien	in	de	proximale	tubuli	van	kinderen	met	NS,	waarschijnlijk	als	gevolg	van	
reabsorptie	van	PACAP	aanwezig	in	het	ultrafiltraat.	Ook	toonden	we	expressie	
van	een	 functionele	VPAC1	receptor	aan	 in	humane	proximale	 tubulaire	HK-2	
cellen.	VPAC2	expressie	was	afwezig	en	PAC1	expressie	was	zeer	zwak	in	HK-2	
cellen,	wat	 suggereert	dat	VPAC1	de	belangrijkste	 actieve	 receptor	 is	 in	deze	
cellen.	 Verder	 onderzochten	 we	 het	 effect	 van	 PACAP	 op	 HK-2	 cellen	
blootgesteld	 aan	 albumine,	 om	 proteïnurie	 gerelateerde	 celschade	 na	 te	
bootsen.	 Toevoeging	 van	 recombinant	 PACAP	 had	 geen	 invloed	 op	 de	
afgenomen	 celviabiliteit	 en	 toegenomen	 TGF-β1	 expressie	 als	 gevolg	 van	
albumine	blootstelling.	
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Summary	
An	elevated	risk	for	thromboembolic	disease,	including	both	deep	venous	and	
arterial	 thrombosis,	 leads	 to	 an	 increase	 in	 morbidity	 and	 mortality	 rates	 in	
nephrotic	 syndrome	 (NS)	 patients.	 Platelet	 alterations	 have	 repeatedly	 been	
observed	 in	 patients	 with	 NS.	 However,	 the	 mechanisms	 underlying	 these	
platelet	 alterations	 in	 NS	 remained	 unclear.	 Pituitary	 adenylate	 cyclase-
activating	 polypeptide	 (PACAP)	 was	 recently	 identified	 as	 an	 inhibitor	 of	
megakaryopoiesis	 and	 platelet	 aggregation,	 and	 inhibition	 of	 PACAP	 or	 its	
receptors	stimulated	platelet	production	and	function.		
In	this	Ph.D.	thesis,	 the	possible	role	of	plasma	PACAP	deficiency	 in	 increased	
platelet	count	and	hyperreactivity	 in	NS	was	studied.	First,	a	small-scale	study	
was	 performed	 in	 4	 patients	 with	 Finnish-type	 congenital	 NS	 (CNS)	 due	 to	
NPHS1	 gene	 mutations.	 Our	 findings	 were	 then	 validated	 in	 a	 prospective,	
multicenter	 	 study,	 investigating	 a	 larger	 group	 of	 24	 patients	 with	 steroid-
sensitive	 idiopathic	 NS	 (INS).	 We	 observed	 plasma	 PACAP	 deficiency	 due	 to	
excessive	 urinary	 excretion	 during	 the	 nephrotic	 state	 in	 both	 CNS	 and	 INS	
patients.	 Plasma	 PACAP	 deficiency	 was	 more	 pronounced	 in	 CNS	 patients.	
During	the	PACAP-deficient	state,	 in	vitro	megakaryopoiesis	was	 increased	for	
CNS	patients	and	this	effect	could	be	reversed	by	the	addition	of	recombinant	
PACAP.	 Thrombocytosis	was	 observed	 in	 all	 CNS	 and	 in	 some	 cases	with	 INS	
during	nephrotic	state.	We	further	 found	that	NF-κB,	a	downstream	target	of	
PACAP,	 was	 reduced	 in	 platelet	 lysates	 of	 CNS	 patients.	 Platelet	
hyperaggregability	was	observed	during	nephrotic	state	in	both	CNS	and	INS.	In	
INS	 patients,	 the	 addition	 of	 recombinant	 PACAP	 to	 patients’	 platelets	 was	
investigated	 and	 resulted	 in	 decreased	 aggregation	 during	 nephrotic	 state.	
Platelet	 aggregation	 correlated	 inversely	 with	 plasma	 PACAP	 levels,	 but	 not	
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with	 serum	albumin	 levels.	Our	observations	highly	 support	 a	 role	 for	PACAP	
deficiency	in	upregulated	megakaryopoiesis	and	increased	platelet	activation	in	
NS.	
In	order	to	further	elucidate	the	role	of	PACAP	deficiency	in	platelet	alterations	
in	 NS,	 two	 zebrafish	 CNS	 models	 were	 studied:	 a	 nephrin	 depleted	 and	 an	
adriamycin	 exposed	model,	 generated	 in	 Tg(cd41:EGFP)	 transgenic	 zebrafish.	
PACAP	 deficiency	 was	 confirmed	 in	 the	 adriamycin	 model,	 but	 not	 in	 the	
nephrin	 depleted	 fish	 embryos.	 Different	 from	 our	 findings	 in	 human	 CNS	
patients,	 we	 did	 not	 observe	 increased	 thrombocytes	 in	 those	 models.	 We	
concluded	 that	 none	 of	 both	 CNS	 zebrafish	 models	 were	 suitable	 for	
investigating	 the	 role	 of	 PACAP	 and	 ceruloplasmin	 deficiency	 in	
megakaryopoiesis	in	CNS.		
	
Furthermore,	 while	 a	 nephroprotective	 effect	 of	 PACAP	 has	 been	
demonstrated	in	a	variety	of	renal	disease	models,	little	was	known	about	the	
expression	of	PACAP	and	 its	receptors	 in	the	kidney.	Moreover,	no	data	were	
available	about	the	role	of	PACAP	in	proteinuria	related	renal	damage.	
In	this	Ph.D.	thesis	the	expression	of	PACAP	and	its	receptors	was	investigated	
in	the	healthy	and	nephrotic	kidney,	as	well	as	the	role	of	PACAP	in	proteinuria	
related	proximal	 tubular	damage	 in	vitro.	Both	 in	healthy	and	nephrotic	 renal	
tissue,	VPAC1	expression	was	detected	 in	 the	proximal	 tubular	epithelial	cells	
and	in	the	glomeruli.	Furthermore,	weak	expression	of	PACAP	was	found	in	the	
proximal	 tubules	 of	 healthy	 renal	 tissue,	 while	 a	 much	 stronger	 signal	 was	
observed	in	the	renal	sections	of	children	with	NS,	probably	due	to	reuptake	of	
filtered	 PACAP.	 We	 further	 demonstrated	 expression	 of	 a	 functional	 VPAC1	
receptor	 in	human	proximal	tubular	epithelial	HK-2	cells.	Expression	of	VPAC2	
was	absent	and	PAC1	was	very	low	in	HK-2	cells,	suggesting	that	VPAC1	is	the	
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main	active	PACAP	receptor	in	HK-2	cells.	We	further	investigated	the	effect	of	
PACAP	 on	 albumin	 exposed	 HK-2	 cells,	 mimicking	 proteinuria	 related	 cell	
damage.	The	addition	of	 recombinant	PACAP	did	not	 influence	decreased	cell	
viability	or	increased	TGF-β1	expression	due	to	albumin	exposure.	
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